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Abstract 
Monoclonal antibodies are a class of therapeutic that is an expanding area of the 
lucrative biopharmaceutical industry.  These complex proteins are predominantly 
produced from large cultures of mammalian cells; the industry standard cell line being 
Chinese Hamster Ovary (CHO) cells.  A number of optimisation strategies have led to 
antibody titres from CHO cells increasing by a hundred-fold, and it has been proposed 
that a further bottleneck in biosynthesis is in protein folding and assembly within the 
secretory pathway.  To alleviate this bottleneck, a CHO-derived host cell line was 
generated by researchers at the pharmaceutical company UCB that stably overexpressed 
two critical genes: XBP1, a transcription factor capable of expanding the endoplasmic 
reticulum and upregulating protein chaperones; and Ero1α, an oxidase that replenishes 
the machinery of disulphide bond formation.  This host cell line, named CHO-S XE, was 
confirmed to have a high yield of secreted antibody. 
The work presented in this thesis further characterises CHO-S XE, with the aim of using 
the information gained to lead the generation of novel host cell lines with more optimal 
characteristics than CHO-S XE.  In addition to antibodies, it was found that CHO-S XE 
had improved production of two other secreted proteins: one with a simple tertiary 
structure and one complex multi-domain protein; and higher levels of a number of 
endogenous protein chaperones.  As a more controlled system of gene expression to 
unravel the specific roles of XBP1 and Ero1α in the secretory properties of CHO-S XE, 
CHO cells with inducible overexpression of XBP1, Ero1α, or a third gene involved in the 
Unfolded Protein Response, GADD34, were generated.  From these cell lines, it was 
shown that more antibody was secreted by cells with induced overexpression of XBP1; 
however, Ero1α and GADD34 overexpression did not improve antibody yield.  Further 
investigation revealed that endogenous XBP1 splicing was downregulated in the 
presence of an abundance of the active form of XBP1.  This result indicated a novel 
aspect of the regulation of the activity of IRE1, the stress-induced endoribonuclease 
responsible for XBP1 splicing.  Overall, the work described in this thesis confirms that 
the overexpression of XBP1 has an enhancing effect on the secretory properties of CHO 
cells; information which could contribute to the development of host cells with a 
greater capacity for antibody production. 
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1.1 The biopharmaceutical industry 
1.1.1 Therapeutic monoclonal antibodies 
Monoclonal antibodies are large, multi-domain proteins which can be used 
therapeutically in a range of diseases, particularly in the treatment of auto-immune 
conditions and certain types of cancer (reviewed in (Ecker et al. 2015).  These 
therapeutic antibodies are delivered to patients intravenously, and can be used alone or 
in conjunction with other treatments such as small molecule pharmaceuticals or 
chemotherapy.  Through their highly variable antigen binding domains, antibodies are 
theoretically capable of binding to any protein or small molecule target, and this 
binding action can be used to fight disease by a number of different molecular 
mechanisms.  For instance, adalimumab is an antibody capable of binding to tumour 
necrosis factor alpha (TNFα), and can be used to alleviate the symptoms of a number of 
auto-immune conditions, including  rheumatoid arthritis or Crohn’s disease, by binding 
and blocking the activity of TNFα, which is dysregulated in these diseases (Scheinfeld 
2003).  Antibody binding can also be used to focus the immune response to a particular 
antigen target, similar to the natural mechanism of action for antibodies in the acquired 
immune response.  Ofatumumab is an antibody which utilises this mechanism to treat 
chronic lymphocytic leukaemia by targeting natural killer cells to cancerous cells that 
express the CD20 antigen, which ofatumumab specifically binds to (Zhang 2009).  
Another mechanism for the therapeutic potential of antibodies is for them to be used as 
a vehicle for drug delivery.  For instance, the radiolabelled antibody ibritumomab 
tiuxetan is used in the treatment of non-Hodgkin’s lymphoma by bringing its conjugated 
radiation dose into the proximity of CD20 expressing cancerous cells, which focuses the 
efficacy of the treatment to where it is required while limiting the damage caused to 
healthy cells (Witzig 2000).  Due to this targeted action, the side effects of antibody 
therapy for cancer treatment are generally considered to be less severe than 
conventional cancer treatments such as chemotherapy (Chung 2008). 
With the development of human-mouse chimera antibodies in the 1990s, which could 
better evade the immune systems of patients and provide treatment without generating 
a dangerous immune reaction, therapeutic antibodies began to gain traction as both a 
viable treatment option for health services, and as a growing segment of the 
pharmaceutical market.  Subsequent developments, reviewed in (Safdari et al. 2013), 
resulted in the generation of humanised antibodies, in which only a small, key 
component of the variable region is of non-human origin, and eventually in the 
production of fully human antibodies which are indistinguishable from a immunogenic 
perspective from the patient’s own adaptive immune response.   
Chapter 1 Introduction  
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These ground-breaking developments, together with the relative tolerability of side 
effects and the wide range of current and potential antigenic targets, have resulted in 
monoclonal antibodies being commercial successes as well as a therapeutic success.  
Global sales of monoclonal antibodies reached $63 billion in 2013, and the market is 
expected to grow by 5% each year (Walsh 2014).  However, the cost of development for 
antibodies, as for any drug, is extremely high, and was estimated to be $2.6 billion per 
FDA approved drug in 2014 (DiMasi et al. 2016).  This development cost has risen on an 
average of 8.2% each year due to a number of factors such as the increasing complexity 
and stringency of clinical trials, together with the increasingly high standards and low 
success rate for regulatory approval, where only 11.83% of drugs entering clinical trials 
will achieve approval for market (DiMasi et al. 2016).  In order to compensate for these 
spiralling costs, and to ensure that drugs remain affordable for patients and health 
services, any drugs which make it to market must be as profitable as possible by having 
the highest yield for the lowest production cost.   
Efforts made towards achieving this ideal yield have been largely successful, and 
production methods for monoclonal antibodies have been steadily optimised over the 
last two decades to obtain antibody titres 100 fold higher than those reported in the 
1990s.  Yields now routinely meet 1g/L, occasionally as much as 10g/L (Wurm 2004) and 
this substantial improvement in the rate of production has been achieved by a number 
of strategies to amplify and optimise the growth of cultured cell lines, as well as in 
improving mechanisms for enhancing transcription, translation and secretion of 
proteins.  These strategies will be summarised and discussed below.  
1.1.2 Overview of therapeutic antibody production 
Generally, the industrial production of therapeutic antibodies is performed in large-
scale suspension cultures of mammalian cells.  These cells are preferentially used over 
prokaryotic or lower eukaryotic cell lines due to their innate capacity to secrete 
exogenous proteins in a bio-active form with the appropriate tertiary structure and 
glycosylation profile for use in human patients.   
The procedure for producing a desired therapeutic protein in a mammalian host cell 
line, reviewed in (Jayapal et al. 2007), is a multi-step process that usually takes around 
three months.  Firstly, the DNA sequence for the protein of interest must be known, and 
this is incorporated into an appropriate mammalian expression vector to be transfected 
into the cells.  Generally the expression vector is stably incorporated into the host cell 
genome, though transient expression systems can be used for smaller, pilot scale 
production.  In a stable integration, the specific site of transgene integration will vary 
Chapter 1 Introduction  
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on a cell-by-cell basis to result in a mixed population of high expressing, low expressing 
and non-expressing cells, due to the presence of enhancing or repressing elements 
acting on the region of the chromosome where gene integration occurred.  In order to 
obtain a homogenous population of high expressing cells, the mixed population must be 
subjected to clonal selection, where the presence of a co-transfected antibiotic 
resistance gene is used to isolate transgene expressing cells from non-expressing.  
Clonal populations derived from single expressing cells can then be obtained by limiting 
dilution.  
The extent of antibody expression is then screened for.  Clones with a high yield of 
antibody can be identified through labour-intensive methods such as antibody capture 
ELISA, or by high throughput methods like fluorescence activated cell sorting (FACS) to 
detect the presence of either secreted protein or a co-transfected fluorescent protein.  
Dedicated systems for the high throughput screening of clones are also available.  One 
such system is ClonePix (Genetix), which uses a fluorescently-tagged antibody binding 
reagent to identify clones growing in the presence of an abundance of secreted 
antibody.  To illustrate the timescales involved with clonal selection: capture ELISA can 
screen the productivity of 1000 clones in eight weeks, whereas the ClonePix system can 
screen 10,000 clones in three weeks (Dharshanan et al. 2011).  After screening, high 
yield clones are expanded over many passages into a homogenous culture of high 
producing cells.  Culture volumes of up to 10,000 L can be achieved in stirred-tank 
bioreactors, capable of producing kilograms of therapeutic protein.   
1.1.3 Optimisation of therapeutic antibody production 
The described process of generating an antibody producing cell line has been steadily 
optimised at each stage in a variety of experiments performed over many years in order 
to increase the final yield of antibody.  Improvements to final product yield can be 
achieved by changes to the culture method, as well as in genetic manipulation of the 
cells and the design of expression vector used.  For instance, it was observed that 
decreasing the temperature of growth from 37°C to 30°C resulted in an increase in the 
productivity of a model protein, secreted alkaline phosphatase (SEAP), by 1.7 - 3.4 fold 
(Kaufmann et al. 1999).  This effect was attributed to an activation of a cold-specific 
signalling response that affected post-translation modifications, as two endogenous host 
cell line proteins were found to be phosphorylated after the culture temperature had 
been lowered to 30°C.  The drop in temperature also caused cell cycle arrest in G1 
phase. 
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Another strategy for increasing yield is the addition of sodium butyrate (NaBu) to cell 
cultures.  This compound is known to improve yield of recombinant proteins, and 
reported increases have ranged from 2 fold to a 9 fold increase, depending on the 
protein expressed (Gorman et al. 1983; Palermo et al. 1991).  Although the mechanism 
is not fully understood, it has been proposed that NaBu functions as an inhibitor of 
histone deacetylase to result in chromatin that is hyper-acetylated in treated cells 
(Kruh 1982).  This hyper-acetylation locks chromatin into an open state which makes it 
more readily accessible by transcription factors and polymerases for gene expression.  
One detrimental effect of NaBu treatment is that it lowers the rate of growth and the 
viable cell density of treated cultures, although it has been reported that this can be 
alleviated by supplementation with N-acetylcysteine, which improves culture viability 
but does not compromise the improvements in yield resulting from NaBu treatment 
(Chang et al. 1999).  It is thought that N-acetylcysteine functions as an antioxidant and 
improves viability by removing reactive oxygen species that are generated by NaBu (Oh 
et al. 2005).   
Similar to the proposed mechanism of NaBu function, another commonly used 
mechanism for improving transgene expression through chromatin modification is in the 
use of scaffold/matrix attachment regions (S/MARs).  These are DNA elements flanking 
a gene that bind to the nuclear scaffold/matrix and are used to hold the chromatin 
structure of the gene of interest in an open state, allowing for easier access by 
transcription factors and, therefore, faster gene transcription.  These DNA elements are 
found in many endogenous genes to enhance expression, and S/MAR sequences can be 
incorporated into the transgene expression vector to improve the final yield of 
recombinant protein (Phi-Van et al. 1990; Zahn-Zabal et al. 2001).   
Translation of exogenous proteins can also be improved by codon optimisation, where 
the sequence of the transgene is optimised at the nucleotide level to use codons more 
commonly found in the host cell line species.  This optimisation does not alter the 
amino acid sequence of the protein, and its benefit is based on the alleviation of 
bottlenecks caused by differences in the abundance of tRNA molecules, where a certain 
tRNA molecule could be very commonly required in one species and therefore expressed 
at a high level, but is expressed at low levels in another species.  For instance, it was 
reported that altering the DNA sequence of the human interferon gamma (INFγ) gene to 
use codons more commonly found in the Chinese hamster allowed for a ten-fold 
increase in the expression of INFγ from Chinese Hamster Ovary (CHO) cells than if the 
nucleotides of the native human DNA sequence were used (Chung et al. 2013). 
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1.1.4 History of Chinese Hamster Ovary (CHO) cells in bioprocessing 
A number of cell line types have been used in the industrial production of monoclonal 
antibodies, such as the Human Embryonic Kidney line HEK293 and mouse myeloma-
derived NS0 cells, but the industry standard is the Chinese Hamster Ovary (CHO) cell 
(Wurm 2004).  This cell line accounts for 70% of all recombinant proteins produced, and 
sales of recombinant proteins produced in CHO cells are worth $30 billion per year 
worldwide (Jayapal et al. 2007).   
The history of the use of Chinese hamsters (Cricetulus griseus) in biological research 
and bioprocessing, reviewed in (Jayapal et al. 2007) and (Yerganian 1972), began with 
their use as a disease model organism since 1919, where they were used to study 
pneumonia.  After the discovery that the hamster had a low chromosome number, with 
ten autosomal chromosome pairs and two sex chromosomes, and that these 
chromosomes were larger than for other model organisms, the species was used 
extensively in genomics, radiation and mutagenesis studies.   
Ovary tissue was extracted from a female hamster in the late 1950s, and was trypsinised 
and grown by in vitro culture methods for use in genetic studies (Puck et al. 1964; Tjio 
and Puck 1958).  These original Chinese hamster ovary cells appeared to be 
predominantly fibroblasts, and were maintained in continuous culture for ten months.  
As these cells did not display the normal senescence associated with multiple passages 
in long-term in vitro culture, it is thought that the cells were able to spontaneously 
immortalise by an unknown mechanism (Wurm 2013).  After ten months in culture, it 
was published that the cells had changed from a recognisably fibroblast morphology to 
an ‘epithelioid’ shape, and proline auxotrophy was also reported in this early culture, 
suggesting that genomic mutations had occurred (Puck et al. 1964). 
Although there were many poorly understood aspects to this early CHO cell line, there 
were also many advantages in their use over other cell models of the time, and CHO 
cells were soon gifted to a number of interested laboratories.  The cells were known to 
be amenable to in vitro culture and had fast generation times, leading to their use 
becoming more established and widespread.  Cultures were found to be relatively easy 
to synchronise through cell-cycle arresting drugs, leading to their use in cell 
proliferation studies, and their unstable genome made them useful for investigating 
chromosome abnormalities and mutagenesis (Chasin and Urlaub 1975; Kao and Puck 
1967).  
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Figure 1-1 – Cartoon of karyotypes from Chinese hamster and CHO DG44 cells. 
Inherent genomic instability in CHO cells led to the spontaneous translocation and 
deletion of chromosome sections, and to the generation of a ‘quasi-diploid’ karyotype.  
Autosomal Chinese hamster chromosome pairs are numbered from 1 to 10, whereas CHO 
chromosomes do not generally form recognisable pairs and are individually named from 
A to T.  CHO chromosome sections are coloured according to their estimated Chinese 
hamster homologue.  Adapted from (Cao et al. 2011) Figure 1.  
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Due to this well-documented genomic instability of CHO cells, the karyotype of modern 
CHO lineages differs greatly from that of the Chinese hamster, and gene inactivation 
and chromosomal arrangements have led to CHO cells being effectively ‘quasi-diploid’, 
as the majority of CHO chromosomes no longer form recognisable pairs (Cao et al. 
2011).  Decades of isolated in vitro culture of this notoriously unstable cell line led to 
the emergence of a variety of CHO subtypes (reviewed in (Wurm 2013).  The CHO-K1 
lineage is believed to be the most closely related to the original CHO cells grown by 
Puck and Kao, and is one of the most widely used subtypes.  Another notable subtype is 
the CHO-S lineage, used throughout this project, which is derived from cells grown at 
the University of Toronto after being adapted for suspension culture (Thompson and 
Baker 1973).  CHO-S is advantageous over other CHO subtypes such as CHO-K1 when 
growing in large-scale suspension cultures, and is therefore a commonly used subtype in 
the bioprocessing industry.   
Another subtype used in industrial scale recombinant protein production is CHO DG44, 
an auxotroph lineage that requires the addition of glycine, hypoxanthine and thymidine 
to the culture medium, in addition to the proline auxotrophy which is a characteristic of 
all CHO lineages (Wurm and Hacker 2011).  The CHO DG44 subtype was purposefully 
engineered to lack the dihydrofolate reductase (DHFR) enzyme required for the 
synthesis of hypoxanthine and thymidine from folate (Urlaub and Chasin 1980), with the 
aim of co-transfecting the required DHFR gene alongside a gene of interest for stable 
protein expression.  Clones with a high uptake of the gene of interest will have high 
uptake of DHFR, and better survival in a culture environment lacking glycine, 
hypoxanthine and thymidine.  The addition of the folic acid analogue methotrexate 
(MTX) to this system reduces the activity of DHFR so that only clones with a high copy 
number of transfected DHFR, and consequently the gene of interest, will be able to 
survive, and is, therefore, used as a method of increasing gene of interest uptake.  The 
DHFR system of stable gene transfection and the utilisation of MTX has resulted in an 
increase in antibody titres, and it is one of the main reasons why CHO cells are the 
industry standard in recombinant protein production today (Kaufman et al. 1985). 
There are many other desirable qualities in CHO cells that make them preferred host 
cell lines in the modern bioprocessing industry (reviewed in (Kim et al. 2012) and 
(Mason et al. 2012)).  For instance, CHO-S and CHO DG44 cells are easily adaptable to 
grow in large suspension cultures, allowing for high cell densities and higher yields of 
secreted protein.  In addition to this, serum-free medium can be readily used in these 
cultures, which reduces potential sources of product contamination.  Also, proteins 
made in CHO cells have a glycosylation profile similar to that of human proteins, due to 
99% of human glycosylation enzymes having a homologue in CHO (Xu et al. 2011).  This 
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allows the recombinant proteins from CHO cells to be safely and effectively used in 
human patients.  Another benefit is that, due to its popularity and long history of use, it 
is relatively easy to be granted approval from regulatory bodies to license new products 
derived from CHO cells, saving time and money and reducing the risk of rejection (Kim 
et al. 2012).  The rate of transgene expression can also be strongly amplified in CHO 
cells using the DHFR system, or the similar glutamine synthetase (GS) gene amplification 
system, to screen for transfected clones with the most favourable growth and secretion 
properties.  
The productivity of high yield CHO lineages is now reported to be in the region of 40-50 
pg of antibody per cell per day (Reinhart et al. 2015; Zboray et al. 2015).  However, 
despite these advances in production methods, bottlenecks that limit the yield from 
CHO cells are still thought to exist, particularly in post translational steps in the 
secretory process such as protein folding and assembly (Bibila and Flickinger 1992; 
Reinhart et al. 2014).  A number of strategies have been investigated to remove these 
hypothetical assembly bottlenecks and improve the rate of recombinant protein folding.  
These strategies are based on the structural details of the protein of interest and the 
mechanisms by which it folds. 
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1.2 Protein folding and disulphide bond formation 
1.2.1 Structure and folding of antibodies 
Antibodies are composed of two light chains (LC) and two heavy chains (HC) connected 
by disulphide bonds to form a Y-shaped tetramer.  There are two types of light chain: κ 
and λ, and each of these chains is composed of one constant domain, CL, and one 
variable domain, VL.  Each heavy chain is composed of four domains: three constant 
domains, CH1, CH2 and CH3, which form the constant region, and one variable domain, 
VH, which forms the antigen binding site together with VL (Huber et al. 1976).  The 
structure of antibodies can be subdivided into two antigen binding fragments (F(ab)), 
consisting of the VH, VL, CH1 and CL domains, and one crystallised fragment (Fc), 
consisting of the CH2 and CH3 domains.  The terms F(ab) and Fc are used to describe 
the structural fragments generated when IgG is treated with the protease pepsin.   
There are five types of heavy chain constant region: μ, γ, α, δ and ε, and each of these 
can bond with either of the two light chain types (Alt et al. 1987).  Depending on the 
type of CH region present, the Ig tetramer can be categorised into one of the isotypes 
IgM, IgG, IgA, IgD and IgE, which correspond to their CH region Greek letter equivalents.  
The number of disulphide bonds in these isotypes varies, and ranges from 16 to 28 bonds 
(Borth et al. 2005).  Each isotype can also be further subdivided into subtypes, for 
example IgG has four subtypes named IgG1 – 4.  These subtypes vary in both their amino 
acid sequence and in the positions of their disulphide bonds; factors which result in 
variation in their properties such as in their stability.  This variation is of such 
significance that the IgG subtypes vary in their stability and have different functions 
within the immune system. 
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Figure 1-2 – Structure of Immunoglobulin G (IgG).    
The structure of IgG consists of two heavy chains (blue) and two light chains (green) 
connected by interchain disulphide bonds.  The highly specific antigen binding site is 
formed from the variable regions, VH and VL.  The quaternary structure of IgG can be 
divided into two antigen binding fragments (F(ab)), consisting of the VH, VL, CH1 and 
CL domains, and one crystallised fragment (Fc), consisting of the CH2 and CH3 
domains.  N-linked oligosaccharides are shown on the CH2 domain in grey.  Adapted 
from (Feige et al. 2010) Figure 1A. 
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A high degree of variability in the antigen binding site is essential for the adaptability 
and function of all antibodies.  This variability is generated by the shuffling of three 
genes: a variable, diversity and joining gene, which are combined at the DNA level to 
form a single allele (Early et al. 1980; Maki et al. 1980).  The joining of these three 
genes is quite crude, which helps to introduce variations into the DNA sequence to 
result in an increase in the variability of the region (Alt et al. 1987).  In addition, 
variability is increased by the process of class switching, where the VH region is 
removed from the IgM constant region and recombined to any of the other constant 
regions (Calame et al. 1980).  While these processes are essential for the function of 
antibody molecules, they also increase the risk of generating non-functional proteins 
that cannot be folded or secreted correctly.  Because of this, antibody production 
depends heavily on a strict quality control system in the ER to ensure that only correctly 
folded and functional antibodies leave the ER, and the misfolded molecules are 
disposed of by the 26S proteasome by the process of ER associated degradation (ERAD). 
The folding of IgG is a multi-step process that involves the interaction of nascent HC 
and LC with the chaperone BiP; members of the Protein Disulphide Isomerase (PDI) 
family of oxidoreductases, which are responsible for the insertion of disulphide bonds 
into folding proteins; and Peptidyl-Prolyl Isomerase (PPIase), which catalyses the 
isomerisation of proline residues.  Upon entering the ER, the HC and LC begin folding 
cotranslationally (Bergman and Kuehl 1979).  Hydrophobic regions on these folding 
chains attract the binding of BiP, which retains the chain in the ER to allow sufficient 
time for complete folding (Haas and Wabl 1983).  The folding of each domain of the HC 
and LC requires the isomerisation of a conserved proline residue from a trans to a cis 
conformation by PPIase (Lilie et al. 1995), and the formation of an intrachain disulphide 
by PDI family members (Roth and Pierce 1987).  These two steps are sufficient for the 
folding of all antibody domains (Feige et al. 2004), with the exception of the CH1 
domain, which remains unfolded and bound by BiP (Feige et al. 2009).  When folding of 
the CH3 domain is completed, the HC forms a homodimer which is stabilised by an 
interchain disulphide bond at the hinge region (Baumal et al. 1971).  The CL domain of 
the folded LC then displaces BiP from the CH1 domain and enables it to finish folding 
(Feige et al. 2009).  The final step in the formation of the IgG tetramer is the insertion 
of an interchain disulphide bond between the LC and HC, at the CL and CH1 domains 
(Huber et al. 1976), and this process is now known to be performed by PDI (Roth and 
Pierce 1987).  The completed, functional molecule can then be exported from the ER to 
the Golgi, from where it can be secreted from the cell.   
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Figure 1-3 – Folding of antibody chains and formation of the IgG tetramer 
IgG heavy chain (HC, shown in blue) and light chain (LC, shown in green) begin to fold 
co-translationally upon entering the ER.  BiP attaches to hydrophobic regions on the 
CH1, CH3 and VL domains and retains the unfolded chains within the ER.  The CL 
domain folds so rapidly that BiP does not bind.  After a conserved proline residue on 
each of the domains is converted from a trans to a cis isomerisation, the VH, CH2 and 
CH3 domains finish folding and intrachain disulphide bonds are inserted by PDI family 
members to stabilise their structure.  The folded CH3 domain induces HC dimerisation 
and an interchain disulphide bond is formed between HCs at the hinge region.  The LC 
folds in parallel to the HC, and the CL domain of the folded LC is able to displace BiP 
from the unfolded CH1 domain.  This brings LC and HC into close proximity, inducing the 
CH1 domain to finish folding, and enabling PDI to insert a final interchain disulphide 
between HC and LC.  This completes the folding of the IgG tetramer, and the protein is 
then exported to the Golgi for secretion from the cell.  Adapted from (Feige et al. 
2010), Figure 4. 
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1.2.2 Role of Protein Disulphide Isomerase family members 
Disulphide bonds are essential for the correct tertiary structure, and therefore the 
correct function, of the majority of secreted proteins including antibodies.  While the 
secondary structure of a protein can usually form spontaneously alongside translation 
through the collapse of hydrophobic residues to the centre of a protein (Fedorov and 
Baldwin 1997), disulphide bond formation is an active process catalysed by members of 
the PDI family of proteins, the most studied of these ER-resident proteins being the 
eponymous PDI (Venetianer 1966).  PDI family members are able to form disulphide 
bonds in newly synthesised proteins, break bonds in proteins about to be degraded, or 
rearrange bonds already formed.  These processes involve the shuttling of electrons 
between the client protein and the active site of the thioredoxin-like domain(s) of PDI 
family members, which contain a conserved CYS-X-X-CYS (CXXC) motif (Chivers et al. 
1996).   
There are more than 20 known PDI family members (reviewed in (Okumura et al. 2015).  
Although these members differ in their amino acid sequence and in the extent of 
their catalytic activity and function, they share a degree of domain structure 
homology, and all contain at least one thioredoxin-like domain.  Some PDI family 
members are able to reduce and oxidise disulphide bonds equally well, such as the 
eponymous PDI, while others specialise in the reduction of disulphide bonds, such as 
ERdj5 (Oka et al. 2013).  Others are catalytically inactive but assist with the activity of 
other family members, such as ERp27, which is thought to bind to and regulate the 
activity of ERp57 by competing with its binding to calreticulin (Kober et al. 2013).  
Another example of a catalytically inactive family member is ERp44, which retains a 
number of ER resident proteins which lack the usual KDEL retention motif within the ER, 
and has Ero1α as a notable client protein (Anelli et al. 2003; Otsu et al. 2006).  There is 
a degree of redundancy between the functions of the many PDI family members; 
however, some are more specific in their protein substrates than others.  For instance, 
ERp57 specifically binds to glycoproteins (Jessop et al. 2007), and P5 forms a non-
covalent complex with BiP and interacts with BiP client proteins, including IgG heavy 
chains (Jessop et al. 2009).  Overall, the numerous PDI family members work in concert 
to ensure the efficiency and accuracy of disulphide bond formation. 
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Figure 1-4 – Disulphide bond formation by PDI family members and the role of Ero1α. 
Sulfhydryl groups on the cysteine residues of proteins can be converted into a disulphide 
bond in a reaction catalysed by oxidised PDI.  Disulphide bonds that are not a 
component of the protein’s native structure can also be reduced by PDI, and repeated 
rounds of sulfhydryl reduction and oxidation can occur before the protein’s native 
structure is obtained.  The oxidation of a client protein reduces the catalytic site of 
PDI, and this must be reoxidised before disulphide bond formation can occur again.  The 
reoxidation of PDI is performed by Ero1α, which generates a disulphide bond in its own 
active site through the conversion of molecular oxygen into hydrogen peroxide, and this 
bond is then transferred to PDI.  Adapted from (Bulleid 2012) Figure 1. 
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1.2.3 Function and regulation of ER oxidoreductin 1  
The formation of disulphide bonds is facilitated by the oxidising environment of the ER, 
which is maintained by an abundance of glutathione in the GSSG oxidised form, relative 
to its reduced GSH form (Chakravarthi and Bulleid 2004).  However, this environment is 
not sufficient to recycle and reoxidise PDI after a disulphide bond is transferred into a 
client protein.  In order to ensure that PDI is efficiently recycled and able to continually 
perform its functions, PDI is reoxidised by ER oxidoreductin 1 (Ero1).  In mammalian 
cells, this reoxidation is performed by the Ero1 family members Ero1α (Cabibbo et al. 
2000) and Ero1β (Pagani et al. 2000).  Ero1α is ubiquitously expressed in all tissues, 
whereas Ero1β is only expressed in the pancreas and has a role in insulin synthesis and 
glucose homeostasis (Zito et al. 2010).  Parallel pathways exist for the reoxidation of 
PDI family members that are mediated by quiescin sulfhydryl oxidase (QSOX), 
peroxiredoxin 4 (PRDX4), glutathione peroxidase 7 and 8 (GPX7 and GPX8) and vitamin K 
epoxide reductase (VKOR) (reviewed in (Bulleid and Ellgaard 2011).  These pathways 
operate independently of Ero1α, and due to this redundancy, mammalian cells can 
survive the knockout of both Ero1α and Ero1β (Zito et al. 2010).  However, in yeast cells 
the oxidation of PDI is performed solely by Ero1p, and the knockout of yeast Ero1p is 
lethal (Frand and Kaiser 1998).   
The activity of mammalian Ero1α is tightly controlled as its reaction results in the 
formation of hydrogen peroxide, a reactive oxygen species which is damaging to 
proteins and DNA (Tu and Weissman 2002).  This regulation is controlled by the presence 
of disulphide bonds between catalytically active and inactive cysteines, which block the 
activity of the active site cysteines (Appenzeller-Herzog et al. 2008).  A similar 
regulatory strategy exists for yeast Ero1p, however, in this case the presence of the 
regulatory disulphide bond presents a physical barrier to PDI entering the Ero1p active 
site (Sevier et al. 2007).  It is thought that PDI is capable of sensing the oxidative state 
of the ER, and when a build-up of hydrogen peroxide causes the ER to become more 
oxidising, Ero1α is inactivated by the PDI family members PDI and ERp46 by the 
formation of these regulatory disulphide bonds (Shepherd et al. 2014).  As Ero1α is 
required to oxidise and activate PDI, the two enzymes exist in a negative feedback loop 
to control the extent of each other’s activity (Appenzeller-Herzog et al. 2010).  When 
the activity of Ero1α is required again the regulatory disulphides are reduced by PDI 
(Chambers et al. 2010; Inaba et al. 2010). 
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Figure 1-5 – Regulation of Ero1α activity. 
The outer active site of Ero1α has two catalytic cysteines (C94 and C99) and two 
regulatory cysteines (C104 and C131).  A disulphide bond is generated by the inner 
active site from molecular oxygen, and this is transferred to C94 and C99 in the outer 
active sire.  This bond can then be transferred to the substrate of Ero1α, PDI.  To 
regulate the activity of Ero1α, disulphide bonds are formed between the active 
cysteines and the regulatory cysteines.  These two bonds cannot be transferred to the 
PDI catalytic site, and the protein is therefore in an inactive form.  Ero1α is converted 
to and from its active form by PDI family members.  Adapted from (Bulleid and Ellgaard 
2011), Box 1, Figure 1.   
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1.3 Quality control and the Unfolded Protein Response 
1.3.1 Calnexin/calreticulin and the glycan code 
As the structure of a protein is essential for its correct function, a number of extensive 
quality control mechanisms exist within the ER which help to ensure the fidelity of 
protein folding; one of these mechanisms is the calnexin/calreticulin cycle.  When 
nascent chains enter the ER through the Sec61 translocon (Matlack et al. 1998), an 
oligosaccharide group is added to an asparagine residue on a conserved Asn-X-Ser/Thr 
motif (Helenius and Aebi 2004).  The presence of this oligosaccharide allows tracking of 
a protein within the ER, and modification of this group by the addition or cleavage of 
sugar molecules forms the basis of a ‘glycan code’, where a variety of fates can be 
specified depending on the ‘code’ of sugar molecules present on the protein (Hebert et 
al. 2005).  The initial core glycan has the structure Glc3Man9GlcNAc2, where ‘Glc’ is 
glucose, ‘Man’ is mannose and ‘GlcNAc’ is N-acetylglucosamine.  When this glycan is 
trimmed to Glc1Man9GlcNAc2 by glucosidase 1 and 2, the nascent protein is able to 
interact with the quality control lectins calnexin and calreticulin through the trimmed 
glucose moiety (Hammond et al. 1994).  Calnexin is a transmembrane protein which can 
simultaneously bind to Glc1Man9GlcNAc2 on client proteins via a carbohydrate binding 
domain, and the oxidoreductase ERp57 by a region called the P domain (Schrag et al. 
2001), bringing the nascent chain into proximity with ERp57 and enabling this PDI family 
member to assist in client protein folding (Frickel et al. 2002).  Calreticulin has shared 
functionality with calnexin, but is localised to the ER lumen as opposed to the ER 
membrane (Ellgaard et al. 2001).   
The client protein is released after interaction with calnexin/calreticulin by further 
trimming of the core glycan to Man9GlcNAc2 by glucosidase 2.  If the protein’s native 
structure has not been achieved it can be sequestered for further interaction with 
calnexin/calreticulin following reglucosylation by Uridine Diphosphate (UDP) glucose 
glycoprotein glucosyltransferase (UGGT), an enzyme that preferentially interacts with 
partially folded glycoproteins (Caramelo et al. 2004; Trombetta 2003).  Multiple rounds 
of the calnexin/calreticulin cycle can be achieved by the addition and removal of 
glucose from folding proteins, which ensures a prolonged period of time within the ER 
for the protein to interact with chaperones and oxidoreductases, and this should be 
sufficient to achieve the protein’s native structure.  If misfolding persists after multiple 
quality control cycles then further interaction with ERp57 is abandoned and the protein 
is instead targeted for ERAD. 
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Figure 1-6 – The calnexin/calreticulin quality control cycle. 
Nascent chains enter the ER through the Sec61 translocon complex, and a core glycan is 
attached to a conserved asparagine residue. Two glucose molecules (shown as yellow 
circles) are trimmed from the glycan by glucosidases 1 and 2 to enable recognition by 
calnexin and calreticulin.  The binding of calnexin/calreticulin brings the unfolded protein 
chain into proximity with the oxidoreductase ERp57, which should lead to the protein 
achieving its native structure and its subsequent export from the ER.  If this structure is 
not achieved, a glucose molecule can be reattached from UDP by UDP glucose-
glycoprotein glycosyltransferase (UGGT) to allow additional exposure to ERp57 via 
calnexin/calreticulin binding.  If the protein remains persistently misfolded, then mannose 
molecules (shown as a blue circle) are sequentially removed by ER mannosidase 1 
(ERMan1) or EDEM2, and then EDEM3 or EDEM1.  This trimming targets the protein for 
ERAD through interaction with OS-9/XTP3-B, leading to the eventual degradation of the 
protein in the 26S proteasome.  Adapted from (Chakrabarti et al. 2011) Figure 1. 
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1.3.2 ER associated degradation 
Protein misfolding and aggregation can be triggered by cellular stresses such as glucose 
starvation, hypoxia or a viral infection (Kaufman et al. 2002).  Misfolded proteins can be 
distinguished from their normal, natively folded counterparts by the presence of 
hydrophobic residues on the outside of the protein, as these are normally embedded in 
the centre of the protein when folded correctly. These hydrophobic residues are 
recognised by BiP, a chaperone which stabilises and retains misfolded client proteins 
within the ER and assists in their refolding, which is mediated by other folding factors.  
If a protein remains persistently misfolded after multiple quality control and protein 
folding cycles, it is instead targeted for ERAD. 
The degradation of terminally misfolded glycoproteins by ERAD in triggered by the 
sequential removal of two mannose groups from the core glycan.  In mammalian cells, 
the trimming of Man9GlcNAc2 to Man8GlcNAc2 is performed by ER mannosidase 1 
(ERMan1) or by ER degradation enhancing α-mannosidase like protein 2 (EDEM2) 
(Ninagawa et al. 2015; Ninagawa et al. 2014).  A second cleavage event to convert 
Man8GlcNAc2 into Man7GlcNAc2 is performed by EDEM3, and to a lesser extent by EDEM1 
(Ninagawa et al. 2015; Ninagawa et al. 2014).  Man7GlcNAc2 is recognised by the 
mannose-specific lectins OS-9 and XTP3-B, which assist in the dislocation of the 
misfolded protein to the ER dislocon.  OS-9 and XTP3-B both exhibit a mannose-6-
phosphate receptor homology (MRH) domain, through which the binding to Man7GlcNAc2 
is mediated, but display little other sequence homology (Satoh et al. 2010).  Knockdown 
of either OS-9 or XTP3-B was shown to cause mild attenuation of ERAD but a double 
knockdown caused a greater reduction in the rate of degradation, suggesting that there 
is a degree of redundancy in their functions (Hosokawa et al. 2009).  Regardless of the 
distinctions between these two lectins, both are thought to interact with the ER 
membrane protein Sel1, a component of the dislocon, through their MRH domains. 
The interaction of OS-9/XTP3-B and Sel1 brings the misfolded protein into contact with 
the dislocon machinery (Jeong et al. 2016).  In addition to Sel1, this complex of 
membrane and soluble proteins contains: ERp90 (Riemer et al. 2011) and ERdj5 (Ushioda 
et al. 2008), PDI family members which reduce any disulphide bonds in the partially 
folded amino acid chain; p97, which assists in ‘threading’ the unfolded protein through 
the dislocon channel and into the cytosol (DeLaBarre et al. 2006); and Hrd1, an E3 
ubiquitin ligase also known as synoviolin (SYVN1) which forms a structural component of 
the channel alongside Derlin1 and also catalyses the addition of ubiquitin to the protein 
to target it for degradation in the 26S proteasome (Carvalho et al. 2010; de Virgilio et 
Chapter 1 Introduction  
33 
 
al. 1999).  This complex mediates the extraction of misfolded proteins from the ER, and 
their disassembly, ubiquitination and eventual degradation in the proteasome. 
1.3.3 The Unfolded Protein Response 
These procedures for quality control ensure that, under normal physiological conditions, 
misfolded proteins are efficiently recycled or disposed of and prevented from 
accumulating in the ER.  However, under stress conditions the load of misfolded 
proteins can exceed the capacity of quality control and ERAD, allowing potentially toxic 
levels of protein accumulation and aggregation.  Under these circumstances, the 
unfolded protein response (UPR) is triggered.  This is an elaborate and extensive stress 
response utilised by the cell in order to remove aggregated proteins and restore the 
normal homeostasis of protein translation, degradation and secretion (reviewed in 
(Chakrabarti et al. 2011)).  
The first strategy undertaken as part of the UPR is for the cell to degrade untranslated 
mRNA transcripts and halt further protein translation, which prevents nascent 
polypeptide chains from entering the already-overloaded ER.  Secondly, the ER 
increases its protein folding capacity by overexpressing chaperones and by physically 
increasing in size, helping to clear the backlog of misfolded proteins.  The process of 
ERAD is also upregulated and proteins that cannot be correctly folded are retained in 
the ER then sent to the 26S proteasome for degradation (Travers et al. 2000).  If these 
two strategies are successful in clearing the build-up of aggregates then translation can 
resume and the stress response is brought to an end.  However, if the backlog cannot be 
cleared then the cell must begin its third strategy and undergo autophagy before, 
finally, apoptosis.   
The wide range of intricately-regulated functions of the UPR are mediated by three 
initial effector molecules in mammalian cells, and the downstream signalling from each 
of these three effectors form three distinct branches of activity.  There is a degree of 
cross-talk between the branches, and each branch can lead to both pro-survival and 
pro-apoptotic functions that are activated under different circumstances.  The three 
effectors of the mammalian UPR are named double-stranded RNA activated protein 
kinase (PKR)-like endoplasmic reticulum kinase (PERK), inositol requiring enzyme (IRE1), 
and activating transcription factor 6 (ATF6).  In contrast, the UPR of lower eukaryotes is 
only mediated by a single effector, Ire1p (Ron and Walter 2007).  Under normal 
physiological conditions, mammalian PERK, IRE1 and ATF6 are bound in an inactive form 
by BiP.  In the presence of hydrophobic residues found on misfolded proteins, BiP 
detaches from the UPR effectors and binds instead to the aggregates, triggering the 
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activation of downstream signalling pathways (Kebache et al. 2004).  When the stress 
response is no longer required, BiP reassociates with PERK, IRE1 and ATF6 to suppress 
their activity. 
 
  
 
Figure 1-7 – Schematic of the Unfolded Protein Response.   
In the presence of protein aggregates, BiP detaches from and activates PERK, ATF6 and 
IRE1.  PERK phosphorylates eIF2α which leads to a global attenuation of protein 
translation.  Under this circumstance, transcripts for the transcription factor ATF4 are 
more readily translated, and a number of targets downstream of ATF4 are upregulated.  
One of these targets is CHOP, which in turn upregulates GADD34.  The phosphatase 
recruited by GADD34, PP1, has the function of dephosphorylating eIF2α and relieving 
the block on protein translation.  In a second functional branch of the UPR, ATF6 is 
exported to the Golgi and cleaved to form a transcription factor, which transcribes 
XBP1u and other adaptive genes.  XBP1u is spliced by IRE1 to generate XBP1s, which is 
translated into an active transcription factor.  XBP1S upregulates chaperones, allowing 
for increased protein folding and ERAD with the aim of clearing the build-up of 
aggregates. If this strategy is unsuccessful, pro-apoptotic genes are triggered and the 
cell undergoes apoptosis.  Adapted from Chakrabarti et al, 2011 Figure 2B. 
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1.3.4 PERK branch 
PERK is a type 1 transmembrane protein consisting of an N-terminal ER stress sensing 
region that binds BiP, and a C-terminal cytosolic kinase.  The dissociation of BiP from 
the N-terminus of PERK allows for the formation of a homodimer, and this is activated 
by subsequent autophosphorylation (Kebache et al. 2004).  The activation of PERK 
triggers the upregulation of cellular inhibitor of apoptosis (cIAP), a pro-survival factor 
(Hamanaka et al. 2009), and also mediates the attenuation of translation by 
phosphorylation of eukaryotic translation initiation factor 2 (eIF2α) (Gebauer and 
Hentze 2004).  Phosphorylated eIF2α is unable to form the eIF2-GTP-tRNAI
met complex 
required for the initiation of translation.  
The repression of protein translation is able to efficiently block the initiation of 
translation for the majority of mRNA transcripts.  However, it is not ubiquitous, and one 
transcript which is known to be able to bypass the block is activating transcription 
factor 4 (ATF4).  Transcripts for ATF4 are constitutively expressed, but are only 
translated under the circumstances of repressed translation induced by peIF2α (Lu et al. 
2004; Vattem and Wek 2004).  ATF4 transcripts have two open reading frames in the 
5’UTR.  Under unstressed conditions, the ribosome complex will translate uORF1 and 
then the 60S ribosome subunit will dissociate.  Due to the abundance of 
unphosphorylated eIF2α, the 60S subunit will quickly reassociate with the 40S subunit to 
resume translation at the next available start codon.  This codon initiates the inhibitory 
uORF2 frame, which translates to a truncated protein and also bypasses the coding 
region for ATF4.  During stress conditions, the reinitiation of translation is less efficient 
due to phosphorylated eIF2α, and the ribosome complex does not reform quickly enough 
to translate uORF2, leading to the resumption of translation at the next available start 
codon, which is the start codon for ATF4 translation.   
ATF4 functions as a transcription factor, and a key UPR component that upregulates 
amino acid synthesis and transport, as well as the secretion of folded proteins, and also 
improves resistance to oxidative stress, all of which assist in alleviating the protein 
folding load of the stressed ER (Harding et al. 2003).  In addition to these pro-survival 
effects, ATF4 upregulates a transcription factor known for its role in apoptosis, C/EBP 
homologous protein (CHOP) (Gachon et al. 2001).  CHOP is thought to promote apoptosis 
on stressed cells by downregulating the pro-survival factor Bcl2 (McCullough et al. 
2001), and by the upregulation of growth arrest and DNA damage inducible protein 34 
(GADD34) (Marciniak et al. 2004), of which the pro-apoptotic function will be discussed 
later. 
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If the attenuation of translation imposed by peIF2α and the pro-survival activity of ATF4 
are able to relieve the build-up of misfolded proteins, then the block on translation can 
be subsequently released.  This function is performed by GADD34, which is induced by 
the transcription factor activity of CHOP and recruits protein phosphatase 1 (PP1) to 
dephosphorylate eIF2α (Novoa et al. 2001).  This action releases the repression of 
translation maintained by the phosphorylation of eIF2α.  However, as the block on 
translation is put in place to protect the ER from an excessive load of unfolded proteins, 
if the block is released in severely stressed cells then the resumption of translation and 
the import of nascent chains into an overloaded ER is fatal to the cell (Marciniak et al. 
2004).  This is used as a mechanism of apoptosis induction in the terminal stages of UPR 
signalling. 
1.3.5 ATF6 branch 
ATF6 has two Golgi-localisation sequences on its C terminal, ER lumen domain, which 
are exposed when BiP dissociates from ATF6 in the presence of misfolded proteins (Shen 
et al. 2002).  With these sequences revealed, the entire 90kDa transmembrane protein 
is translocated from the ER membrane to the Golgi by COPII vesicle mediated ER-Golgi 
transport (Haze et al. 1999).  After export, the N-terminus of ATF6 is cleaved by 
sequential activity of site-1 and site-2 proteases, and exported from the Golgi to the 
nucleus as a 50kDa transcription factor (Chen et al. 2002).  The transcription factor 
ATF6 transcribes genes with either ATF/cAMP responsive elements (CRE) (Wang et al. 
2000) or ER stress elements (ERSE) (Kokame et al. 2001).  Genes upregulated by ATF6 
include chaperones and folding factors, such as BiP and PDI, as well as a key component 
of the UPR, X-Box Binding Protein 1 (XBP1), a transcription factor which will be 
discussed in more detail later (Yamamoto et al. 2007).   
Like PERK, ATF6 is also able to induce apoptosis in the event of prolonged UPR 
activation, and this is performed through the upregulation of regulator of calcineurin 1 
(RCAN1) (Belmont et al. 2008).  RCAN1 sequesters the calcium-activated phosphatase, 
calcineurin, which would otherwise be able to dephosphorylate Bcl2 antagonist of cell 
death (BAD).  In its phosphorylated state, BAD sequesters the pro-survival protein Bcl2, 
leading to a pro-apoptotic environment (Wang et al. 1999). 
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1.3.6 IRE1 branch 
Similar to the activation of PERK and ATF6, IRE1 activity is generally thought to be at 
least partially mediated by the chaperone BiP.  During stress conditions, BiP dissociates 
from IRE1, leading to the formation of IRE1 homodimers and subsequent 
autophosphorylation (Bertolotti et al. 2000; Kimata et al. 2003).  Once active, the IRE1 
homodimer is then able to bind directly to misfolded proteins to mediate its own 
downstream signalling (Gardner and Walter 2011; Kimata et al. 2007).  This model is 
controversial, however, and it has also been proposed that IRE1 is not capable of 
binding to misfolded proteins and BiP dissociation is sufficient to trigger IRE1 activity 
(Oikawa et al. 2009).  An alternate model is that IRE1 can be activated either directly or 
through the dissociation of BiP, but these are two distinct mechanisms that respond to 
different stress stimuli (Promlek et al. 2011). 
Once activated, IRE1 has two distinct modes of activity.  It has an endoribonuclease 
domain that mediates the cleavage of certain RNA molecules, and a serine/threonine 
kinase domain.  The most well characterised substrate of the IRE1 endoribonuclease 
domain is XBP1.  The gene expression of XBP1 is constitutive under normal conditions 
and, as previously mentioned, it is upregulated by ATF6 during the UPR (Yamamoto et 
al. 2007).  However, transcripts of XBP1 must be spliced by IRE1 to be converted into an 
active form that can be translated into the transcription factor XBP1S (Lee et al. 2002).  
The removal of a 26bp intron from the transcript causes a shift in the open reading 
frame, which leads to the translation of a 370 amino acid protein, as opposed to the 266 
amino acid chain that is translated from the unspliced transcript.  The splicing of XBP1 
by IRE1 is considered unconventional as occurs only in the cytoplasm and it does not 
utilise the usual spliceasome machinery.  It is instead performed entirely by IRE1, which 
performs the cleavage of the intron, and the tRNA ligase complex component RTCB, 
which ligates the molecule back together after the intron is excised (Jurkin et al. 2014).  
A small degree of XBP1 splicing occurs under normal physiological conditions (Wang et 
al. 2015), but it is far more prolific under conditions of ER stress where IRE1 is 
activated.   
The XBP1S transcription factor generated from spliced XBP1 transcripts upregulates a 
range of chaperone genes and physically expands the contents of the ER, thereby 
increasing its capacity to fold proteins (Lee et al. 2003).  XBP1S has also been shown to 
upregulate secretory pathways and increase ribosome numbers, giving it a wide range of 
adaptive functions (Travers et al. 2000).  Another gene upregulated by XBP1S is p58IPK, 
an inhibitor of PKR and PERK, which represents one degree of cross-regulation between 
the UPR branches.  High levels of p58IPK were shown to cause a reduction in eIF2α 
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phosphorylation, a major function of PERK (van Huizen et al. 2003).  As the upregulation 
of p58IPK occurs many hours after the activation of PERK, it is thought that p58IPK 
signalling represents the shift from the adaptation strategy of the UPR to the cell death 
phase (Szegezdi et al. 2006), and therefore XBP1, like many aspects of the UPR, has 
downstream effects that can be both pro-apoptotic and pro-survival. 
In yeast, translation of the unspliced form of XBP1 is blocked by a mechanism that is 
poorly understood, and only the orthologue of XBP1s, hac1, can be translated (Hetz and 
Glimcher 2009).  However, in mammalian cells XBP1u is translated into XBP1U, a protein 
with a rapid rate of degradation (Chen et al. 2014) that functions by sequestering bound 
proteins to the 26S proteasome for degradation (Yoshida et al. 2006).  Two known 
substrates of XBP1U are XBP1S (Yoshida et al. 2006) and the active form of ATF6 
(Yoshida et al. 2009), and XBP1U therefore functions as a regulator of the activity of 
these two proteins by downregulating these potent signalling molecules when the UPR 
stress response has ended. 
IRE1 can also mediate other adaptive functions through its endoribonuclease domain 
beside those that are related to XBP1.  Substrate transcripts that display the same 
stem-loop structure as XBP1u are degraded by cleavage (Moore and Hollien 2015) as part 
of a process named IRE1-mediated RNA degradation (RIDD) (Hollien and Weissman 
2006).  This degradation occurs predominantly in transcripts for transmembrane 
proteins, and it is thought that these proteins are especially challenging for the ER to 
fold and export.  The degradation of these transcripts, therefore, provides a protective 
effect to a stressed ER, similar to the principle behind the attenuation of protein 
translation by PERK (Han et al. 2009; Hollien et al. 2009).  
The IRE1 cytosolic kinase domain mediates pathways that are largely triggered late in 
the UPR and are pro-apoptotic (Yamamoto et al. 1999).  For instance, IRE1 binds a 
mediator protein, tumour necrosis factor receptor associated factor 2 (TRAF2), to 
interact with Jun kinase and p38MAP kinase (Urano et al. 2000b), which promote cell 
death by downregulation of the pro-survival factor Bcl2 (Yamamoto et al. 1999).  
Phosphorylation of Bim by these kinases also promotes Bax-mediated apoptosis (Lei and 
Davis 2003). 
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Figure 1-8 – Generation of the transcription factor XBP1S by splicing of XBP1 
transcripts. 
The reading frame of unspliced XBP1u transcripts has a stop codon after 801 
nucleotides, which translates to a polypeptide chain of 266 amino acids and a protein of 
approximately 35kDa.  Removal of the 26bp intron from XBP1u transcripts by IRE1 
creates a frameshift in the open reading frame.  This new reading frame has a stop 
codon after 1113 nucleotides, which translates to a polypeptide chain of 370 amino 
acids and a protein of approximately 60kDa that functions as a transcription factor.  
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1.4 Optimisation of protein production 
1.4.1 Increasing productivity via genetic manipulation of folding factors 
In addition to the previously described optimisation of host cell lines described in 
section 1.1, protein production can also be improved through genetic manipulation.  
The overexpression of an individual gene in a host cell line can often achieve the effect 
of amplifying its activity, although it should be noted that the effect of gene 
overexpression is not always predictable or beneficial.  A number of gene manipulation 
strategies have been published with the aim of increasing the productivity of an 
exogenous protein from a host cell line.  One such strategy is to optimise protein folding 
by amplification of folding factors, including PDI family members and chaperones.   
The rationale behind this strategy is that it has been observed that recombinant gene 
transcript levels (Schroder and Friedl 1997) and gene copy number (Schroder et al. 
1999) do not directly correlate with the amount of secreted antibody, suggesting that 
there is a bottleneck in protein production in post-translational steps such as protein 
folding (Mohan and Lee 2010).  Due to this observation, it was hypothesised that 
overexpressing PDI or chaperones such as BiP may result in a faster rate of protein 
production and higher yields due to an increase in the rate of disulphide bond 
formation.  This result was achieved in yeast (Xu et al. 2005); however, no such result 
has been obtained in mammalian cells.  PDI family members were overexpressed in LBO-
1 cells, a CHO derivative cell line, and no increase was observed in IgG4 formation 
(Hayes et al. 2010).  The discrepancy between these two results highlights the 
differences between experiments performed in higher eukaryotes, where there is known 
overlap between the functions of folding factors, compared to lower eukaryotes, where 
these proteins are essential.  It is also an example of the unpredictable nature of the 
ultimate effects of gene overexpression.   
It has also been predicted that the recycling of PDI could be a rate limiting step in 
protein production (Lyles and Gilbert 1991).  As this recycling reaction is now known to 
be catalysed by Ero1, the effect of the overexpression of Ero1 in host cell lines has been 
investigated.  Ero1p was overexpressed in yeast and an increase in protein production 
was observed (Shusta et al. 1998).  However, when mouse Ero1β was stably 
overexpressed in NS0 myeloma cells, no increase in monoclonal antibody production was 
observable (Hayes et al. 2010).  A small increase in yield was seen with transient Ero1α 
overexpression in CHO cells (Mohan and Lee 2010) and a greater increase when Ero1α 
and PDI were co-overexpressed.  However, this effect was only seen in transiently 
transfected cells, and stable cell lines showed a reduction in productivity.  Western 
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blotting and immunostaining showed higher levels of intracellular antibody than normal, 
suggesting that Ero1α overexpression promotes antibody retention in the ER and a 
reduction in secretion. 
As calnexin and calreticulin have an essential role in glycoprotein folding and quality 
control, the manipulation of these proteins in host cell lines has also been investigated.  
Calnexin was overexpressed alongside subunits of nicotinic acetylcholine receptor 
(AChR)2, a transmembrane channel protein, and it was reported that the folding rate of 
AChR had increased by twofold and the rate of degradation had decreased in COS and 
HEK293 cells (Chang et al. 1997).  A similar effect was observed in CHO cells, where the 
inducible overexpression of either calnexin or calreticulin increased the yield of 
recombinant thrombopoeitin (Chung et al. 2004). 
1.4.2 Increasing productivity via manipulation of the Unfolded Protein Response 
As the UPR has such a wide impact on the ability of cells to produce and fold proteins, 
and in cell survival, a number of elements of the UPR have been studied with the aim of 
exploiting in the industrial production of recombinant proteins.  For instance, the yeast 
homologue of XBP1, hac1, was overexpressed in Saccharomyces cerevisiae to achieve an 
improvement in the production of two recombinant proteins, α-amylase and 
endoglucanase.  In a mammalian equivalent to this approach, XBP1S was overexpressed 
in Chinese Hamster Ovary (CHO) cells, which resulted in an increase in the capacity of 
the ER and Golgi and a four-fold increase in the production of recombinant Vascular 
Endothelial Growth Factor (VEGF) (Tigges and Fussenegger 2006).  A similar study found 
that overexpression of XBP1S increased the production of antibody, interferon and 
erythropoietin in both CHO cells and NS0 myeloma cells (Ku et al. 2008).  This effect 
was observed when the cells’ secretory pathways were saturated, and XBP1S was 
hypothesised to be able to overcome secretory bottlenecks, but was not hypothesised to 
have an effect when the pathways were not saturated.  The inducible overexpression of 
XBP1s was also found to trigger a three-fold increase in yield of stably expressed 
antibody from CHO-K1 cells (Gulis et al. 2014).  Interestingly, this increase was 
improved further by dropping the temperature of growth from 37°C to 30°C. 
The UPR induced genes ATF4 (Ohya et al. 2008) and CHOP (Nishimiya et al. 2013) were 
overexpressed in CHO cells to achieve an increase in antithrombin III and IgG production 
respectively.  The active form of ATF6 was overexpressed by Pybus and colleagues in 
CHO cells to achieve an increase in yield of a range of different ‘difficult to express’ 
antibodies.  A similar improvement in yield was observed by this group with 
overexpression of BiP, PDI or XBP1s, and another noteworthy result was the observation 
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that reducing the extent of ATF6 or XBP1s overexpression improved the viability of the 
cell as well as the productivity of antibody, leading to an overall improvement in yield 
(Pybus et al. 2014).  Together, these studies highlight the complexity of the balance 
between protein folding, degradation and secretion in mammalian cells, and also the 
unpredictability of engineering cells to possess the optimum properties for heterologous 
protein production. 
1.5 Project aims and objectives 
The first aim of the project was to identify potential genes or signalling pathways which 
could be manipulated in order to engineer CHO-derived host cell lines with increased 
capacity for producing high yields of recombinant protein.  The initial approach to 
achieving this aim was to investigate protein folding pathways and the unfolded protein 
response, based on successes described in the literature achieved in this area.  The 
project began with an investigation into the characteristics of an existing CHO-derived 
host cell line with a known high antibody yield, with the ambition that if the 
contributing factors towards this yield were known then further improvements could be 
made when developing future host cell lines.  The cell line investigated was called CHO-
S XE and was engineered by researchers at the pharmaceutical company UCB to stably 
overexpress the active form of XBP1, XBP1s, and the oxidoreductase Ero1α (Cain et al. 
2013).  It was hypothesised that the high yield of CHO-S XE was a direct consequence of 
the activity of these two overexpressed genes, and the characterisation experiments 
performed in this cell line aimed to find to what extent this was the case. 
A second aim of the project was to obtain a greater understanding of the stress 
responses of the cell; in particular, the activity and regulation of XBP1 during the UPR.  
This aspect of the project was investigated in the CHO-S XE cell line, and also in two 
other CHO-derived cell lines with inducible overexpression of XBP1s.  By further 
elucidating the role of XBP1 in the UPR, and the attributes of cells that overexpress this 
key UPR component, it was thought that this information could contribute towards 
further improvements in the productivity and viability of antibody producing host cell 
line.  As the activity of XBP1 is known to be tightly and complexly regulated, any 
potentially novel aspects of this regulatory process were sought in order to increase the 
overall understanding of this intricate signalling process. 
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These two project aims were approached with the following objectives: 
 To characterise the high yield host cell line CHO-S XE. 
 To generate a series of CHO-derived cell lines with inducible overexpression of 
the genes XBP1s, Ero1α or GADD34. 
 To find if the overexpression of these genes individually leads to an increase in 
antibody yield.  
 To investigate the effect of co-overexpressing these genes on antibody yield. 
 To find if a chemical inhibitor of IRE1 is able to improve viability and overall 
productivity of the XBP1s inducible cell line. 
 To investigate the effect of exogenous XBP1s expression on endogenous XBP1 
expression and the regulation of IRE1 activity. 
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2.1 Materials 
2.1.1 Sources of chemicals, reagents and equipment 
Unless otherwise stated, plasticware was sourced from Falcon, general reagents were 
sourced from Fisher and tissue culture plasticware was from Corning. 
2.1.2 Solutions 
Unless otherwise stated, solutions were made up in deionised water and stored at room 
temperature. 
2.2 Cell culture methods 
2.2.1 Maintenance of cell lines 
Chinese Hamster Ovary suspension cells (CHO-S; Life Technologies) and CHO-S-derived 
cell lines were grown in a 25 mL culture volume of CD CHO medium (Gibco) 
supplemented with 4 mM glutamine (Gibco) in 125 mL vented Erlenmeyer flasks 
(Fisher). They were grown at 37°C with 95% humidity and 5% CO2 on a SeaStar shaking 
platform (Heathrow Scientific) at 120 rpm with an orbital throw of 19 mm. They were 
diluted every 3-4 days to a density of 2-3 x 105 cells/mL.   
When CHO-S cells were grown in adherent culture, the medium used was DMEM 
supplemented with 10% foetal bovine serum (FBS), 2mM glutamine, and non-essential 
amino acids at a working concentration of 10 μM for each amino acid (all Gibco).  Cells 
were grown on a stationary platform at 37°C with 95% humidity and 5% CO2, and split 
every 3-4 days using a standard trypsin protocol. Briefly, confluent cells in a T75 flask 
were washed once with approximately 8 mL of Phosphate Buffered Saline (PBS) (Gibco) 
and then treated with 1.5 mL 0.05% Trypsin-EDTA (Gibco).  The cells were incubated at 
37°C for around 5 min, and then visualised under a light microscope to confirm that the 
cells had dissociated.  Medium was added to the dissociated cells to a final volume of 10 
mL, and 1 mL of this cell suspension was added to a fresh T75 flask to achieve a 1/10 
split.  An additional 11 mL of fresh medium was added to the split cells, including any 
appropriate selection: CHO-S XE cells were grown in medium supplemented with 1 
mg/mL G418 (Sigma) and 200 μg/mL zeocin (Invitrogen); cells containing the pTetOne 
vector were grown in medium containing 5 μg/mL puromycin (Sigma); and the ER-BFP 
vector was maintained with 1mg/mL G418.   
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2.2.2 Cell count and viability  
Cells were counted and the viable cell density was calculated using a Countess II FL cell 
counter (Life Technologies) by adding 10 μL of cell suspension to 0.4% (w/v) trypan blue 
in PBS and mixing thoroughly.  The mixture was loaded onto a cell counting slide with 
10 μL into each side and inserted into the cell counter for analysis.  A Vi-CELL cell 
viability analyser (Beckman Coulter) was also used to count cells for some experiments. 
2.2.3 Cryopreservation of cells  
Suspension cell lines were counted and pelleted by low speed centrifugation, and then 
resuspended in CD CHO containing 10% (v/v) DMSO to achieve a cell density of 
approximately 1 x 107 cells/mL.  Of this suspension, 1 mL was added to a 1.5 mL 
cryovial (Alpha Laboratories) and the vial was quickly chilled to -80°C.  If long term 
storage was required, the cryovials were later transferred to a liquid nitrogen tank.  
Adherent cell lines were frozen by a similar method, but using FBS with 10% (v/v) DMSO 
instead of CD CHO.  
2.2.4 Thawing cells from frozen stocks 
Frozen cryovials were thawed carefully in a 37°C water bath and added to 9 mL pre-
warmed cell culture medium.  The cells were pelleted and resuspended in fresh medium 
and added to an appropriate cell culture flask. 
2.2.5 Generation of stable cell lines 
pTetOne stable cells were made by transfecting 4 μg of pTetOne vector (Clontech) 
containing cDNA for either GADD34, Ero1α or XBP1s into CHO-S cells, co-transfected 
with 200 ng of a linear selectable marker for puromycin (a vector:marker ratio of 20:1) 
with 4.2 μL of the transfection reagent NovaCHOice (Novagen).  Transfected cells and 
untransfected control cells were grown in a 6 cm diameter dish in adherent culture, and 
after 24 h of growth were trypsinised and 1/10 of the cells were transferred to a 15 cm 
dish and grown in 20 mL medium containing 12.5 μg/mL puromycin.  The transfected 
cells were grown for approximately 10 days, refreshing the selection medium every 3-4 
days, until single cell derived colonies started to form in the dish.  Colonies were 
identified and removed from the dish using trypsin-soaked colony discs and transferred 
into the wells of a 12 well plate, with one colony per well.  The clones were grown 
under selection for another 3-5 days until the well was confluent, then the surviving 
clones were transferred into T25 flasks and later T75 flasks.   
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To generate a cell line containing ER-localised blue fluorescent protein, XBP1-pTetOne 
cells were transfected with BFP construct (a gift from Dr Erik Snapp (Costantini et al. 
2015)) using the same method as described above.  The vector for this construct 
contained a G418 resistance gene, and therefore the linear selectable marker was not 
required.  Transfected cells were maintained under the dual selection of both 12.5 
μg/mL puromycin, to maintain the XBP1-pTetOne construct, and 2 mg/mL G418 
(Promega) to maintain the BFP construct.  Successful integration of the gene of interest 
was confirmed using western blotting. 
2.2.6 Doxycycline treatment 
Doxycycline was prepared as a 1 mg/mL solution in water.  This was shielded from light 
and stored at -20°C.  Doxycycline was diluted to 1 μg/mL in fresh medium and added to 
the cells. 
2.2.7 Tunicamycin treatment 
Tunicamycin was prepared as a 10 mg/mL stock in DMSO and stored at -20°C.  It was 
generally used at a working concentration of 10 μg/mL, unless otherwise stated. 
2.2.8 4μ8C treatment 
The IRE1 inhibitor 8-formyl-7-hydroxy-4-methylcoumarin (4μ8C) (Cross et al. 2012) was 
prepared as a 100 mM stock in DMSO.  The stock was shielded from light and stored at -
20°C.  It was used at a working concentration of 32 μM. 
2.2.9 Transient transfection 
20 μg plasmid DNA was mixed with 20 μL of the chemical transfection reagent 
NovaCHOice (Novagen) in 2 mL warm CD CHO medium. The reagents were mixed 
thoroughly and incubated at room temperature for 10 min.  After this period the 
transfection mixture was added to cells growing at a density of 1 x 106 cells/mL, for a 
total culture volume of 25 mL.  For determining antibody yield, pTetOne inducible cells 
were transfected with γ heavy chain and κ light chain of an IgG1 antibody targeting 
A33, a protein marker of colorectal cancer (Heath et al. 1997).  Transfected cells were 
split 24 h post-transfection into six flasks.  Three of these flasks were induced with 
doxycycline and three were left uninduced, and an anti-clumping agent (Gibco) was 
added at a 1:1000 dilution to all flasks.  pTetOne cell lines were grown without 
puromycin when transfected.  The cells were grown for a further three days in a culture 
volume of 12 mL, and then counted, pelleted by low speed centrifugation and the 
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medium was extracted for analysis using an antibody capture ELISA.  Medium samples 
were stored at 4°C until required. 
2.2.10 ER Tracker treatment 
ER Tracker Green BODIPY FL Glibenclamide (Molecular Probes) was dissolved in DMSO to 
a 1 mM stock concentration.  Experimentally treated cells were stained with 250 nM ER 
Tracker in Hank’s Balanced Salt Solution (HBSS) for 30 min, then trypsinised and 
resuspended in DMEM.     
2.2.11 Flow cytometry 
Cells were washed once in HBSS then run on either a FACSCalibur or FACSCanto II flow 
cytometer (BD Biosciences) in HBSS.  Dead cells were not generally excluded from the 
analysis, and 10000 events were counted for each sample. If dead cells were required to 
be identified then the cells were stained with 5 µg/mL propidium iodide before 
analysis, and detected using the FL3 filter on the FACSCalibur flow cytometer.  ER 
Tracker Green has an excitation at 504 nm and emission at 511 nm, which can be 
detected using the FITC filter on the FACSCanto flow cytometer.  Blue fluorescent 
protein has an excitation of 385 nm and emits at 448 nm, which is detectable using the 
Pacific Blue filter.  The data obtained was analysed using Flowing Software (Turku 
Bioimaging). 
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2.3 DNA methods 
2.3.1 Subcloning of pTetOne vector 
Primers were designed to amplify cDNA for GADD34, Ero1α or XBP1 using CLC Genomics 
Workbench (CLC Bio).  Primer sequences are shown in Appendix 1.  The forward primer 
sequence for each of these three genes contained a Not1 site, and the reverse primer 
contained an Age1 site.  The cDNAs of interest were amplified by PCR, and the PCR 
products and pTetOne vector (Clontech) were treated with 20 units Not1 and Age1 
(NEB) for 2 h at 37°C sequentially.  The insert was ligated into the cut pTetOne vector 
using 1 unit DNA ligase (Promega), and the resulting vector was incorporated into XL1 
Blue competent cells.  These cells were grown overnight and the following day the 
pTetOne plasmid was purified out by alkaline lysis.  To confirm the presence of the 
gene of interest in the pTetOne vector, a portion of the purified vector was treated 
with Not1 and Age1 and analysed by agarose gel electrophoresis.  The presence of a DNA 
band at the appropriate size for the gene of interest confirmed that it had been 
successfully subcloned into pTetOne. 
2.3.2 Plasmid prep 
Plasmids were diluted 1:10 and added to XL1 Blue competent cells, and incubated on 
ice for 30 min.  The cells were then heat shocked at 42°C for 90 s, briefly chilled on ice, 
and 800 μL LB, made from 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract and 1% 
(w/v) NaCl was added and the cells were shaken for 1 h at 37°C at 220 rpm in an Innova 
4400 shaking incubator (New Brunswick Scientific).  After shaking, 100 μL of this culture 
was streaked onto agar plates, which were made with LB containing 1.5% (w/v) bacto-
agar and a selection antibiotic (either 100 μg/mL ampicillin (Sigma) or 50 μg/mL 
kanamycin (Roche) depending on vector) and grown overnight at 37°C.  Colonies were 
picked the next day and grown in 2 mL LB with antibiotic selection for 6 h, then added 
to 100 mL LB with antibiotic selection and grown overnight.  The culture was pelleted at 
1400 x g for 15 min and then the protocol for a MidiPrep (Qiagen) was followed.  The 
resulting DNA was resuspended in 100 μL DEPC-treated dH20 and its concentration and 
purity (absorbance at 260 nm/280 nm) were measured on a Nanodrop 2000 
spectrophotometer (Thermo), or a Spectrostar Nano LVis plate reader (BMG Labtech). 
2.3.3 Agarose gel electrophoresis 
Agarose gels were prepared by adding agarose (Biorad) to 40 mM Tris containing 20 mM 
acetic acid and 1 mM EDTA (TAE buffer), and heated until completely melted.  
Generally, 1% (w/v) agarose gels were used.  The mixture was cooled to 50-60°C and 
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SYBR Safe (Invitrogen) was added at a 1:10000 dilution, and the gels were poured and 
set at room temperature.  DNA was mixed with 6x purple loading dye (NEB) and added 
to the wells along with an appropriate DNA ladder (NEB). Gels were typically run at 100 
V for 1 h, and then developed on a Uvidoc gel reader (Uvitec).  Any DNA fragments 
requiring purification were cut from the gel with a scalpel and purified using a gel 
extraction kit (Qiagen), following the manufacturer’s protocol. 
2.3.4 XBP1 splice assay 
RNA was extracted from stress treated cells using Trizol Reagent (Ambion) following the 
manufacturer’s recommended protocol.  First strand cDNA was synthesised using 
Superscript II Reverse Transcriptase (Invitrogen) with oligo dTs (Invitrogen) according to 
the manufacturer’s specifications.  cDNA for endogenous XBP1 was amplified using 
primers specific to the Chinese hamster XBP1 sequence, and the PCR yielded a 247 bp 
fragment for XBP1u and a 215 bp fragment for XBP1s, plus a hybrid band of 
approximately 280 bp.  Both endogenous and exogenous XBP1 were amplified 
simultaneously with a second, less specific set of primers which can anneal to either the 
Chinese hamster or the human XBP1 sequence.  PCR using these primers yielded the 
same fragments as the previous primer set but with the addition of a fragment of 221 bp 
for exogenous XBP1s.  PCR was performed with Accuzyme DNA polymerase (Bioline) with 
an initial melting step of 95°C for 5 min, then 35 cycles of: 95°C for 45 s, an annealing 
step for 45 s, and 72°C for 45 s, followed by a final elongation step of 72°C for 10 min.  
The endogenous-only primers used an annealing temperature of 60°C and the 
exogenous/endogenous primers used 62°C.  PCR products were run on a 2% (w/v) 
agarose gel in TAE buffer at 80 V for 1 h 40 min and then developed on a Uvidoc gel 
reader (Uvitec).  If required, densitometric analysis was performed using ImageJ 
(National Institute of Health). 
2.4 Molecular methods 
2.4.1 Cell lysis 
Suspension cells were counted using either a hemacytometer or a Countess II cell 
counter (Life Technologies), using 0.4% (w/v) trypan blue to exclude dead cells, then 
isolated by low speed centrifugation and resuspended in 5 mL PBS containing 20 mM N-
ethylmaleimide (NEM). After 5 min the cells were isolated by centrifugation and 
resuspended in 1 mL of 50 mM Tris-HCl buffer containing 150 mM NaCl, 5 mM EDTA, 1% 
Triton X-100 (lysis buffer) and left on ice for 10 min. The lysates were centrifuged at 
21000 x g for 10 min at 4°C, and the supernatant was extracted.  If the lysate was not 
required immediately then it was frozen at -20°C. 
Chapter 2 Materials and methods  
51 
 
Adherent cells were lysed by a similar method.  After removing culture medium from 
the 6 cm diameter dish, the cells were washed with 20 mM NEM in PBS for 10 min.  This 
was removed and 120 μL lysis buffer was added to the monolayer and the cells were 
scraped into the buffer.  This suspension was left on ice for 10 min, centrifuged at 
maximum speed for 10 min and the supernatant was extracted. 
2.4.2 Preparation of polyacrylamide gels  
Polyacrylamide gels were generally prepared on the day they were required.  The 
resolving layer was usually 7.5%, 10% or 12% (v/v) acrylamide (National Diagnostics), 
depending on the protein of interest and the degree of separation required.  The 
desired percentage of acrylamide was mixed with 5 mL 1.5 M Tris-HCl buffer (pH 8.8), 
200 μL of 10% (w/v) ammonium persulfate (APS) , 200 μL of 10% (w/v) sodium dodecyl 
sulphate (SDS) and the appropriate volume of water to achieve a final volume of 20 mL.  
After mixing, 25 μL tetramethylethylenediamine (TEMED) was added and the mixture 
was poured into a mould and allowed to set.  A thin layer of isopropanol was poured on 
top of the setting resolving layer to ensure an even surface.  The stacking layer was 
prepared in a similar method as the resolving layer, except using 4% (v/v) acrylamide 
and 2.5 mL 0.5 M Tris-HCl buffer (pH 6.8), in a final volume of 10 mL.  The isopropanol 
was removed from the mould and stacking mixture was added to the top of the 
resolving layer, and a 10 well or 15 well comb was set into the top.  If the gel was not 
used immediately then it was wrapped in wet paper and cling film and stored at 4°C 
until required. 
2.4.3 SDS PAGE 
Crude lysates were mixed with 0.2 M Tris-HCl (pH 6.8) containing 10% (w/v) SDS, 20% 
(v/v) glycerol and 0.05% (w/v) bromophenol blue (sample buffer) in a 4:1 ratio of lysate 
to sample buffer.  Dithiothreitol (DTT) was generally added as a reducing agent at a 
working concentration of 20 mM, unless the samples were required to be run under non-
reduced conditions.  Polyacrylamide gels were loaded with 20 μL – 30 μL of this sample 
mixture and run at 300 V and 20 mA per gel for approximately 2 h in a 25 mM Tris 
solution containing 200 mM glycine and 2.8 mM SDS.  
2.4.4 Western blot 
After separation, the samples were transferred to a nitrocellulose membrane (GE 
Healthcare) by wet transfer for 1 h at 300 V and 250 mA using 25 mM Tris containing 200 
mM glycine, 3.5 mM SDS and 20% (v/v) methanol.  The blots were blocked in 5% (w/v) 
non-fat milk powder (Marvel) in 50 mM Tris buffer (pH 7.5) containing 150 mM NaCl and 
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0.1% (v/v) Tween (TBST) for 1 h.  Primary antibodies were diluted in TBST and generally 
incubated overnight, unless known to produce a sufficient signal within 1 h.  Washes 
were performed three times for 10 min in TBST.  Secondary antibodies were diluted in 
TBST and incubated for 1 h, and the blots were shielded from light throughout the 
incubation.  Blots were developed using the Odyssey SA scanner (Licor) and analysed 
using Photoshop (Adobe) and ImageJ (National Institute of Health). 
The following primary antibodies were used: anti-FLAG, mouse, 1:250 (Sigma); anti-
Ero1α, mouse, 1:500 (a gift from Dr Roberto Sitia; (Ronzoni et al. 2010)); anti-PDI, 
rabbit, 1:500 (Jessop et al. 2009); anti-XBP1S, rabbit, 1:500 (Biolegend); anti-GFP, 
rabbit, 1:1000 (Thermo Scientific); anti-GAPDH, mouse, 1:10000 (Ambion); anti-V5, 
mouse, 1:10000 (Novex); anti-tPA, goat, 1:250 (Cambio); anti-tubulin, mouse, 1:40 
(Santa Cruz); anti-actin, rabbit, 1:500 (Abcam); anti-calnexin, rabbit, 1:2000 
(Stressgen); anti-calreticulin, rabbit, 1:1000  (Stressgen); anti-BiP, rabbit, 1:500 
(a gift from Dr Richard Zimmerman (Schäuble et al. 2012)) 
The following secondary antibodies were used: anti-mouse, 1:10000 (Licor); anti-rabbit, 
1:10000 (Licor); anti-goat, 1:10000 (Licor). These antibodies are conjugated with a 
fluorescent molecule which emits at 800 nm.  Fluorescently tagged Protein A was 
generated by Donna McGow using a method described in (Schellenberger et al. 2004).  
This targets the Fc region of antibodies and was used as a secondary probe at a 1:10000 
dilution. 
2.4.5 Protein A affinity purification 
Medium from transfected cells was extracted and treated with 50 μL 10% (w/v) 
Sepharose beads for 30 min to pre-clear the medium.  The samples were centrifuged at 
5500 x g for 5 min and the supernatant was kept.  This was treated with 50 μL 10% (w/v) 
Protein A Sepharose beads overnight.  The samples were spun again at 5500 x g for 5 
min to pellet the beads, these were kept and the supernatant discarded. The beads 
were resuspended with 1 mL of 50 mM Tris-HCl (pH 7.5) containing 1% (v/v) Triton X-
100, 150 mM NaCl, 2 mM EDTA and 0.5 mM PMSF (immunoisolation buffer) and briefly 
centrifuged.  The supernatant was removed and another 1 mL of immunoisolation buffer 
added.  This washing was repeated two more times and then the beads were 
resuspended in 40 μL of 100 mM Tris-HCl (pH 6.8) containing 4% (w/v) SDS, 0.2% (w/v) 
bromophenol blue and 20% (v/v) glycerol (sample buffer).  The samples were frozen at -
20°C.  
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2.4.6 TCA precipitation 
Medium was removed from cell cultures and centrifuged at maximum speed to remove 
any floating cells, and then 1.2 mL of this medium was added to 300 μL ice cold 100% 
(v/v) trichloroacetic acid and incubated on ice for 30 min.  The samples were 
centrifuged at 21000 x g for 15 min at 4°C to generate a protein pellet.  This was 
washed in 300 μL of -20°C acetone, left on ice for 5 min then centrifuged for 5 min at 
21000 x g.  The acetone was removed and 100 μL of sample buffer was added to the 
pellet and neutralised with 1M Tris solution.  The samples were frozen at -20°C. 
2.4.7 Antibody capture ELISA 
Immulon 96 well flat-bottom plates (Dynatech Laboratories) were coated with 100 
μL/well anti-human CH1 antibody (UCB) in PBS and incubated at 4°C overnight.  The 
plate was washed three times with PBS containing 0.1% (v/v) Tween (Sigma) and then 
blocked with 200 μL/well of PBS containing 3% (w/v) BSA and 1% (v/v) Tween for 1 h.  
The plate was washed three times and then antibody-containing medium samples were 
added to the plate, diluted 1:20 in conjugate buffer (a 1/5 dilution of the blocking 
buffer in PBS).  A standard IgG1 antibody (UCB) was added at 0.5 μg/mL, and this was 
serially diluted in conjugate buffer across the plate with a 1/2 dilution each time.  
Antibody samples and standards were incubated for 1 h and then the plate was washed.  
The reveal antibody was a polyclonal mouse anti-human peroxidase-conjugate (Southern 
Biotech) used at a 1:5000 dilution in conjugate buffer; 100 μL/well was added and 
incubated for 1 h at room temp.  O-phenylenediamine dihydrochloride (OPD) substrate 
was made up by dissolving one urea buffer tablet and one OPD tablet (Sigma) in 20 mL 
dH20, and this was added to the washed wells at 100 μL/well.  After incubating for 20 
min, the OD at 450 nm was read on a Pherastar plate reader (BMG Labtech) and 
adjusted for path length.  The standard concentrations were calculated on a parabolic 
curve using Mars software (BMG Labtech) and these were used to calculate the 
concentrations of the medium samples. 
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2.5 Statistical methods 
Densitometric analysis was performed using ImageJ (Schneider et al. 2012).  
Experimental variation was calculated using a Student’s T test (two tailed, two sample 
equal variance) using Microsoft Excel.  Variation was determined to be statistically 
significant when p<0.05.  Unless otherwise stated, error bars on graphs represent 
standard deviation across triplicate samples. 
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3.1 Introduction 
3.1.1 Generation of a high yield host cell line 
Chinese Hamster Ovary (CHO) cells are the most commonly used mammalian cell line for 
the industrial scale production of recombinant proteins.  Due to the long history of the 
use of CHO cells, it is relatively easier to be granted licensor approval for products 
derived from CHO cells than for products made from a less commonly used cell type 
(Kim et al. 2012).  Consequently, if a pharmaceutical company was seeking to increase 
the yield of therapeutic protein by engineering a novel host cell line with more 
advantageous characteristics over wild type CHO, it would be less risky for this company 
to use an engineered host cell line derived from a CHO lineage, than to invest 
significant time and resources in developing an entirely novel host cell line that may be 
rejected by regulatory bodies.  Therefore, new methods of improving the yield of 
protein from CHO cells are being continuously sought by pharmaceutical companies.  
These methods, which are discussed in detail in Chapter 1, could involve changes to cell 
culture strategy, or genetic manipulation of the cells. 
One aspect of the secretory process that has received relatively less attention as a 
strategy for the optimisation of yield is protein folding and the biochemistry of the ER.  
It was hypothesised that the folding of recombinant IgG antibodies – large, multi-domain 
proteins with 16-25 disulphide bonds, depending on the isotype (Frangione et al. 1968; 
Pink and Milstein 1967) – could be rate limiting (Mohan and Lee 2010).  Disulphide bond 
formation was, therefore, identified as an area of potential improvement by the 
pharmaceutical company UCB, and a novel CHO cell line was developed by researchers 
that contained two stably overexpressed genes thought to be capable of improving the 
efficiency of protein folding (Cain et al. 2013).  These two genes were XBP1s – a 
component of the UPR encoding a transcription factor that upregulates genes for 
chaperones and ER expansion (Lee et al. 2003; Shaffer et al. 2004) – and Ero1α – a 
protein involved in the reoxidation and recycling of PDI (Cabibbo et al. 2000). 
This novel cell line was named CHO-S XE and the first stage of its generation was to 
stably integrate an XBP1s overexpressing construct into CHO-S cells.  The resulting 
intermediate cell line, named CHO-S X, was shown to have a higher yield of antibody 
than wild type CHO-S cells (Cain et al. 2013).  CHO-S X was subsequently transfected 
with an Ero1α overexpressing construct and put through another round of limiting 
dilution and clonal selection.  Clones of CHO-S XE were selected based on antibody 
yield, and subsequent studies confirmed that three clones: XE1, XE2 and XE3, had 
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higher yield than both CHO-S and CHO-S X for a number of different antibody 
constructs, including difficult to express antibodies.   
3.1.2 Preliminary characterisation of CHO-S XE 
After engineering of the CHO-S XE clones XE1, XE2 and XE3, preliminary characterisation 
of these clones was performed by researchers at UCB and the PhD student Cathy Page at 
the University of Manchester.  The XE clones were studied and compared to both wild 
type CHO-S and the intermediate cell line CHO-S X in a number of characteristics (Cain 
et al. 2013; Page 2012).  Firstly, western blots of lysates from these five cell lines 
confirmed that the XE clones had higher Ero1α protein levels than the endogenous levels 
found in CHO-S and CHO-S X, showing that these clones had successfully integrated the 
Ero1α construct. The nomenclature of the XE clones reflects the extent of exogenous 
Ero1α expression, in that XE1 had the highest expression of Ero1α and XE3 had much 
lower expression, and not much higher than the endogenous protein levels found in 
CHO-S and CHO-S X.  Western blots using an anti-XBP1S antibody showed that the three 
XE clones and CHO-S X had roughly equivalent XBP1S protein levels.   
After confirming that the engineered cells contained the relevant genes of interest, the 
effect of the presence of these exogenous proteins on other signalling pathways in the 
cell was sought.  It was found that XE1 and XE2 had upregulated levels of ERp57, a 
component of the calnexin/calreticulin quality control cycle; ERdj4, a chaperone and 
reductase upregulated as part of the UPR; and ATF4, a transcription factor involved in 
the UPR that operates downstream of PERK signalling.  As these three proteins have a 
role in protein folding, they are possibly contributors to the increased rate of antibody 
production in CHO-S XE.  While the upregulated ERp57 and ERdj4 are likely to be a 
direct result of XBP1s overexpression, ATF4 is not known to be upregulated by XBP1s.  It 
is, therefore, likely that there is a low level of UPR activation present in CHO-S XE, with 
all three branches of the UPR active to some extent and not only the signalling 
downstream of exogenous XBP1s.   
The growth rate and viability of the engineered cell lines was then investigated.  All of 
the XBP1s overexpressing cell lines were found to grow faster than CHO-S and cultures 
reached a maximum viable cell density 1-2 days earlier.  These traits are desirable in a 
good host cell line, as an increased cell count results in an increased amount of 
secreted protein from the culture.  It is reported in the literature that there is often a 
trade-off between cell growth rate and protein secretion rate, and high producing cell 
lines often grow slower than their low producing counterparts (Stansfield et al. 2007).  
However, this did not appear to be the case for CHO-S XE.  Additionally, glucose 
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consumption and lactate production were also lower for XE1 cultures than for CHO-S, 
and these are both traits associated with high producing cell lines (Zagari et al. 2013).   
CHO-S and CHO-S XE1 were later stably transfected with two antibody constructs in 
order to carry out experiments involving the rate and reproducibility of recombinant 
protein production.  One of these constructs was known to be relatively easy to express 
(Ab1), and the other was a difficult to express antibody (Ab2).  For cells stably 
transfected with Ab1, the majority of the transfected CHO-S XE1 clones recovered 
showed expression of Ab1 to some extent: low expressing clones and high expressing 
clones were recovered, and very few clones were non-expressing.  The maximum titre 
observed was 95 µg/mL.  For CHO-S, there were far fewer clones that expressed Ab1 
and the majority were non-expressing, but of the few clones that did express, the 
maximum titre recorded was also around 95 µg/mL.  This data suggests that CHO-S XE1 
is more amenable to stable transfection and construct integration than wild type CHO-S; 
however, the potential maximum yield of antibody is the same for both cell lines.  A 
similar result was observed for Ab2, in that the majority of XE1 clones showed 
expression of Ab2 after stable transfection, although the titres were much lower with a 
maximum of 15 µg/mL.  None of the CHO-S clones recovered showed any expression of 
Ab2.   
The conclusion drawn from these experiments implies that the difference between the 
phenotypes of CHO-S and CHO-S XE is one of DNA uptake and retention, rather than of 
an increased efficiency of protein folding as originally intended.  In order to test this 
hypothesis, DNA uptake from a transient transfection by electroporation was measured 
using a fluorescein labelled DNA probe.  The fluorescence of the cells after transfection 
was measured by flow cytometry; however, it was found to be not significantly different 
between CHO-S and CHO-S XE1 at either 3 hours or 6 hours post-transfection.   
As DNA uptake appeared to be the same for both cell lines, protein folding and 
secretory characteristics of the cell were studied instead.  The size of the ER and Golgi 
were compared between the cell lines by transferring the cells from suspension to 
adherent culture in the presence of FBS, staining with organelle specific stains and 
mounting on coverslips for microscopy analysis.  The CHO-S XE clones were seen to have 
a more dispersed and fragmented ER and Golgi than CHO-S, and the total staining of 
each organelle, as measured by pixel intensity, was significantly lower for the XBP1s 
overexpressing cell lines.  This result was unexpected and counterintuitive, considering 
the well documented role of XBP1s in lipid biogenesis and ER expansion (Sriburi et al. 
2004), and so researchers at UCB followed up on this experiment by using flow 
cytometry to measure the fluorescence of cells treated with an ER specific fluorescent 
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stain.  This experiment showed an increase in ER size in CHO-S XE compared to CHO-S, 
which correlates more with what is known about the function of XBP1s.   
In addition to ER size, the ability of the cells to cope with ER stress was also 
investigated.  CHO-S XE1 showed a significantly faster rate of recovery from reductive 
stress, in the form of exposure to a strong dose of the reducing agent DTT, than CHO-S.  
It is possible that this increased rate of the restoration of redox balance is related to 
the larger ER size observed by flow cytometry.  The extent of endogenous XBP1u 
splicing after tunicamycin treatment was also determined using PCR.  Unexpectedly, the 
cell lines with exogenous XBP1s expression were found to have increased endogenous 
XBP1 splicing, and the counterintuitive nature of this result will be discussed in more 
detail in Chapter 5. 
Although the specific contribution of XBP1s and Ero1α to the high yield phenotype of 
CHO-S XE could not be clarified in more detail, it was still hypothesised that any 
differences observed between CHO-S and CHO-S XE were due to the function of 
exogenous XBP1s, Ero1α or a combination of the two.  In order to identify any effect on 
antibody yield caused by a depletion of one of the exogenously overexpressed genes in 
this cell line, Ero1α expression in CHO-S XE1 was knocked down using siRNA.  There was 
found to be a small reduction in stably expressed antibody with Ero1α siRNA knockdown, 
but this reduction was not determined to be statistically significant when using a 
Student’s T test.  A similar experiment involving the knockdown of XBP1s was 
attempted, but XBP1s transcript levels could not be successfully lowered by siRNA and 
actually resulted in an increase in XBP1S protein, possibly through activation of the 
UPR.  As both exogenous genes could not be knocked down simultaneously, it could not 
be determined if the loss of the exogenous genes would compromise the high yield 
phenotype of CHO-S XE1.   
3.1.3 Objectives 
The overall aim of this project was to identify methods of increasing the yield of 
secreted antibody in mammalian host cells through improving the efficiency of protein 
folding.  The initial approach to achieving this aim was to expand on the promising 
results observed in CHO-S XE (Cain et al. 2013) and further characterise this cell line to 
determine the specific contribution of the co-overexpressed genes XBP1s and Ero1α 
towards the high yield phenotype.  It was thought that this information could then be 
used in the generation of novel host cell lines with greater yield than CHO-S XE.  
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The characterisation of CHO-S XE was continued in this project by comparing it to CHO-
S, aiming to repeat some of the work performed by Cathy Page and Cain et al., and 
expand on any unanswered questions or other notable observations.  For these 
experiments CHO-S cells were obtained from Life Technologies, and the CHO-S XE1 
clone was received from UCB.  It should be noted that for the remainder of this thesis 
the XE1 clone will be referred to as ‘CHO-S XE-D’, for CHO-S XE-derivative, as a number 
of differences were observed between the XE1 cells grown for this project and the cells 
described by Cain et al., and these differences will be discussed in detail throughout 
this chapter.  No other clones of CHO-S XE were investigated during this project.  CHO-S 
and CHO-S XE-D were compared in their viability and rates of growth, as well as in their 
yields of a number of different recombinant proteins in addition to antibodies. Another 
factor that was investigated was the relative abundance of endogenous proteins 
involved in protein folding and stress.  These were compared between CHO-S and CHO-S 
XE-D as an indication of whether CHO-S XE-D has a larger ER than the parental cell line.  
ER size was also examined more directly using an ER specific stain which was detectable 
using flow cytometry, which was also used to determine overall cell size and mortality 
after transfection.  
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3.2  Results 
3.2.1 CHO-S XE-D has a slower rate of growth than CHO-S 
The first attribute that was investigated in CHO-S XE was a comparison of the rate of 
growth with that of CHO-S.  Although this attribute was already documented by Cain et 
al, it was quickly observed after a few passages of culturing the cell lines that the CHO-
S XE cells grown for this project (CHO-S XE-D) had a much slower rate of growth than 
previously reported for the CHO-S XE1 clone.  In order to document this observation, 
CHO-S and CHO-S XE-D cells were cultured alongside CHO-S XE1 and an earlier passage 
of CHO-S, labelled EP in Figure 3-1.  The cells were counted on a daily basis, as shown 
in Figure 3-1A, and the percentage of viable cells was calculated, shown in Figure 3-1B. 
Both passages of CHO-S were shown to grow quickly in suspension culture, and reach a 
maximum cell count of 11-12 x 106 cells/mL on the fourth day of culture.  The viability 
of these cells remained constant across the time period and remained above 95% at all 
times.  For CHO-S XE-D, not only was there a noticeably slower rate of growth than for 
CHO-S but there was also a discrepancy between the growth rate of XE-D and XE1, with 
XE-D having a cell count of 3.5 x 106 cells/mL after four days compared to 8 x 106 
cells/mL for XE1.  The viability of CHO-S XE-D was also low, and fluctuated between 65-
75% during days 2-4 of culture and dropped as low as 55% on the first day of growth.  
The viability of XE1 was better, fluctuating between 80-95% across the time period.  
The data presented is representative of a consistent trend for the growth characteristics 
of CHO-S and CHO-S XE-D throughout the project.   
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Figure 3-1 – CHO-S XE-D has a slower rate of growth than CHO-S 
CHO-S and CHO-S XE-D cells were grown for four days and (A) cell counts (cells/mL) 
and (B) the percentage of viable cells were measured daily using a Vi-CELL cell 
counter.  The growth characteristics of an earlier passage of CHO-S, labelled early 
passage (EP), and CHO-S XE1 were also investigated.  A direct comparison of the 
growth and viability of these four cell types was performed only once, although the 
data represents a trend observed consistently throughout the project for CHO-S and 
CHO-S XE-D, as well as previously observed data for CHO-S XE1. 
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3.2.2  CHO-S XE-D has a high yield of secreted proteins 
It was hypothesised that there may be a correlation between the number of disulphide 
bonds in a recombinant protein and the yield of that protein from CHO-S XE.  The 
rationale behind the creation of the CHO-S XE lineage was that the overexpression of 
XBP1s in CHO-S XE would cause the ER of these cells to enlarge, and the overexpressed 
Ero1α would increase the rate of recycling for PDI, which would in turn increase the 
rate by which disulphide bonds could be inserted into nascent proteins.  By this 
rationale, CHO-S XE would be more efficient at producing a heavily disulphide bonded 
protein than CHO-S, and would, therefore, have a higher yield, but both cell lines 
should be equally capable of secreting proteins with no disulphide bonds.  In order to 
test this hypothesis, CHO-S and CHO-S XE-D cells were transiently transfected with one 
of three recombinant proteins: IgG1 antibody heavy and light chains; alpha 1 anti-
trypsin (α1AT); or tissue plasminogen activator (tPA), and then grown for three days.  Of 
these proteins tPA has the most disulphide bonds, 23, followed by IgG1 with 16 
disulphide bonds, and α1AT has no disulphide bonds.   
After the three day growth period, the cells and medium were harvested.  IgG1 was 
purified using protein A affinity isolation, and tPA and α1AT were precipitated using 
TCA.  The amount of exogenous protein in the medium or lysate was quantified using 
western blotting.  Figure 3-2A shows the amount of IgG, α1AT or tPA present in the 
medium, and Figure 3-2B shows levels of IgG and α1AT in the lysate.  The lysate blot of 
tPA is not shown as a sufficiently clear blot was not obtained.  As previously mentioned, 
CHO-S has a faster growth rate than CHO-S XE-D and it was observed that the cell count 
for CHO-S was consistently 2-3 fold higher than for CHO-S XE-D after three days of 
growth.  In order to take this into consideration, the protein bands were quantified 
using ImageJ software and normalised against the number of cells.   
The relative increase in yield for CHO-S XE-D compared to CHO-S when normalised 
against the cell count is shown in Figure 3-2C for the medium samples and Figure 3-2D 
for lysates.  The yield of IgG was 4.2 fold higher in CHO-S XE-D than CHO-S for secreted 
material, and 5.4 fold higher for intracellular material.  For α1AT the secreted material 
yield was 3.7 - 8.1 fold higher in CHO-S XE-D and the intracellular yield was 2.8 - 11.2 
fold higher.  The yield of tPA was quantified as being 15.2 fold higher in CHO-S XE-D in 
the blot shown, but this result cannot be directly compared to the others as it is derived 
from a single blot and not triplicate blots.  The tPA produced from CHO-S was often too 
low to accurately quantify, and too few clear and quantifiable repetitions were 
obtained to perform accurate statistical analysis.  Overall, the amount of transfected 
protein can be seen to be much higher for CHO-S XE-D than for CHO-S, even when its 
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lower cell count is not taken into consideration.  While the high yield of CHO-S XE-D was 
anticipated due to the previously published work on the productivity of CHO-S XE1 (Cain 
et al. 2013), the nature of this high yield, in that it appears to be applicable to any 
secreted protein regardless of its structural complexity, is contrary to what was 
hypothesised.  Despite this, a host cell line with an ability to potentially secrete any 
recombinant protein in high abundance is more desirable and industrially relevant than, 
for instance, a host cell line that can produce high titres of multi-domain proteins or 
single domain proteins would be. 
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Figure 3-2 - CHO-S XE-D has a high yield of secreted proteins  
(A) Western blots showing levels of recombinant protein present in the medium of 
CHO-S and CHO-S XE-D cells transiently transfected with one of the following 
proteins: IgG antibody; alpha 1 anti-trypsin (α1AT), a protein with no disulphide bonds 
in its structure; or tPA, a protein with many disulphide bonds.  (B) Western blots of 
intracellular material from transiently transfected CHO-S and CHO-S XE-D. (C) 
Quantification of the fold increase in yield for CHO-S XE-D for secreted material and 
(D) intracellular material.  Error bars represent the standard deviation across 
triplicate flasks.  Experiment was performed at least three times for each model 
protein. 
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3.2.3 CHO-S XE-D has higher levels of transiently transfected GFP  
The high yield of CHO-S XE-D was further investigated by comparing the fluorescence 
from transiently transfected GFP between CHO-S and CHO-S XE-D using flow cytometry.  
Cells were transfected with either eGFP or empty vector, or were left untreated, and 
then grown for three days.  At the end of the transfection period the cells were lysed 
and a western blot of transfected cell lysates probed with an anti-GFP antibody is shown 
in Figure 3-3A.  More eGFP protein can be seen in CHO-S XE-D lysates than CHO-S from 
an equivalent number of cells.  This result is similar in some aspects to the results 
shown in Figure 3-2, in that CHO-S XE-D displays higher productivity of a transfected, 
exogenous protein than CHO-S.  However, one key difference between the experiments 
is that eGFP is not a secreted protein, and is localised to the cytosol of transfected 
cells.  This result, therefore, suggests that the basis of the high yield phenotype of CHO-
S XE-D is not related to the secretory pathway, and is instead due to an increase in 
efficiency in an earlier stage of protein production such as gene transcription, protein 
translation, or aspects of protein folding and maturation other than disulphide bond 
formation. 
In order to further explore this finding, green fluorescence from the transfected cells 
was analysed by flow cytometry.  This experimental approach would reveal the 
abundance of correctly folded, functional eGFP as only protein in this state has the 
ability to emit fluorescence, whereas a western blot would be capable of detecting 
misfolded or aggregated proteins in addition to correctly folded GFP.  The amount of 
folded and functional eGFP present in the cells was estimated by comparing the 
fluorescence of the untreated and mock transfected controls (autofluorescence) with 
that of the eGFP transfected cells.  Figure 3-3A shows histograms of green fluorescence 
intensity emitted by each cell plotted against cell count.  The intensity of emitted 
fluorescence was categorised arbitrarily into regions of ‘low, ‘medium’ or ‘high’ 
intensity on the histograms, and the percentage of cells found in each of these regions 
is indicated in the tables below the histograms.  The number of cells found in the ‘low’ 
and ‘medium’ intensity regions in untreated cells is similar between CHO-S and CHO-S 
XE-D, and these values can be considered to be autofluorescence.  The intensity of 
fluorescence from mock transfected cells is higher than that of untreated samples, 
possibly due to a small degree of cell stress resulting from exposure to the transfection 
reagent, but this increase in autofluorescence does not vary between CHO-S and CHO-S 
XE-D.  Fluorescence intensity from GFP transfected CHO-S cells is found predominantly 
in the ‘low’ and ‘medium’ regions, which could represent autofluorescence or cells with 
a low transfection efficiency, and only the 23.49% of cells have emission higher than 
autofluorescence, found in the ‘high’ region.  For the population of CHO-S XE-D cells 
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transfected with GFP, only 1.84% of cells emit ‘low’ fluorescence, whereas 52.24% of 
cells have ‘medium’ emission and 45.93% have ‘high’ emission.  This indicates that the 
average intensity is higher for CHO-S XE-D cells than for CHO-S.  The overlaid histograms 
in Figure 3-3B further highlight the increase in fluorescence intensity emitted from the 
CHO-S XE-D population compared to the CHO-S population.  This experiment was 
performed three times and the results from a representative experiment are shown.  
The western blot and flow cytometry data together suggest that CHO-S XE-D is able to 
produce more correctly folded eGFP protein than CHO-S under the same transfection 
conditions, although the exact mechanism for this increase is not clear. 
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Figure 3-3 - CHO-S XE-D has higher levels of fluorescence from transiently 
transfected eGFP.   
(A) Anti-GFP western blot of equivalent numbers of CHO-S and CHO-S XE-D lysates.     
(B) Flow cytometry analysis of fluorescence from CHO-S and CHO-S XE-D cells transiently 
transfected with eGFP or mock transfected.  Fluorescence emitted from cells is 
categorised into regions of low, medium or high intensity.  The percentage of cells 
found in each category of intensity is indicated in the table below each histogram.  
Experiment was performed three times, data from a representative experiment is 
shown. 
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3.2.4 CHO-S XE-D has high levels of endogenous proteins 
In order to confirm that the genes XBP1s and Ero1α were overexpressed in CHO-S and 
CHO-S XE-D, lysates from equivalent numbers of cells were separated by SDS-PAGE 
under non-reducing conditions and probed with antibodies targeting XBP1S or Ero1α 
protein by western blot.  Figure 3-4 shows that both proteins can be seen in CHO-S XE-
D, whereas in CHO-S XBP1S can be seen only faintly and Ero1α not at all.  Ero1α appears 
as a doublet on a non-reduced gel because the protein is present in two forms: the top 
band represents the active form and the lower band represents the inactive form.  The 
regulation of the activity of Ero1α by the rearrangement of active site disulphide bonds 
is explained in more detail in Section 1.2.3.  The western blot indicates that these 
proteins are more abundant in CHO-S XE-D than CHO-S because they are exogenously 
overexpressed.  
The relative abundance of a range of proteins involved in disulphide bond formation, 
protein folding and the UPR was then compared between the two cell lines, with the 
aim of determining whether these genes were being upregulated by either of the 
exogenous genes in CHO-S XE-D.  Lysates from an equivalent number of CHO-S and CHO-
S XE-D cells were separated by SDS-PAGE under reducing conditions and probed with a 
range of antibodies against proteins which are known to be involved either with XBP1s 
or with Ero1α.  The proteins investigated were: BiP, involved in identifying and 
stabilising unfolded proteins; calnexin, a lectin localised to the ER membrane that has a 
role in the quality control of protein folding; calreticulin, a homologue of calnexin 
localised to the ER lumen; CHOP, involved in apoptotic UPR signalling; PDI, which 
inserts, rearranges and reduces disulphide bonds and is a client protein of Ero1α; and 
PRX4, a member of the peroxiredoxin family.  The protein folding/UPR related proteins 
shown in Figure 3-4 were analysed using ImageJ to measure the pixel intensity of the 
bands, and each of these proteins was found to be expressed between 1.41 - 3.28 fold 
higher levels in CHO-S XE-D when normalised against the number of cells.   
As an alternative method of normalising the data, a range of commonly used 
‘housekeeping’ proteins were also probed for in a western blot.  These proteins were 
expected to remain relatively constant between the cell lines; however, the levels of 
both actin and tubulin are found to be 1.60 fold and 1.32 fold higher, respectively, in 
CHO-S XE-D than CHO-S.  If it had been found that every identified endogenous protein 
was expressed at higher levels in CHO-S XE-D than CHO-S, then these results could 
perhaps be attributed to a flaw in the method for counting the cells, and it could be 
concluded that the lysates had not been taken from equivalent cell numbers.  However, 
this appeared to not be the case as it was also found that GAPDH, a very commonly used 
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housekeeping protein, was found at approximately 50% lower abundance in CHO-S XE-D 
as in CHO-S.  In fact, the images shown in Figure 3-4C for actin and GAPDH are cropped 
images taken from the same original blot, and therefore from the same samples of CHO-
S and CHO-S XE-D.  It was, therefore, unclear which housekeeping protein was the best 
to normalise the other data to in order to accurately measure endogenous protein levels 
in the two cell lines. 
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Figure 3-4 – CHO-S XE-D has high levels of endogenous proteins  
Lysates from an equivalent number of CHO-S and CHO-S XE-D cells were probed with 
antibodies targeting XBP1S and Ero1α, the genes that are overexpressed in CHO-S XE-D.  
Lysates were also probed for a range of endogenous proteins involved in either protein 
folding and the UPR, or general housekeeping.  Values represent the number of folds 
higher of protein in CHO-S XE-D than CHO-S ± standard deviation across triplicate 
samples.  Quantification is not shown for XBP1S and Ero1α due to the unquantifiable 
levels present in CHO-S. 
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3.2.5 CHO-S XE-D cells are larger than CHO-S  
While culturing both CHO-S and CHO-S XE-D, it was observed that CHO-S XE-D cells 
appear noticeably larger than their wild type counterparts under a microscope.  This 
observation, together with the western blot data showing that both ER and cytoskeletal 
proteins are found at higher abundance in CHO-S XE-D, suggesting that these cells may 
have a larger size than CHO-S, was further investigated using flow cytometry.  
Untransfected cells were analysed by the flow cytometer to measure forward 
scattering, an indication of cell size, and the forward scattering histograms are shown in 
Figure 3-5.  CHO-S XE-D is shown to have a larger average cell size than CHO-S, which 
supports the previous observations from microscopy, and the western blot data on the 
levels of ER and cytoskeletal proteins.  Dead cells and debris were not excluded from 
the analysis, and the CHO-S XE-D data appears to show more debris present than for 
CHO-S, as shown in the left hand of the histogram representing the smallest 
measurements for forward scattering. 
 
Figure 3-5 – CHO-S XE-D cells are larger than CHO-S.   
Flow cytometry analysis of untransfected living CHO-S cells (solid line) and CHO-S XE-D 
cells (dashed line) showing forward scattering, an indication of cell size.  Experiment 
was performed in triplicate, representative histograms are shown. 
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3.2.6 CHO-S and CHO-S XE-D have the same amount of ER membrane 
In order to determine the effect of constitutively overexpressed XBP1s on the amount of 
ER membrane, CHO-S and CHO-S XE-D cells were stained with ER Tracker, a 
glibenclamide based fluorescent green dye which binds specifically to potassium 
channels prominent in the ER membrane.  After staining, the cells were quenched, 
washed and analysed by flow cytometry in order to measure the green fluorescence 
from the two populations of cells.  The green fluorescence emitted from each cell 
should be proportional to the amount of ER membrane contained within that cell.  
Figure 3-6 shows histograms of data gathered using the FITC filter on the flow 
cytometer, which detects green fluorescence.    
The FITC histograms of CHO-S and CHO-S XE-D overlap closely, showing that the green 
fluorescence produced by both populations of cells is the same.  This suggests that both 
cell lines have the same amount of ER membrane, despite the presence of increased 
levels of XBP1s in CHO-S XE-D, and this is contradictory to what is known about the 
function of XBP1s (Shaffer et al. 2004). 
 
Figure 3-6 – CHO-S and CHO-S XE-D have the same size of ER membrane 
Flow cytometry analysis of untransfected living CHO-S cells (solid line) and CHO-S XE-D 
cells (dashed line) showing data from the FITC channel, an indication of green 
fluorescence.  Experiment was performed in triplicate, representative histograms are 
shown. 
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3.2.7 CHO-S XE-D shows higher cell mortality when transiently transfected 
It was observed that CHO-S XE-D cells are more prone to clumping than CHO-S, 
particularly when transfected, and this may be another indication of the reduced 
viability seen in Figure 3-1.  This observation was further investigated by using 
propidium iodide (PI) to stain dead cells, which allowed for any dead cells in a 
population to be identified using flow cytometry as the dye does not enter living cells.  
This staining was used to determine the viability of transiently transfected CHO-S and 
CHO-S XE-D when using the chemical transfection reagent NovaCHOice.   
Cells with high PI fluorescence are shown in the blue regions of the histograms in Figure 
3-7, and the percentage of cells found in this region is indicated.  CHO-S showed 16.01% 
mortality when mock transfected and 13.01% mortality when transfected with GFP, 
whereas CHO-S XE-D showed 23.68% mortality when mock transfected and 19.97% 
mortality when transfected with GFP.  This increase in post-transfection mortality may 
be an indication that CHO-S XE-D is under a higher level of stress than CHO-S under 
normal conditions, and the increased stress caused by transient transfection is fatal to 
more cells than in CHO-S.   
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Figure 3-7 – CHO-S XE-D shows higher cell mortality when transiently transfected.   
Flow cytometry analysis of fluorescence from propidium iodide (PI) stained cells.  
Only dead cells are stained by PI as the dye does not permeate the plasma membrane 
of living cells, and therefore cells with high PI fluorescence (indicated in the blue 
region) can be identified as dead.  The percentage of dead cells in each sample is 
indicated.  Experiment was performed in triplicate, representative histograms are 
shown. 
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3.3 Discussion 
CHO-S XE was originally engineered to be a host cell line capable of producing more 
recombinant protein than could be produced by wild type CHO-S.  This criterion was 
confirmed during the preliminary characterisation experiments, and the high yield 
phenotype was seen to apply to a range of different antibody constructs (Cain et al, 
2013).  However, the ability of the cells to secrete other recombinant proteins had not 
been tested, and nor had the effect of varying disulphide bond complexity on the yield 
of secreted protein.  In order to investigate this, the ability of CHO-S XE-D to secrete 
antibody was compared to its ability to secrete tPA, a heavily disulphide bonded 
protein, and α1AT, which has no disulphide bonds in its native structure.  As CHO-S XE-D 
was thought to be more capable of inserting disulphide bonds into nascent proteins than 
CHO-S due to the presence of exogenously expressed XBP1s and Ero1α, it was expected 
that CHO-S XE-D would secrete more tPA than CHO-S, but both cell lines would produce 
a similar amount of α1AT.  Contrary to this expectation, CHO-S XE-D was seen to 
secrete more α1AT, more tPA and more antibody than CHO-S.  This suggests that the 
mechanism behind the high yield of CHO-S XE-D is not related to the complexity of the 
protein being secreted. 
The data appears to show a greater increase in tPA secretion in CHO-S XE-D than the 
increase observed for α1AT, which to some extent would support the original hypothesis 
that CHO-S XE-D has a greater capacity to secrete complex proteins than CHO-S.  
However, the lack of reproducibility in the results means that this cannot be reliably 
confirmed, and therefore the only conclusion that can be drawn is that CHO-S XE-D 
produces more of each of the three proteins tested, and the extent of this increase 
cannot be quantified from this data.  The lack of reproducibility in the tPA experiments 
is attributed to the poor quality of primary antibody used in the western blot.  Although 
alternative probes were tested and extensive optimisation carried out, western blots 
that showed clear and unambiguous bands for tPA produced by both CHO-S and CHO-S 
XE-D samples were rarely obtained.  The increased variation in the results for α1AT may 
be due to the different methods used for protein isolation, or it could be due to the 
differences in the probes used for western blotting.  Overall, although CHO-S XE-D had a 
consistently lower cell count, the amount of recombinant protein secreted into the 
medium by those fewer cells was greater than that produced by a higher number of 
CHO-S cells. 
The observation that CHO-S XE-D grows slower and has a lower viability than both CHO-
S, and also the CHO-S XE1 lineage that XE-D is derived from, has two possible 
explanations.  The first is that the cells were cultured in a different environment for 
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this project than the method they had been grown at UCB.  The main difference in 
culture method was that the cells at UCB were grown in a dry incubator on a shaking 
platform with a larger orbital throw, whereas the cells cultured at the University of 
Glasgow were grown in a humidified environment on a smaller shaking platform.  All 
other factors were equivalent, such as the culture medium, the temperature, and the 
concentration of selection antibiotics and glutamine added to the medium.  It is 
possible that CHO-S XE cells are more susceptible to subtle environmental changes than 
CHO-S, and being thawed and cultured in an environment that they had not been 
adapted to was sufficient to cause a drop in cell viability.  One contradiction to this 
hypothesis is the data showing that CHO-S XE1 was able to recover from ER stress, 
caused by a strong dose of the reducing agent DTT, faster than CHO-S was able to (Cain 
et al. 2013).  This implies a greater ability in CHO-S XE1 to cope with stress; however, 
this ability may be specific to restoring redox balance and is not a general ability to 
cope with other forms of stress. 
CHO lineages are notorious for being prone to genomic mutations (Chasin and Urlaub 
1975), so it is possible that CHO-S XE1 is a mixed population of genotypes where some 
cells are more susceptible to stress than others.  The stress of environmental change 
may have caused a speciation event, where the more vulnerable, faster growing cells 
were killed and the sturdier, slow-growing cells survived.  One potential cause for a 
speciation event was the method by which cryopreserved cells were thawed.  At the 
beginning of the project, vials containing CHO-S and CHO-S XE1 cultures frozen in CD 
CHO medium and 10% (v/v) DMSO were warmed briefly in a water bath and then 
transferred to a flask of pre-warmed CD CHO.  The disadvantage to this thawing method 
is that a residual trace of DMSO remained in the initial culture passage; however, the 
reason why this method was used was to avoid the additional stress of centrifugal force 
and prolonged exposure to DMSO during its removal.  The trace of DMSO in the initial 
culture was 0.4% (v/v) in CD CHO medium.  The concentration at which DMSO becomes 
cytotoxic is debated, but concentrations under 0.5% (v/v) are generally considered to 
cause no adverse effects to cells (Qi et al. 2008).  However, the cytotoxicity of DMSO 
varies depending on the cell type or tissue type being treated, and as no data has been 
published that specifically examines the effect of DMSO toxicity on CHO cells, it cannot 
be discounted that genomic mutations or epigenetic changes may have been caused by 
the freeze-thaw process in CHO-S XE.  Regardless of the origin of the differences 
between CHO-S XE1 and CHO-S XE-D, the extent of these differences was not explored 
beyond the variation in growth characteristics, and all further experiments were only 
performed in CHO-S XE-D. 
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The drop in the viability of CHO-S XE-D was also supported by flow cytometry data 
showing that CHO-S XE-D cells show a greater extent of cell mortality when transiently 
transfected.  It may be the case that CHO-S XE-D cells have compromised viability even 
under normal cell culture conditions, for an unknown reason, and the additional stress 
caused by chemical transfection is too much for CHO-S XE-D to cope with, whereas CHO-
S cells are more capable of adapting to changing in cell culture conditions and with the 
stress of transient gene expression.  It is also possible that the protocol for NovaCHOice, 
the chemical transfection reagent used, was optimised specifically for use with CHO-S 
and the concentrations of reagent used are not suitable for CHO-S XE-D.  With further 
optimisation the viability of CHO-S XE-D could perhaps be improved, but this may be at 
the expense of reduced post-transfection viability for CHO-S or reduced yield for CHO-S 
XE-D. 
CHO-S XE-D cells were also seen to have higher green fluorescence per cell when 
transiently transfected with GFP than the green fluorescence produced by the 
equivalent CHO-S cells.  This result was unexpected, as it was originally anticipated that 
any increases to protein production in CHO-S XE-D would be achieved through an altered 
ER biochemistry caused by XBP1s and Ero1α overexpression.  To see such a large 
increase in the levels of a protein synthesised in the cytosol that has no disulphide 
bonds in its native structure implies that the increase in transfected GFP protein seen in 
CHO-S XE-D is a result of a mechanism other than the rate of disulphide bond formation.  
It is not clear which stage in the process of GFP production is the cause of this large 
increase, in other words whether it is due to improved gene transcription, protein 
translation or another aspect of protein folding.   
Previous work showed that the uptake of fluorescently labelled DNA is the same 
between CHO-S and CHO-S XE1, implying that the differences in protein production 
between these cell lines is not due to changes in DNA uptake (Page 2012).  However, 
another experiment indicated that stably transfected CHO-S XE cells produce more 
positively transfected clones than CHO-S, which does suggest a difference in DNA 
uptake or integration.  This data appears to be conflicting, but the experiments are in 
fact testing different aspects of transfection and are not directly comparable.  The first 
experiment is a measure of DNA transferred across the plasma membrane into the 
cytosol, whereas the second is a measure of the efficiency of DNA uptake into the 
nucleus and integration with the genomic DNA.  Therefore, the experiment measuring 
the presence of fluorescently labelled DNA inside the cell may not be an accurate 
representation of the DNA uptake required for successful integration of a transfected 
gene.  It is reported in the literature that cell lines can have a similar rate of DNA 
uptake across the plasma membrane, but can differ in their extent of nuclear 
Chapter 3 Characterisation of the high yield cell line CHO-S XE  
79 
 
integration.  For instance, both human primary cells and HeLa cells were shown to take 
up an equivalent amount of transfected DNA into the cytosol, but the human primary 
cells were more efficient at expelling foreign DNA from the nucleus than HeLa cells 
were, resulting in the HeLa cells having a greater transfection efficiency (Coonrod et al. 
1997).  It is therefore possible that CHO-S XE-D has a more sluggish rate of nuclear 
expulsion of DNA than CHO-S does, giving it a greater transfection efficiency, although 
this is not known to be an effect of either XBP1s or Ero1α.  Further work will need to be 
performed to compare the other stages of protein production between the two cell 
lines. 
In regards to the western blot data confirming the presence of both exogenous genes in 
CHO-S XE-D, and their relative absence in CHO-S, it should be noted that both 
antibodies used are only documented to target the human version of these proteins, and 
their capability to recognise Chinese hamster proteins is not known.  CHO-S XE-D 
overexpresses the human version of the XBP1S and Ero1α, but also expresses its own 
endogenous Chinese hamster proteins, whereas CHO-S only expresses the Chinese 
hamster versions of XBP1 and Ero1α.  The human and Chinese hamster sequences for 
XBP1S are known to be quite similar, and therefore the antibody used in the western 
blot should be able to detect both forms of the protein, and the band shown in the blot 
should represent a combination both exogenous human and endogenous Chinese 
hamster XBP1S.  However, the sequences for Ero1α show more variation between human 
and Chinese hamster, and therefore it is possible that only the human form is being 
detected on the blot, and this may be why no band can be seen for Ero1α in CHO-S.  
This possibility could be tested by using an antibody raised specifically against the 
Chinese hamster form of Ero1α.  
It was also discovered that CHO-S XE-D lysates contain higher levels of a number of 
different ER-localised endogenous proteins compared to CHO-S.  These results could 
suggest that the ER of CHO-S XE-D is more abundant; however, it was also found that 
the cytoskeletal proteins tubulin and actin are expressed at higher levels in CHO-S XE-D.  
This could suggest that CHO-S XE-D has a larger overall size than CHO-S and has both a 
larger ER and cytosol, or that cytoskeletal proteins are being upregulated in CHO-S XE-D 
by an unknown mechanism. This hypothesis is supported by the flow cytometry data 
showing that the size of CHO-S XE-D cells was greater than CHO-S.   
The observation that GAPDH, a protein involved in glycolysis that is commonly 
considered a ‘housekeeping’ protein for the purposes of normalising data, was 
expressed at lower levels in CHO-S XE-D was unexpected.  The reason why this is the 
case is unclear, but it could suggest that the basic metabolism and glycolysis of the two 
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cell lines are different.  A point which may support this hypothesis is that the CHO-S XE1 
cell line was shown to have a lower uptake of glucose from the medium than CHO-S 
(Cain et al. 2013), suggesting that the rate of glucose metabolism of XE cells is slower, 
and this could be a related to the lower levels of GAPDH. 
It was also shown by flow cytometry that CHO-S XE-D cells have the same amount of ER 
as CHO-S cells.  This result contradicts what is previously published on CHO-S XE1 (Cain 
et al. 2013) and it is also counterintuitive to what is known about the role of XBP1s in 
ER expansion and lipid biogenesis during the UPR (Shaffer et al. 2004).  However, the 
conclusion drawn was based on the assumption that the uptake of ER Tracker dye and 
emission of green fluorescence was proportional to the amount of ER and would remain 
proportional after any expansion to the ER has occurred.  This may not necessarily be 
the case, and the possibility exists that the potassium channels that ER Tracker 
specifically binds to are not upregulated to the same extent as the lipid component of 
the membrane.  This could result in an expansion in ER membrane not being accurately 
reflected by a corresponding increase in green fluorescence, and ER expansion would 
therefore be undetectable by this method.  However, as the ER Tracker dye has been 
used to reveal ER expansion in previous publications (Gulis et al. 2014), it appears more 
likely that the dye is able to accurately represent ER expansion.  This validates the 
result in CHO-S XE-D, and indicates that CHO-S and CHO-S XE-D have the same amount 
of ER.  An alternative method of measuring the amount of ER in CHO-S XE-D would be to 
analyse the cells by electron microscopy.  This technique would allow for high 
resolution, direct imaging of organelle size, and could also be used to examine ER 
morphology between CHO-S and CHO-S XE-D. 
Overall, when the results of these characterisation experiments and those undertaken 
by Cain et al are considered and rationalised together, one common conclusion is that 
both CHO-S XE1 and CHO-S XE-D differ from CHO-S in more ways than they are similar.  
Almost every experiment performed was a comparison between CHO-S and CHO-S XE-D, 
but as there is very little common ground to normalise the cells to it is difficult to draw 
any conclusions on which attributes of CHO-S XE-D are caused directly by the two 
overexpressed genes, and which are incidental or a result of spontaneous genomic 
mutation.  In order to more reliably find the specific effects of exogenous expression of 
XBP1s and Ero1α, a more controlled environment was required where the expression or 
absence of each of these genes was the only variable.  To this end, a number of CHO-S 
cell lines with inducible overexpression of exogenous genes were engineered in order to 
better study the function of these genes and their effect on the yield of recombinant 
protein. 
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Attribute of CHO-S XE-D Difference to CHO-S 
Cell size Larger 
ER size Same 
Growth rate Slower 
Productivity of IgG Higher 
Productivity of α1AT Higher 
Productivity of tPA Higher 
Productivity of GFP Higher 
Chaperone levels Higher 
Actin levels Higher 
GAPDH levels Lower 
General viability Lower 
Viability after transfection Lower 
Table 1 – Summary of differences between CHO-S and CHO-S XE-D.  
The results of the experiments described in Chapter 3, indicating whether a particular 
attribute can be considered greater in CHO-S XE-D than in CHO-S, lesser, or the same. 
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4.1 Introduction 
4.1.1 Rationale behind the use of an inducible gene system 
As the results from the comparative experiments in CHO-S and CHO-S XE-D did not shed 
light on the specific role of overexpressed XBP1s and Ero1α in the high yield phenotype 
of CHO-S XE-D, another experimental approach was taken where each gene of interest 
was overexpressed in an inducible system, in separate cell lines.  The advantage to this 
approach was that cell samples could be compared where the only variable was the 
presence or absence of the gene of interest, and all other factors could be kept 
constant.  The main factor that was compared between induced cells and uninduced 
was the ability of the cells to secrete transiently transfected antibody, calculated as pg 
of secreted antibody per cell.  Other factors such as ER expansion and XBP1 splicing 
upon gene induction will be discussed in Chapter 5. 
4.1.2 Inducible CHO-S derived cell lines 
Initially, three cell lines were generated from CHO-S: one with inducible overexpression 
of XBP1s; one with inducible Ero1α; and a third with GADD34 overexpression.  XBP1s and 
Ero1α were chosen for investigation due to their presence in CHO-S XE (Cain et al. 
2013), and GADD34 was chosen due to its role in the regulation of protein translation 
during the UPR (Novoa et al. 2001).   
GADD34 functions downstream of the PERK branch of the UPR, and recruits a 
phosphatase to phosphorylated translation initiation factor (eIF2α) (Brush et al. 2003).  
This reactivates eIF2α by dephosphorylation, alleviating the attenuation of protein 
translation mediated by PERK during earlier UPR signalling (Novoa et al. 2001).  It was 
hypothesised that the overexpression of GADD34 could reduce the extent of eIF2α 
phosphorylation and ensure that the majority of eIF2α remains in the active, non-
phosphorylated form, and thereby improve the rate of protein translation in transiently 
transfected cells.   
However, GADD34 signalling during the UPR is also known to be capable of triggering 
apoptosis (Hollander et al. 1997).  The repression of translation by eIF2α 
phosphorylation has a protective effect to the cell under severe stress conditions where 
an abundance of misfolded proteins has built up in the ER, and resuming a normal rate 
of protein translation under these circumstances causes the level of stress to worsen 
and the cell to enter apoptosis.  Therefore, depending on the extent of eIF2α 
phosphorylation during a standard transient transfection, it was possible that the 
induction of GADD34 overexpression could either improve the rate of translation, which 
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may contribute to a higher yield of protein, or it could reduce cell viability and increase 
mortality. 
The inducible system chosen for controlled expression of XBP1s, Ero1α and GADD34 is 
named pTetOne, and functions on a Tet-On basis (Gossen and Bujard 1992) where gene 
expression is active in the presence of doxycycline, a tetracycline derivative, and 
inactive in the absence of doxycycline (Zhou et al. 2006).  Unlike other Tet-On based 
systems where the gene of interest and the Tet responsive element exist on separate 
vectors, and need to be incorporated into the cells in separate rounds of stable 
transfection, the TetOne system has the promoter for the subcloned gene of interest 
and the transactivator protein for this promoter situated on the same vector.  The 
transactivator protein is constitutively expressed by the pTetOne vector in an inactive 
conformation, and is switched to its active conformation by the presence of doxycycline 
in the cell culture medium.  The advantage to having these two components on the 
same vector was that only one period of transfection and clonal selection was required, 
which not only reduced the time taken to engineer the cell lines but also reduced the 
risk of a speciation event resulting from spontaneous genomic mutation occurring during 
the process of clonal selection.  After subcloning the gene of interest into pTetOne, the 
construct was co-transfected into CHO-S cells along with a linear puromycin resistance 
marker.  Positively transfected clones were initially identified by puromycin resistance, 
and later confirmed by western blotting of the protein of interest.   
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Figure 4-1 – Map of pTetOne vector showing activation by doxycycline. 
The gene of interest (GOI) situated in the multiple cloning site (MCS) is transcribed by 
the Tet-On 3G transactivator protein.  This protein is expressed constitutively in an 
inactive conformation from another location on the pTetOne vector.  The binding of 
doxycycline changes the transactivator protein into its active conformation, allowing it 
to function as a promoter for the GOI.  Adapted from Tet-One Inducible Expression 
System User Manual (Clontech), pages 3 and 14. 
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The cell lines generated were named CHO-S XBP1s-pTetOne (abbreviated to X1), Ero1α-
pTetOne (E1) and GADD34-pTetOne (G1).  A derivative of X1 was later generated which 
constitutively overexpressed ER-localised blue fluorescent protein (BFP) (Costantini et 
al. 2015), and this cell line was named X1-B.  It was intended that the presence of BFP 
in this cell line could be used to monitor any expansion of the ER caused by the 
overexpression of XBP1s in living cells.  However, it was subsequently found that XBP1s 
overexpression actually caused a reduction in both BFP protein levels and the amount of 
blue fluorescence in the cell (data shown in Chapter 5), and therefore this cell line 
could not be used for its intended purpose.  Despite this setback, it was found that X1-B 
had better growth characteristics and XBP1s induction than its parental cell line, X1, 
and therefore X1-B remained in use as an alternative example of an XBP1s 
overexpressing cell line. 
It was also intended that a cell line be made with inducible overexpression of XBP1s and 
Ero1α, to function as an inducible equivalent of CHO-S XE.  To achieve this, the E1 cell 
line was stably co-transfected with XBP1s-pTetOne and a linear hygromycin resistance 
marker, resulting in a cell line with overexpression of both XBP1s and Ero1α controlled 
by the addition of doxycycline.  The selected clone from this transfection, named EX1, 
could grow in medium containing an otherwise lethal dose of puromycin and 
hygromycin, and initial western blot screening confirmed the presence of both Ero1α 
and XBP1S.  However, a later experiment to confirm GOI expression showed only 
endogenous levels of XBP1S, suggesting that expression of the second transgene had 
been lost over time.  EX1 had retained expression of Ero1α, however, and was therefore 
used as an alternative cell line to E1 with inducible Ero1α overexpression. 
In a similar principal to engineering EX1, an XBP1s co-overexpressing derivative of G1 
was also made, where the presence of doxycycline could have potentially triggered the 
expression of both GADD34 and XBP1s.  This would have been a novel combination of 
UPR genes which had not been previously investigated, but unfortunately, preliminary 
western blot screening of the selected GX1 cells showed no expression of XBP1S in any 
of the clones.  The GX1 cell line was, therefore, abandoned and no subsequent 
experiments were performed in these cells. 
Some success has been reported in the literature in increasing recombinant protein 
production by inducible overexpression of genes relevant to the secretory and stress 
response.  These studies are discussed in detail in Chapter 1, but the work by Gulis and 
colleagues is of particular relevance to this work.  In that study, XBP1s induction was 
controlled by a T-REx Tet-On inducible system in CHO-K1 cells that had constitutive 
expression of antibody (Gulis et al. 2014).  The addition of doxycycline to these cells led 
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to a three-fold increase in antibody productivity after seven days of XBP1s induction, 
indicating that XBP1s overexpression can cause a demonstrable increase in antibody 
yield in cells with stable antibody expression.  This project will expand on the work of 
Gulis and colleagues by investigating the effect of XBP1s overexpression, as well as that 
of Ero1α and GADD34, in cells that have been transiently transfected with antibody.  
Although a transient gene expression system has some experimental disadvantages 
compared to a stable expression system, most notably the variation in transfection 
efficiency between experiments, it was chosen for use in this project as it more 
accurately reflects the production methods employed by UCB in the industrial scale 
manufacture of therapeutic proteins. 
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Figure 4-2 - Generation of CHO-S derived inducible cell lines. 
Populations of CHO-S were transfected with GADD34-pTetOne, XBP1s-pTetOne or 
Ero1α-pTetOne and puromycin resistant clones were selected and screened for GOI 
expression by western blotting.  The resulting cell lines were then subsequently 
transfected: G1 and E1 with XBP1s-pTetOne, and X1 with an ER-localised blue 
fluorescent protein. 
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4.2 Results 
4.2.1 Screening for GOI expression in X1 cells. 
The engineered cell lines were first screened for GOI expression.  In order to confirm 
expression of XBP1S in CHO-S X1, cells were either treated with doxycycline for the 
time periods indicated in Figures 4-3, or left uninduced.  After this treatment period the 
cells were lysed, the lysates were separated by SDS PAGE and probed for the presence 
of XBP1S with an anti-XBP1S primary antibody by western blotting.   
Figure 4-3A (i) displays an anti-XBP1S western blot performed with induced lysates of X1 
cells.  XBP1S is seen to be induced after 1 day of doxycycline treatment, and levels 
remain high on the second and third days of treatment.  The protein bands of the anti-
XBP1S blot, as well as that of an anti-GAPDH blot of the same samples, were quantified 
by densitometric analysis, and Figure 4-3B(ii) shows a graph of XBP1S intensities 
normalised against the GAPDH loading control.  The y axis units of the graph are 
arbitrary, and reflect the relative abundance of XBP1S intensity when divided by the 
pixel intensity of GAPDH.  These units have the potential to vary significantly between 
experiments, depending on the primary and secondary antibodies used and the 
development settings on the Licor Odyssey scanner.  Therefore, the y axis units cannot 
be used to compare the expression of different proteins on different western blots, only 
for comparing the relative intensity of bands on the same blot.  The quantification 
confirms the low levels of XBP1S in the uninduced control, and high protein levels in 
samples induced with doxycycline. 
In order to find if the protein induced in X1 was capable of functional downstream 
signalling, the induced X1 lysates were later probed with anti-PDI, as this is a protein 
that is upregulated downstream of XBP1 signalling (Kaufman et al. 2002).  The anti-PDI 
blot shown in Figure 4-3B(i) and the equivalent quantification in Figure 4-3B(ii) shows 
that PDI levels rise when X1 is treated with doxycycline, suggesting that this increase is 
due to upregulated XBP1S.   
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Figure 4-3 – Screening for XBP1S expression in X1 cells. 
(A) (i) Western blot of lysates induced with doxycycline for the indicated number of 
days, probed with anti-XBP1S and anti-GAPDH, n=3, a blot a representative of the 
results obtained is shown (ii) Densitometric analysis of this blot, quantifying XBP1S 
normalised to GAPDH.  (B) (i) Western blot of the same samples probed with anti-PDI, 
n=1.  (ii) Quantification of this blot, showing PDI normalised to GAPDH expression. 
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4.2.2 Screening for GOI expression in E1 cells. 
GOI induction in E1 cells was confirmed in a similar manner to X1 cells.  The anti-Ero1α 
blot in Figure 4-4A(i) and quantification in (ii) shows induction of Ero1α after 16 hours of 
doxycycline treatment, and levels remain high at 20 hours, 24 hours and 40 hours post-
induction.  The concentration of doxycycline required for induction was also titrated, 
and the abundance of Ero1α after 48 hours of treatment with the indicated 
concentrations shown in Figures 4-4B(i) and (ii).  No induction is seen with either no 
doxycycline treatment or treatment with 1 ng/mL doxycycline, but a small degree of 
induction is seen at treatments with 10 ng/mL and 100 ng/mL doxycycline.  The highest 
extent of induction is seen with 1000 ng/mL doxycycline.  As doxycycline is known to 
have a relatively short half-life of 24 hours in cell culture medium (Gossen et al. 1995), 
this dose was determined to be optimal to allow a high degree of GOI induction without 
causing cell mortality, as it has been reported that concentrations of doxycycline above 
1 μg/mL can compromise cell viability (Gulis et al. 2014). 
Ero1α protein exists in both an active form and an inactive form, and these two forms 
are distinguished by the presence of an additional, regulatory disulphide bond in the 
inactive form which blocks the exchange of disulphide bonds between Ero1α and its 
client proteins (Appenzeller-Herzog et al. 2008).  The difference in disulphide bond 
configuration can be visualised by a band shift on an SDS PAGE gel when Ero1α protein 
samples are separated under reducing and non-reducing conditions.  In a reducing 
environment, Ero1α exists entirely in a fully reduced form which appears on an SDS 
PAGE gel at around 58 kDa, whereas under non-reducing conditions Ero1α appears as a 
doublet around 48 kDa - 52 kDa, where the upper band of this doublet is representative 
of the active form and lower band represents the inactive form.  Figure 4-4C shows 
lysates of induced E1 cells separated in the presence or absence of the reducing agent 
DTT.  The non-reducing sample shows a band for Ero1α at 48 kDa, which appears to 
represent the inactive form, and only a faint smear can be seen above this to represent 
the active form.  This suggests that the Ero1α induced in E1 cells is found predominantly 
in the inactive form. 
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Figure 4-4 – Screening for Ero1α expression in E1 cells. 
(A) (i) Western blot of lysates induced with doxycycline for the indicated number of 
hours, probed with anti-Ero1α and anti-GAPDH, n=1.  (ii) Quantification of this blot, 
showing Ero1α normalised to GAPDH.  (B) (i) Western blot of lysates from cells treated 
with the indicated concentrations of doxycycline for 48 hours, n=1.  (ii) Quantification 
of Ero1α normalised to GAPDH expression.  (C) Induced E1 lysates were separated by 
SDS PAGE in the presence or absence of the reducing agent DTT, to allow clearer 
identification of the active and inactive forms of the protein, n=1. 
Chapter 4 Effect of inducible gene overexpression on antibody yield  
93 
 
4.2.3 Screening for GOI expression in G1 cells. 
The presence of GADD34 in induced G1 cells was probed for using an anti-FLAG 
antibody, as the sequence for GADD34 in the pTetOne vector was designed to 
incorporate a FLAG tag.  G1 cells were treated with a range of doxycycline 
concentrations for 48 hours, and lysates of these cells were separated by SDS PAGE and 
probed with the anti-FLAG antibody.  The western blot in Figure 4-5 (i) and 
quantification in Figure 4-5 (ii) indicates that G1 cells respond to lower concentrations 
of doxycycline in a similar manner to E1 cells, in that 1000 ng/mL doxycycline produces 
the strongest GOI induction, and lower concentrations produce lower levels of GADD34. 
 
 
 
 
 
 
  
 
Figure 4-5 – Screening for GADD34 expression in G1 cells. 
(i) Western blot of lysates from cells treated with the indicated concentrations of 
doxycycline for 48 hours, probed with anti-FLAG (to detect FLAG-tagged GADD34) and 
anti-GAPDH, n=1.  (ii) Quantification of this blot showing GADD34 normalised to GAPDH 
expression. 
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4.2.4 Screening for GOI expression in X1-B cells. 
The derivative cell line of X1, named X1-B, was engineered to stably express an ER-
localised form of BFP in addition to the inducible overexpression of XBP1s.  X1-B was 
characterised in terms of its retention of XBP1S expression and the presence of BFP 
protein.  The western blot in Figure 4-6A (i) and the equivalent quantification in Figure 
4-6A (ii) shows the induction of XBP1S with doxycycline, indicating that the clone of X1-
B selected has retained the XBP1s-pTetOne vector. 
In order to confirm the presence of stable BFP expression, CHO-S, X1 and X1-B cells 
were transiently transfected with the same BFP vector that was used to make X1-B, or 
left untransfected, to act as a positive control for the presence of BFP.  Each of the cell 
lines was then either induced with doxycycline or left uninduced, and then lysed 48 
hours later.  Figure 4-6B(i) displays an anti-BFP western blot of these lysates, and Figure 
4-6B(ii) shows the quantification of the BFP normalised to GAPDH.  X1-B is seen to stably 
express BFP, whereas S and X1 do not, but the extent of stable BFP expression in X1-B is 
lower than the BFP protein levels observed after a transient transfection in any of the 
three cell lines.  Although it may be expected that transiently transfected X1-B would 
have higher BFP levels than CHO-S or X1, as X1-B has two sources of BFP expression, it 
does not appear that the BFP derived from stable expression and transient expression in 
X1-B are cumulative.  It can also be observed that there is a small decrease in BFP 
expression in untransfected X1-B cells that are induced, compared to uninduced 
samples, and this observation will be expanded on in Chapter 5. 
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Figure 4-6 – Screening for XBP1s induction and BFP expression in X1-B cells. 
(A) (i) Immunoblot of lysates from X1-B cells treated with or without doxycycline probed 
with anti-XBP1S, n=1.  (ii) Quantification of XBP1S band intensity normalised against 
intensity of GAPDH.  (B) (i) Anti-BFP western blot of induced and uninduced CHO-S, X1 
and X1-B lysates that have been transiently transfected with BFP as a positive control, 
or left untransfected, n=1. (ii) Quantification of this blot. 
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4.2.5 Screening for GOI expression in EX1 cells. 
The EX1 cell line is a derivative of E1, and was generated by stable transfection of E1 
with XBP1s-pTetOne, the same inducible vector that was used to make the X1 cell line.  
It was intended that EX1 would have both XBP1s and Ero1α expression controlled by the 
presence of doxycycline, and this was tested by western blots of induced EX1 lysates.  
Figure 4-7A (i) shows the initial anti-XBP1S blot of lysates from selected EX clones.  The 
EX1 clone is seen to have higher XBP1s induction than that of another selected clone of 
EX, which for this experiment is named EX-null.  Although XBP1s expression after 
doxycycline treatment is high in EX1, it is also fairly high in untreated cells which 
suggests that the expression is leaky.  The anti-Ero1α immunoblot of the same lysates, 
shown in Figure 4-7A(ii), displays very high induction of Ero1α in doxycycline treated 
EX1, and little to no Ero1α expression in untreated EX1 or the EX-null clone. 
An additional screen for continued GOI expression was performed after the EX1 clone 
had been freeze-thawed once and cultured for around 10 passages.  In this screen 
induced and uninduced lysates were compared to samples from X1-B, which has been 
shown previously in Figure 4-6 to have XBP1S induction and is included as a positive 
control for XBP1 expression.  In the anti-XBP1S western blot in Figure 4-7B(i), EX1 is 
seen to have much lower expression of XBP1S than X1-B, and appears to not have 
induction of XBP1S at all.  This disappointing result meant that EX1 could not be used as 
an example of a cell line with both XBP1S and Ero1α overexpression, proteins that 
would have been interesting to investigate together due to their relevance to the CHO-S 
XE cell line.  However, an anti-Ero1α immunoblot showed the presence of Ero1α in 
induced EX1 cells, shown in Figure 4-7B(ii), and EX1 was therefore retained in culture as 
an alternate sample of an Ero1α overexpressing cell line.  
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Figure 4-7 – Screening for XBP1S and Ero1α induction in EX1 cells. 
(A) Initial screening of clones of E1 stably transfected with XBP1s-pTetOne.  Cells 
were treated with or without doxycycline and probed with (i) anti-XBP1S or (ii) anti-
Ero1α.  The clone with the highest expression of XBP1S and Ero1α was named EX1, 
and expression is shown in comparison to another selected EX clone with little to no 
expression of the two GOI, named EX-null.  (B) (i) Anti-XBP1S and (ii) anti-Ero1α 
western blots of lysates from cells that had been freeze-thawed once and grown for 
approximately 10 passages after thawing.  EX1 lysates were examined with X1-B 
lysates as a positive control in the anti-XBP1S blot and a negative control in the anti-
Ero1α blot.   
Chapter 4 Effect of inducible gene overexpression on antibody yield  
98 
 
4.2.6 Comparison of induction in XBP1s expressing cell lines 
In order to find if XBP1s was induced to a similar extent in X1-B as in X1, and how this 
compares to the stable overexpression of XBP1s in CHO-S XE-D, induced and uninduced 
samples of each of the XBP1s expressing cell lines were separated by SDS PAGE and 
probed with anti-XBP1S.  Samples from CHO-S, X1 and X1-B are shown in Figure 4-8A(i) 
and XE-D and EX1 samples are shown in Figure 4-8A(ii).  The quantification of XBP1s 
expression normalised to GAPDH is shown Figure 4-8B(i) for S, X1 and X1-B and Figure 4-
8B(ii) for XE-D and EX1.  As the different samples were loaded onto two different SDS 
PAGE gels, the relative quantification of XBP1 induction in B(i) and B(ii) cannot be 
directly compared. 
X1-B is seen to have the highest induction of XBP1 with doxycycline treatment, higher 
than the equivalent expression in X1.  This increase in expression in X1-B compared to 
X1 was observed on multiple occasions, and as the only known difference between X1 
and X1-B is the presence of BFP in X1-B, it is not immediately apparent why X1-B would 
have higher XBP1 expression. 
EX1 has previously been shown (Figure 4-7) to have no additional expression of XBP1 in 
the presence of doxycycline, implying that the inducible vector was lost with successive 
passages.  EX1 is, therefore, functioning as a negative control for XBP1 expression for 
the purposes of this western blot, and XE-D is seen to have higher expression of XBP1 
than EX1, as would be expected based on previous gene expression data for XE-D.  
Somewhat surprisingly, doxycycline treated XE-D samples appear to have higher 
expression than uninduced.  This was unexpected as the promoter for XBP1 in XE-D is 
not doxycycline responsive.  As previously mentioned, the expression of XBP1 cannot be 
quantitatively compared between X1, X1-B and XE-D, but visual comparison of the 
western blot data suggests that the stable expression of XBP1 in XE-D is lower than the 
inducible expression in X1 and X1-B. 
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Figure 4-8 – Comparison of XBP1 induction in X1, X1-B, XE-D and EX1 cells. 
(A) Anti-XBP1 immunoblots of induced and uninduced lysates from (i) CHO-S, X1, X1-B 
(ii) XE-D and EX1.  Samples of doxycycline treated and untreated cells were obtained at 
least three times for CHO-S, X1 and X1-B, and once for XE-D and EX1.  A side-by-side 
comparison of these samples was performed once.  (B) Quantification of the above 
western blots, normalising XBP1 expression to GAPDH.  The y axis units are arbitrary; 
quantifications derived from different western blots cannot be directly compared, and 
the only comparison that can be reliably made is the relative difference between 
samples on the same blot. 
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4.2.7 Determining altered antibody yield in induced cells. 
After determining that each of the engineered cell lines had the ability to overexpress 
the intended GOI, other than the exceptions previously mentioned, the effect of 
inducible gene expression on antibody yield was then investigated.  A population of one 
of the inducible cell lines was transiently transfected with IgG heavy and light chains 
using a chemical transfection method and grown in a small scale (25 mL) suspension 
culture overnight.  The following day, this single transfected population was split evenly 
into six flasks: three of these flasks were induced with doxycycline and three were left 
uninduced.  As it was observed that transfected CHO-S cells are prone to clumping, an 
anti-clumping agent was added to all six flasks.  The cells were grown for a further 
three days, and on the final day the number of viable cells in each flask was counted 
using duplicate readings and a sample of medium containing secreted antibody was 
extracted.   
The concentration of antibody in this sample was determined using an antibody capture 
ELISA against a standard curve of a known concentration of IgG1 antibody.  Medium 
samples were loaded onto the ELISA plate in triplicate, and the triplicate readings for 
each of the three flasks of the same treatment were averaged together to calculated an 
overall average for doxycycline treated and untreated cells.  Productivity was 
calculated by dividing the average final concentration of antibody in each flask by the 
average number of viable cells in that flask at the end of the three day period to obtain 
a value for productivity measured in pg/cell. 
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Figure 4-9 – Schematic of antibody yield experiments. 
A single transfection was performed per experiment, and three separate experiments 
were performed for each cell line.  In a single experiment: cells were transfected and 
split 24 hours post transfection into six identical flasks.  Doxycycline was added at 
this point to three flasks.  After three days of growth, medium samples were taken 
from each flask and the concentration of antibody was read in triplicate by antibody 
capture ELISA.  An average was taken of the replicate readings and the triplicate 
flasks to obtain an overall average of antibody concentration calculated from nine 
readings.  This value was normalised against the average final cell count of the three 
flasks to calculate the productivity of cells under each treatment.  Productivity was 
represented by pg of antibody per cell (pg IgG/cell)  
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4.2.8 Antibody yield in wild-type CHO-S cells 
As wild-type CHO-S cells do not contain any genes under the control of a doxycycline 
responsive promoter, this cell line was used a control to ensure that the doxycycline 
treatment was not impairing the growth of the cells.  Figure 4-10 shows the average 
concentration of transiently transfected antibody across the triplicate flasks at the end 
of the three day period; the average cell count of the transfected cells; and the average 
productivity of the flasks (pg/cell), calculated as the concentration of antibody (in 
ng/mL) divided by the cell count (cells/mL).  The data for triplicate experiments are 
shown separately and labelled as experiments 1, 2 and 3, where each of these 
experiments represents a single initial transfection.   
The concentration of antibody post-transfection does not vary significantly between 
untreated and doxycycline treated cells for each of the three experiments.  Cell count 
is also not significantly altered by doxycycline treatment, suggesting that any changes 
observed in cell count for the inducible cells lines is due to the activity of the induced 
gene, and not caused by the presence of doxycycline in the medium.  The cell count 
does appear to vary between the triplicate experiments, however, and the average cell 
count of experiment 3 is almost three times the cell count of experiment 1.  It is not 
clear why this is the case, as the number of cells transfected in each experiment was 
the same.  Productivity is shown to be significantly higher in doxycycline treated CHO-S 
for one of the three experiments, as determined by a Student’s T Test (p = <0.05), 
significantly lower in doxycycline treated cells in another experiment, and the third 
experiment showed no significant difference between treated and untreated cells.  
Therefore, there does not appear to be a consistent effect of doxycycline on either the 
growth of CHO-S or the ability of the cell to secrete antibody. 
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Figure 4-10 – Antibody yield from transiently transfected CHO-S cells. 
The concentration of secreted antibody (ng/mL) present in the medium of cells 
treated with or without doxycycline for three days was measured by antibody capture 
ELISA.  This was normalised against the final cell count (cells/mL) to calculate 
productivity (pg/cell).  The experiment was performed three times; each experiment 
represents a single transfection.  Samples marked with * are significantly different (p 
= <0.05 as determined by T test) to the differently treated sample for that 
experiment. 
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4.2.9 Antibody yield in X1 cells 
X1 cells were transfected with antibody using the same experimental protocol as 
described for CHO-S.  The final concentration of antibody, cell counts and calculated 
productivity are shown in Figure 4-11.  Antibody concentration does not vary 
significantly between XBP1s induced and uninduced cells, but the cell count is shown to 
be significantly lower in cells which overexpress XBP1s.  Due to this lower cell count, 
when the productivity of each sample is calculated by dividing the antibody 
concentration by the number of cells, the productivity is significantly higher in 
doxycycline treated cells.  This significant difference is consistent across the three 
experiments, and suggests that XBP1s overexpression is compromising the viability of 
the transfected cells.  However, as antibody concentration remains the same between 
doxycycline treated and untreated cells, it is possible that there is a small increase in 
yield in XBP1s overexpressing cells that makes up for the lower number of cells in these 
flasks. 
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Figure 4-11 – Antibody yield from transiently transfected X1 cells. 
The concentration of secreted antibody (ng/mL) present in the medium of cells 
treated with or without doxycycline for three days was measured by antibody capture 
ELISA.  This was normalised against the final cell count (cells/mL) to calculate 
productivity (pg/cell).  The experiment was performed three times; each experiment 
represents a single transfection.  Samples marked with * are significantly different (p 
= <0.05 as determined by T test) to the differently treated sample for that 
experiment. 
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4.2.10 Antibody yield in E1 cells 
The final concentration of antibody from transfected E1 cells is equivalent between 
cells with induced Ero1α and uninduced cells, as shown in Figure 4-12.  The cell count 
also remains equivalent, with the exception of the uninduced cells in experiment 3 
which have a significantly higher number of viable cells.  This variation in cell count 
leads to a significantly higher value for productivity for Ero1α induced cells in 
experiment 3.  However, as there is no observable difference in productivity in 
experiments 1 or 2, it is most likely that the overexpression of Ero1α has no significant 
effect on cell viability or antibody yield. 
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Figure 4-12 – Antibody yield from transiently transfected E1 cells. 
The concentration of secreted antibody (ng/mL) present in the medium of cells 
treated with or without doxycycline for three days was measured by antibody capture 
ELISA.  This was normalised against the final cell count (cells/mL) to calculate 
productivity (pg/cell).  The experiment was performed three times; each experiment 
represents a single transfection.  Samples marked with * are significantly different (p 
= <0.05 as determined by T test) to the differently treated sample for that 
experiment. 
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4.2.11 Antibody yield in G1 cells 
The induction of GADD34 in G1 cells causes a significant drop in the concentration of 
transfected antibody in all three experiments.  It appears that the transfection 
efficiency was fairly low in experiment 1 as the concentration of antibody and cell 
count is much lower for experiment 1 than for the other two experiments. The cell 
count does not vary significantly in induced cells in either experiment 2 or 3, which 
suggests that the drop in antibody productivity observed is not as a result of a drop in 
cell viability.  This is surprising as GADD34 has a known role in apoptosis, and so the 
drop in antibody yield appears to be mediated by an unknown mechanism. 
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The concentration of secreted antibody (ng/mL) present in the medium of cells treated 
with or without doxycycline for three days was measured by antibody capture ELISA.  
This was normalised against the final cell count (cells/mL) to calculate productivity 
(pg/cell).  The experiment was performed three times; each experiment represents a 
single transfection.  Samples marked with * are significantly different (p = <0.05 as 
determined by T test) to the differently treated sample for that experiment. 
  
 
Figure 4-13 - Antibody yield from transiently transfected G1 cells. 
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4.2.12 Antibody yield in X1-B cells 
The X1-B cell line has inducible, doxycycline responsive expression of XBP1s and 
constitutive expression of ER-localised BFP.  When the antibody yield of this cell line 
was measured by the same procedure as previously described, there is a significant rise 
in the final concentration of antibody for one of the three experiments, and no 
variation in yield for the other two, as shown in Figure 4-14.  However, there does not 
appear to be the same drop in cell viability in induced X1-B as there was in X1, as only 
experiment 3 has a significantly lower cell count for induced cells.  Productivity is 
calculated to be significantly higher in experiments 1 and 3, and it appears that this 
increase is representative of an increased capacity for X1-B to produce antibody, and 
not simply a reflection of lowered cell viability as was seen in X1. 
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Figure 4-14 - Antibody yield from transiently transfected X1-B cells. 
The concentration of secreted antibody (ng/mL) present in the medium of cells 
treated with or without doxycycline for three days was measured by antibody capture 
ELISA.  This was normalised against the final cell count (cells/mL) to calculate 
productivity (pg/cell).  The experiment was performed three times; each experiment 
represents a single transfection.  Samples marked with * are significantly different (p 
= <0.05 as determined by T test) to the differently treated sample for that 
experiment. 
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4.2.13 Antibody yield in EX1 cells 
The EX1 cell line is a derivative of E1 that was stably transfected with XBP1-pTetOne, 
the same inducible XBP1 vector used to generate X1.  Despite the initial western blot 
screening of this cell line that showed both XBP1 and Ero1α expression in the presence 
of doxycycline, a later screen showed that although Ero1α induction had been retained, 
XBP1 expression had been lost.  The experiments to measure antibody productivity in 
EX1 had been performed immediately prior to this screen, so it can be assumed that at 
the time of these experiments the addition of doxycycline to EX1 would only induce the 
expression of Ero1α, and not XBP1. 
The concentration of secreted antibody and viable cell density of induced and 
uninduced, transiently transfected EX1 cells were measured and the productivity 
calculated, as shown in Figure 4-15.  Antibody concentration is not significantly higher 
in doxycycline treated EX1 cells, which is similar to the result observed in E1.  The 
average cell count is also significantly lower in one of these experiments, but not in the 
other two, which is also similar to E1.  Productivity is significantly higher in two out of 
three experiments for EX1, whereas only one experiment was higher for E1.  Generally, 
there does not appear to be a consistent positive effect of doxycycline treatment on 
antibody productivity in EX1, but EX1 appears to have slightly better secretory 
properties than E1.  
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Figure 4-15 – Antibody yield from transiently transfected EX1 cells. 
The concentration of secreted antibody (ng/mL) present in the medium of cells treated 
with or without doxycycline for three days was measured by antibody capture ELISA.  
This was normalised against the final cell count (cells/mL) to calculate productivity 
(pg/cell).  The experiment was performed three times; each experiment represents a 
single transfection.  Samples marked with * are significantly different (p = <0.05 as 
determined by T test) to the differently treated sample for that experiment. 
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4.3 Discussion 
The purpose of engineering the inducible cell lines was to analyse the effect of the 
overexpression of a single gene on the ability of the cell to secrete antibody in a tightly 
controlled environment.  It was first confirmed that each of the cell lines was capable 
of inducing the intended GOI, and then the concentration of secreted antibody from 
induced and uninduced cells was measured.  X1 and X1-B were shown to strongly induce 
XBP1S after 24 hours of doxycycline treatment, and the levels of induced protein 
remained high for at least a further two days.  Out of these two cell lines, X1-B was 
shown to have higher induction of XBP1S than its parent, X1.   
X1 was calculated to have higher productivity in induced cells for all three of the 
experiments; however, a closer examination of the data revealed that this apparent 
increase could be mostly attributed to a significant drop in viable cell density.  
Therefore, it appears that doxycycline treatment in X1 did not cause any desirable 
improvement to the cells’ secretory phenotype, and merely reduced the viability of the 
cell.  Despite this finding, the derivative of X1, X1-B, did appear to show a genuine 
improvement in antibody productivity when induced.  X1-B also did not display the same 
drop in viability upon doxycycline treatment as was observed in X1, although it should 
be noted that the cell counts were much lower for X1-B than X1 in the three antibody 
yield experiments whether they were induced or not.  The discrepancy between the 
results observed in X1 and X1-B could be attributed to the increased extent of XBP1s 
induction in X1-B, resulting in there being a greater distinction between induced and 
uninduced X1-B than there was for X1. 
Although the induction of XBP1s in X1-B causes around a 1.4 fold, statistically significant 
increase in productivity, it is smaller than the three fold increase observed by Gulis et 
al when using a similar XBP1s inducible system (Gulis et al. 2014).  There are a number 
of notable differences in methodology between this work and the experiments 
performed in X1 and X1-B which could contribute to the differences in results.  Gulis et 
al performed their experiments in CHO-K1 cells stably transfected with antibody, grown 
in adherent culture, and induced XBP1s using a T-REx system over seven days; whereas 
X1 and X1-B are CHO-S derived cell lines, transiently transfected with antibody, grown 
in suspension culture and induced XBP1s by a pTetOne system over three days.  Of these 
factors, perhaps the most significant would be the use of a transient antibody 
transfection with a shorter period of induction.  It is possible that the effect of XBP1s on 
the ability of the cell to secrete antibody is consistent between the experiments, but a 
longer period of induction would have allowed a greater degree of distinction between 
induced and uninduced cells.  
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E1 was shown to have strong induction of Ero1α, but the induced Ero1α also appears to 
mostly exist in an inactive form.  This finding could perhaps explain the similarity of the 
antibody secretion and cell counts of induced and uninduced E1, as the induced Ero1α 
protein is mostly not functional and is not able to recycle PDI.  In the literature, it has 
been shown that CHO-K1 cells stably transfected with Ero1α had increased antibody 
productivity than wild-type CHO-K1 (Cain et al. 2013).  Ero1α was also one of the 
overexpressed genes in CHO-S XE, alongside XBP1s, and was presumed to have an 
essential role in its high yield phenotype.  Therefore, it would be expected that the 
inducible overexpression of Ero1α would have a similar effect on antibody expression in 
E1, but this does not seem to be the case.  One possible explanation for this discrepancy 
is that the exogenous Ero1α in CHO-S XE1 was shown to exist in roughly equal 
abundance of the active and inactive forms (Cain et al. 2013), whereas the Ero1α in E1 
is almost entirely inactive.  This suggests that the Ero1α in CHO-S XE1 has a greater 
ability to recycle PDI than the Ero1α in E1, which may explain why CHO-S XE1 has higher 
productivity than induced E1.  In order to compensate for the low levels of active Ero1α 
induced in E1, it is possible that sustained induction for a time period of longer than 
three days would allow accumulation of active Ero1α, and this would show a more 
pronounced effect on the secretory properties of the cell. 
G1 cells induced with doxycycline displayed a lower final concentration of secreted 
antibody in all three of the experiments performed.  The cell count is significantly 
lower in one of the experiments, and lower in the other two but not to a significant 
degree.  This reduction in the number of viable cells could explain the lower 
concentration of secreted antibody, and could be due to the activity of overexpressed 
GADD34 triggering apoptosis in the cells.   
The observed results in G1 are contradictory to the findings published by Omasa and 
colleagues, who reported a two-fold increase in recombinant antithrombin III (AT-III) 
production in a clone with constitutive expression of both GADD34 and AT-III, compared 
to its parental cell line which only expressed AT-III (Omasa et al. 2008).  In this study, 
the GADD34 overexpressing clone had a slower rate of growth and lower maximum 
viable cell density than its parent population, which is similar to the results seen in G1.  
However, no increase was observed in recombinant protein production in G1, and this 
could be due to a number of factors.  The experiments by Omasa and colleagues were 
performed over six days, whereas the experiments in G1 were performed over three 
days, and therefore, as previously mentioned, a longer period of GADD34 induction and 
antibody secretion could have revealed a greater distinction between induced and 
uninduced G1.  Another difference between the experiments is that a transient system 
was used in G1, for both GADD34 expression and recombinant protein expression, and 
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the cell line used by Omasa et al. utilised stable gene expression.  It has been reported 
that stable and transient gene expression can generate different results involving the 
same recombinant proteins (Ku et al. 2008), and this discrepancy may depend on the 
function of the exogenous proteins, and the presence and extent of bottlenecks in the 
secretory pathways. 
Although EX1 appeared to lose expression of XBP1s with subsequent passages, 
productivity was shown to be higher in induced EX1 than uninduced in two out of the 
three experiments.  Therefore, it is possible that induction of XBP1s was not lost 
completely in EX1, but the extent of induction was reduced to levels that are slightly 
higher than endogenous, but still indistinguishable from uninduced by a western blot.  
This could perhaps explain why EX1 appears to have a different capacity to secrete 
antibody than E1, when the western blot suggests that E1 and EX1 induce the same 
proteins. 
One hypothetical basis for the differences between EX1 and E1, and between X1-B and 
X1, is that EX1 and X1-B have both been subjected to two rounds of transfection and 
clonal selection, whereas E1 and X1 were only transfected once.  During a stable 
transfection the vector containing the transgene is incorporated into the host genome 
at a random site, which can disrupt the host cell genome in unexpected ways and lead 
to gene silencing or enhancement.  CHO cells are also notorious for genomic instability 
(Chasin and Urlaub 1975), therefore, it is possible that unexpected mutations arose in 
EX1 and X1-B during the second round of stable transfection that led to an improvement 
in XBP1s induction and viability in X1-B, and a small increase in antibody secretion in 
EX1. 
For all of the cell lines tested, it could be proposed that lengthening the period of 
doxycycline induction from three days to between five and seven days could improve 
the reliability of the results obtained.  In fact, a time period of five days was used 
initially for induction during the antibody productivity experiments; however, a number 
of technical problems were encountered when using this protocol.  The most severe of 
these problems was that the cells were observed to reach a maximum cell density four 
days after the addition of doxycycline and a large proportion of cells on the final day of 
the experiment were shown to be dead.  In order to rectify this, the number of 
transfected cells in each flask was reduced, but this only resulted in the cells taking 
longer to reach the exponential phase of growth.  It is possible that the culture period 
could be extended even further to account for this, if the medium and doxycycline were 
to be refreshed at appropriate intervals, but this would reduce the throughput of 
experiments.   
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Additionally, as a transient transfection system was used it is possible that the 
expression of transgene would drop with a lengthened culture time, as gene expression 
from a transient transfection is known to be diluted by successive cell divisions (Wong 
et al. 2015).  The experimental protocols described in (Gulis et al. 2014) and (Omasa et 
al. 2008) both employ stable expression of antibody, and therefore an increased 
experimental time period would not affect transgene expression.  By this logic, the 
inducible CHO-S cells used could be stably transfected with antibody to allow longer 
periods of transgene expression and doxycycline induction.  Experiments performed in 
these hypothetical cell lines would produce interesting results that could be contrasted 
with the results obtained using transient expression. 
Another alternative experimental procedure that could be performed with the inducible 
cell lines would be to swap the order of transfection and induction treatments.  If the 
cells were first induced with doxycycline over a period of two or three days and then 
subsequently transfected with antibody, the effect of inducible gene overexpression on 
antibody secretion could become more pronounced.  In addition to the previously 
mentioned disadvantages of lengthening the experiment by a few days, another 
disadvantage of this method is that there would be an increased level of statistical 
variation between induced and uninduced cells as each population would have been 
transfected separately.  As transfection efficiency is generally highly variable, and the 
results obtained when performing a single transfection were already seen to vary 
significantly between successive experiments in the same cell line, it was thought that 
performing two separate transfections in each experiment instead of one would 
increase statistical variation to unacceptable levels and reduce the reliability of the 
results obtained, and this is the primary reason why this experimental protocol was not 
used.  With a sufficient degree of optimisation, this alternative protocol could perhaps 
be utilised, and it has the potential to generate very useful and relevant data. 
As the greatest increase in antibody productivity was seen in cells overexpressing XBP1s: 
namely X1 and X1-B, as well as the previous findings from CHO-S XE-D, the focus of the 
project was refined onto the overall consequences of XBP1s overexpression on the 
phenotype of the cell.  The results from this section of work will be discussed in the 
next chapter. 
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5.1 Introduction 
5.1.1 Further investigation of CHO-S X1 and CHO-S X1-B 
This chapter will expand on the characterisation experiments described in Chapter 4 of 
the stable cell line named CHO-S X1, which has inducible expression of XBP1s, and the 
derivative of this cell line named CHO-S X1-B, which contains stably expressed ER-
localised blue fluorescent protein (ER-BFP) (Costantini et al. 2015).  These cell lines 
were chosen for further analysis as the induction of XBP1s overexpression appeared to 
have the greatest impact on the phenotype of the cell, namely the significant increase 
in antibody yield observed in X1-B and the significant drop in viability seen in X1.  This, 
together with the results described in Chapter 3 from the XBP1s overexpressing cell line 
CHO-S XE-D, pointed to XBP1s being a more compelling candidate for further study, as 
opposed to either GADD34 or Ero1α.  The consequence of XBP1s induction on the 
biochemistry of the ER was studied to find potential explanations for the previously 
observed improvements to antibody yield, which could lead to further areas of 
improvement in engineered host cell lines.  It was also thought that experiments 
utilising the controlled overexpression of XBP1s could be used to gain a greater 
understanding of the regulation of ER stress response signalling, an intricate and 
incompletely understood area of biochemistry.  
After determining the extent of XBP1s induction in X1 and X1-B in Chapter 4, and the 
effect of this induction on the yield of transiently transfected secreted antibody, the 
impact of XBP1s induction on other characteristics of the cell was investigated; in 
particular, the extent of ER expansion and endogenous XBP1 splicing after exogenous 
XBP1s induction.  An additional line of investigation was into the observed depletion of 
BFP in induced X1-B cells.  It was originally planned that the ER-localised BFP in X1-B 
could be used to monitor ER expansion in living cells, but unfortunately it was 
discovered that BFP was degraded during stress conditions and, therefore, was not fit 
for the purpose of the planned experiments.  However, as the X1-B cell line was found 
to have slightly higher levels of induced XBP1S than X1, it was retained in culture and 
used as an alternate example of an XBP1s inducible cell line.  In addition to the 
experiments quantifying the yield of antibody from these cells shown in Chapter 4, the 
mechanism behind the depletion of BFP was sought as it appeared to occur as a 
consequence of the upregulation of XBP1s in X1-B.  Therefore, it may have been an 
indication of upregulated ERAD, which is a known effect of XBP1s signalling (Acosta-
Alvear et al. 2007).  This possibility was tested using a proteasome inhibitor alongside 
the upregulation of XBP1s by either doxycycline or tunicamycin treatment.  Tunicamycin 
is an inhibitor of N-linked glycosylation which is able to induce the UPR through 
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disruption of the quality control procedures that would normally ensure the correct 
folding of proteins (Surani 1979).   
5.1.2 Quantification of XBP1 splicing 
The extent of XBP1 splicing was visualised and quantified using an RT-PCR based assay 
(Shang and Lehrman 2004).  As mentioned in Chapter 1, the splicing of XBP1 is 
performed by the endoribonuclease IRE1 under stress conditions and forms part of the 
UPR.  Spliced XBP1 transcripts are translated into XBP1S protein, a transcription factor 
which upregulates genes for chaperones, ERAD and lipid biogenesis as part of a 
concerted effort to expand the ER and increase the abundance of chaperones, in order 
to clear any misfolded proteins that may have triggered the UPR in the first place.  It 
should be noted that, although considered to be a hallmark of ER stress, a basal level of 
XBP1 splicing does occur as part of normal cell physiology (Wang et al. 2015).  Unspliced 
XBP1 transcripts are translated to XBP1U, which is not a transcription factor but can 
instead bind to XBP1S and target it to the proteasome as a method of regulating the 
abundance of XBP1S after a stress response has ended (Yoshida et al. 2006).  This 
degradation occurs at a rate almost equivalent to synthesis, and continued activation of 
IRE1 is required for sustained downstream XBP1S signalling (Tirosh et al. 2006).   
By designing primers that flank the XBP1 spliced intron, cDNA derived from XBP1s and 
XBP1u transcripts can be amplified by PCR and distinguished from each other by a 
subtle, 26bp difference in product size when run on an agarose gel.  This assay is also 
known to generate a third PCR product, shown diagrammatically in Figure 5-1, which is 
thought to be a hybrid double-stranded cDNA product consisting of one strand XBP1s and 
one strand XBP1u.  This hybrid product migrates above double-stranded XBP1u on an 
agarose gel due to its bulkier structure (Shang and Lehrman 2004).   
Two sets of primers were designed for the assay.  The first set was designed to only 
anneal to the endogenous Chinese Hamster sequence of XBP1, and these primers were  
used to quantify only endogenous XBP1s and XBP1u.  A second set of primers was 
designed to bind to both forms of endogenous CHO XBP1, and also to the exogenous 
human XBP1s transcripts that are expressed only by the pTetOne vector in response to 
doxycycline, allowing visualisation of all forms of XBP1 present in the cell.  These 
primer sets were utilised in the assay to determine the effect of exogenous induction of 
XBP1s on the regulation of endogenous XBP1 splicing. 
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Figure 5-1 – cDNA products generated by RT-PCR XBP1 splicing assay. 
Schematic of the three possible cDNA products generated by primers that flank the 
XBP1 spliced intron, which is indicated in blue.  Single stranded cDNA, reversed 
transcribed from unspliced XBP1 or spliced XBP1, can anneal to either its 
complementary strand to generate double stranded XBP1u and XBP1s products, or to a 
non-complementary strand to generate a hybrid, XBP1h, formed from one strand 
XBP1u and one strand XBP1s.  Of these three PCR products, XBP1s migrates the 
furthest on an agarose gel, followed by XBP1u and then by XBP1h, leading to the 
appearance of three distinct DNA bands.  Adapted from Shang and Lehrman, 2004, 
Figure 1B. 
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5.2 Results 
5.2.1 ER size in XBP1s overexpressing CHO cell lines.   
As XBP1s has a known role in ER expansion and lipid biogenesis (Shaffer et al. 2004), it 
was hypothesised that CHO cells with upregulated XBP1s would display a greater amount 
of ER than cells with endogenous XBP1s levels.  In order to determine the effect of high 
levels of XBP1s on the amount of ER, CHO-S, CHO-S X1, CHO-S X1-B and CHO-S XE-D cells 
were grown with or without doxycycline for three days, and then stained with ER 
Tracker.  This green fluorescent dye binds specifically to potassium channels prominent 
on the ER membrane (Zünkler et al. 2004), and the extent of green fluorescence taken 
up by the cell should be proportional to the amount of ER membrane.  Green 
fluorescence from stained cells was quantified using flow cytometry, as displayed in the 
histograms in Figure 5-2.  The blue line on the histograms represents the fluorescence 
of the population of cells not treated with doxycycline, and the red line represents 
doxycycline treated cells.   
CHO-S X1 and CHO-S X1-B show an increase in average green fluorescence per cell in 
response to doxycycline whereas CHO-S cells do not, implying that induced XBP1s is 
causing the ER to expand.  This result confirms that the XBP1s expressed by the 
pTetOne vector is functional as a transcription factor, and also provides a potential 
explanation for the increase in antibody productivity observed in X1-B cells in Chapter 
4.  It could perhaps be expected that CHO-S XE-D cells would display a larger ER than 
parental CHO-S cells due to the constitutively upregulated levels of XBP1s present in 
this cell line.  However, similar to the result observed in Chapter 3, CHO-S XE-D is seen 
to have the same amount of ER as both CHO-S, and uninduced X1 and X1-B. 
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Figure 5-2 – ER expansion is triggered by doxycycline in XBP1s inducible cell lines.   
Cells treated with doxycycline (red line) or without doxycycline (blue line) for three 
days were analysed by flow cytometry to measure green fluorescence after staining with 
ER Tracker.  Histograms of green fluorescence intensity against event count are shown 
for CHO-S, CHO-S XE-D, CHO-S X1 and CHO-S X1-B.  Experiment was performed three 
times, data from a representative experiment is shown. 
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5.2.2 Investigation of the loss of BFP in induced X1-B cells 
In the anti-BFP western blot shown in Figure 4-6, it was noted that a small decrease in 
BFP could be seen when X1-B was induced with doxycycline.  This observation was 
expanded on: firstly to confirm that the observed drop was genuine and reproducible, 
and secondly to find the cause of this depletion of BFP.  As a clarification of the 
differences between the two constructs in X1-B: only XBP1s expression should be 
altered by the presence of doxycycline, as the expression of BFP is controlled by a 
constitutive promoter. 
X1-B cells were treated with doxycycline for three days, or left untreated, and 
subsequently lysed.  Lysates were separated by SDS PAGE and probed with an anti-BFP 
antibody, and the resulting western blot is shown in Figure 5-3(i).  The intensity of BFP 
protein was normalised to the expression of GAPDH in the same lysates, and this 
normalised quantification of BFP is shown in Figure 5-3(ii).  The quantification confirms 
that BFP is found in lower abundance in doxycycline treated X1-B cells than untreated 
cells, and the logical implication of this is that the drop in BFP protein levels is caused 
directly by the upregulation of XBP1s.  GAPDH is seen to drop in doxycycline treated X1-
B cells, though this reduction is not equivalent to the drop seen for BFP.  The reduction 
in GAPDH could be a reflection of reduced cell viability, which would be similar to the 
reduction in viable cell density observed for doxycycline treated X1 cells in Chapter 4.  
It is also possible that the reduction in GAPDH is a direct effect of XBP1s 
overexpression, as CHO-S XE-D was observed to have consistently lower levels of GAPDH 
than CHO-S in equivalent numbers of cells. 
 
Figure 5-3 – BFP is depleted by XBP1s overexpression in X1-B cells. 
(i) Anti-BFP western blot of lysates from X1-B cells induced with doxycycline for 48 
hours, and anti-GAPDH blot of the same lysates, n=1.  (ii) Quantification of this 
western blot showing BFP expression normalised to GAPDH expression. 
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5.2.3 The loss of BFP in induced X1-B corresponds to a reduction in blue 
fluorescence 
In order to further explore the observed depletion of BFP, the effect of doxycycline 
treatment on the blue fluorescence from CHO-S X1-B cells was compared to the effect 
of tunicamycin treatment, which should upregulate endogenous XBP1s via triggering of 
the UPR.  CHO-S X1 and CHO-S X1-B cells were treated with either doxycycline or 
100ng/mL tunicamycin, or a combination of the two, for seven days.  Treatments were 
refreshed once after three days of incubation, and at the end of the seven day 
treatment period the cells were trypsinised, washed once, and then analysed by flow 
cytometry.  Figure 5-4 shows histograms of data captured using the Pacific Blue filter, 
which corresponds to the emission spectrum from BFP.   
Samples of X1 cells display a single peak of low intensity blue fluorescence, which 
represents autofluorescence as X1 cells do not contain the BFP construct.  
Autofluorescence is not seen to alter with either doxycycline or tunicamycin treatment.  
X1-B samples display the same peak for autofluorescence as X1, but also display a 
second, smaller peak of higher intensity fluorescence which represents blue 
fluorescence emitted by BFP.  It can be inferred from the large size of the 
autofluorescence peak in X1-B that the X1-B cell line is not clonal for BFP expression, 
and only a small subset of the population shows expression of BFP.  For instance, in the 
histogram of untreated X1-B cells, only 37.9% of cells emit a higher intensity of blue 
fluorescence than the equivalent X1 population. 
When the histograms for each cell line are overlaid, the right hand, higher intensity 
peak for fluorescence is seen to be largest in untreated X1-B cells, and smaller in cells 
treated with either doxycycline or tunicamycin.  Cells incubated with both treatments 
are seen to have the lowest blue fluorescence of all, which suggests that the 
downstream effects of doxycycline and tunicamycin are cumulative.  The reduction in 
blue fluorescence would appear to correlate with the previous result where levels of 
BFP protein were seen to decrease with doxycycline, and also expands on it with the 
observation that tunicamycin can cause a similar drop in the number of high fluorescing 
cells as that triggered by doxycycline.  This suggests that the depletion of BFP is 
mediated by XBP1s, and that this XBP1s can be derived from either exogenous or 
endogenous sources. 
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Figure 5-4 – BFP fluorescence in CHO-S X1-B cells is reduced by XBP1s induction or 
treatment with tunicamycin. 
Histograms of blue fluorescence against cell count data from CHO-S X1 and CHO-S X1-
B cells treated with doxycycline and/or tunicamycin.  Two overlaid histograms are 
shown for each cell line below the histograms of single samples.  These display the 
same data, but the bottom histogram has a shortened y axis scale to allow a clearer 
comparison of the data.  Experiment was performed three times, data from a 
representative experiment is shown. 
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5.2.4 Proteasomal inhibition does not affect the loss of BFP in CHO-S X1-B 
From the results obtained, it was hypothesised that the depletion of BFP was mediated 
by an upregulation of ERAD triggered by XBP1s overexpression, as this is a known 
downstream effect of XBP1s signalling (Acosta-Alvear et al. 2007).  In order to test the 
validity of this hypothesis, the proteasome inhibitor MG132 was used to block ERAD in 
CHO-S X1-B cells to determine if any reduction in BFP depletion could be observed.  
CHO-S X1-B cells were incubated with following treatments: 1 μg/mL doxycycline or 100 
ng/mL tunicamycin for three days; and/or 50 µM MG132 for six hours.  Lysates from 
these cells were probed with anti-BFP, as shown in Figure 5-5, or anti-XBP1, as shown in 
Figure 5-6.   
BFP is seen to decrease in abundance in cells treated with either doxycycline or 
tunicamycin, which correlates with the previous result from flow cytometry obtained 
for blue fluorescence.  Contrary to what was hypothesised, the subsequent addition of 
MG132 to these treated cells does not inhibit the loss of BFP, and in fact makes the 
depletion more severe than in cells not treated with MG132.  It can be seen that cells 
that were only treated with MG132 have a small increase in BFP, however, as each 
western blot was performed only once, no statistical analysis can be performed to 
determine if this increase is significant.  Similar to the western blot in Figure 5-3, a 
drop in GAPDH expression can be seen in cells treated with either doxycycline or with 
tunicamycin when compared to untreated cells.  As previously mentioned, this could be 
attributed to a drop in viable cell density caused by the added treatment, or could 
reflect a change in cell metabolism caused directly by XBP1s overexpression. 
  
Chapter 5 Consequence of XBP1s overexpression  
128 
 
 
Figure 5-5 – Proteasome inhibition does not block the depletion of BFP in induced 
X1-B cells. 
Anti-BFP western blot of lysates from X1-B cells treated with (A) doxycycline (B) 
tunicamycin, and/or the proteasome inhibitor MG132, n=1. (ii) Quantification of these 
western blots showing the relative abundance of BFP normalised against GAPDH 
expression. 
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The same lysates as shown in Figure 5-5 were probed with anti-XBP1S, and the resulting 
western blots are shown in Figure 5-6.  XBP1S is seen to be induced by doxycycline, 
indicating that the inducible construct is functional and responds to doxycycline.  There 
is a large increase in XBP1S abundance in cells treated with both doxycycline and MG132 
when compared to cells only treated with doxycycline.  As XBP1s protein is known to be 
turned-over rapidly by proteasomal degradation (Tirosh et al. 2006), the sharp increase 
in XBP1S in the presence of MG132 is likely to be due to the accumulation of protein 
that cannot be degraded, rather than any increase in gene expression.  This result 
indicates that the dose and time period of MG132 treatment used is sufficient to inhibit 
the activity of the proteasome and, therefore, the loss of BFP observed in Figures 5-3, 
5-4 and 5-5 appears to be mediated by a mechanism other than proteasomal 
degradation. 
In Figure 5-6B(i), cells treated with tunicamycin for six hours are not seen to display any 
quantifiable upregulation of XBP1S.  However, there does  appear to be an increase in 
endogenous XBP1S in MG132 treated cells, which is likely to be due to the accumulation 
of protein which would otherwise be degraded by the proteasome, similar to the 
accumulation observed in Figure 5-6A. 
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Figure 5-6 – XBP1S protein levels with proteasome inhibition. 
Anti-XBP1S western blot of lysates from CHO-S X1-B cells treated with (A) doxycycline 
(B) tunicamycin, and/or the proteasome inhibitor MG132, n=1. (ii) Quantification of 
these western blots showing XBP1S protein levels normalised against GAPDH 
expression. 
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5.2.5 Quantification of XBP1 splicing in the presence of tunicamycin 
The activity of XBP1 is known to be tightly controlled at both the transcriptional level 
(Lee et al. 2002; Shang and Lehrman 2004) and the protein level (Tirosh et al. 2006; 
Yoshida et al. 2006) . The effect of induced overexpression of exogenous XBP1s on this 
intricately regulated system was examined: firstly, to investigate the possibility of 
exogenous XBP1s conferring resistance to ER stress, and secondly, to further elucidate 
the molecular mechanisms that regulate the activity of XBP1.   
The splicing of XBP1 after the induction of exogenous XBP1s expression was analysed 
using an RT-PCR assay; the principle of this assay is described in Section 5.1.2.  CHO-S 
and CHO-S X1-B cells were treated with doxycycline for 3 days, and/or tunicamycin for 
3 hours, or left uninduced.  RNA was extracted from the cells using Trizol reagent, and 
converted into cDNA by RT-PCR.  Figure 5-7 shows the products amplified using primers 
that recognise only endogenous XBP1.  Untreated CHO-S cells show a band for XBP1u 
and XBP1h.  As XBP1h is formed from one spliced strand and one unspliced strand of 
XBP1, it may be surmised that untreated, unstressed cells contain a small amount of 
spliced XBP1.  This result is consistent with a basal level of UPR signalling active under 
normal physiological conditions (Wang et al. 2015).  The results were consistent across a 
number of experiments performed, and similar results were published by Shang and 
Lehrman. Therefore, the results seen in Figure 5-7 can be considered representative of 
unstressed cells.   
The addition of doxycycline to CHO-S does not alter XBP1 splicing, but adding 
tunicamycin causes XBP1u to be spliced into XBP1s, represented by a band shift on the 
agarose gel.  X1-B cells show the same band shift when treated with tunicamycin, 
however, when cells are pre-treated with doxycycline and then with tunicamycin, XBP1 
splicing is shown to be remarkably reduced and the majority of XBP1 remains in the 
unspliced form.  This reduction in splicing may indicate a resistance to ER stress, which 
could have implications for cell viability which will be explored more fully in future 
experiments.  It could also be an indication of an additional level of regulation of XBP1, 
where IRE1 is able to detect the level of XBP1s present in the cell, and modulate its 
own endoribonuclease activity to downregulate the splicing of XBP1 in the presence of 
an abundance of XBP1s.  
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Figure 5-7 – Endogenous XBP1 splicing in tunicamycin treated cells.   
(A) XBP1 splice assay of cDNA extracted from either (i) CHO-S or (ii) CHO-S X1-B cells 
treated with doxycycline and/or tunicamycin, using primers that anneal only to the 
endogenous CHO XBP1 sequence.  Experiment was performed four times, data from a 
representative experiment is shown.  (B) Densitometric quantification of the above 
agarose gels.  For the purposes of quantification, XBP1h is considered to be 50% spliced 
and 50% unspliced.   
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When the same cDNA samples as in Figure 5-7 were amplified using the primer set that 
recognises both endogenous and exogenous XBP1, a different pattern of bands were 
observed for the X1-B samples, but not for CHO-S, as seen in Figure 5-8.  This primer 
pair is able to detect the spliced human XBP1 expressed by the doxycycline-inducible 
vector, in addition to both forms of endogenous XBP1.  The exogenous XBP1s band can 
be seen in X1-B samples treated with doxycycline, and runs at the same mobility as 
endogenous XBP1s.  A band for XBP1s also can be seen to a lesser extent in uninduced 
X1-B, and this is likely to be caused by leaky expression from the pTetOne vector in the 
absence of doxycycline.  Intriguingly, XBP1u is shown to be upregulated with 
doxycycline treatment, as seen in both Figure 5-7A(ii) and Figure 5-8A(ii).  There is no 
exogenous source of XBP1u in X1-B. Therefore, the additional XBP1u observed must be 
endogenous.  It is thought that XBP1S is able to induce the transcription of its own gene 
(Shang and Lehrman 2004; Yoshida et al. 2000), and the observed increase in XBP1u 
transcripts that occurs with a rise in XBP1S would appear to support this hypothesis.    
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Figure 5-8 – Total XBP1 transcripts in tunicamycin treated cells.   
(A) XBP1 splice assay of cDNA extracted from either (i) CHO-S or (ii) CHO-S X1-B cells 
treated with doxycycline and/or tunicamycin, using primers that anneal to both the 
endogenous sequence and the exogenous human XBP1s transcripts induced in the 
presence of doxycycline.  Experiment was performed three times, data from a 
representative experiment is shown.  (B) Densitometric quantification of the above 
agarose gels.  For the purposes of quantification, XBP1h is considered to be 50% spliced 
and 50% unspliced.   
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In order to determine if the results observed in induced CHO-S X1-B, namely the 
upregulation of XBP1u and the downregulation of XBP1 splicing in the presence of 
exogenous XBP1s, are also seen in cells that stably overexpress XBP1s, a similar XBP1 
splicing assay was performed in CHO-S XE-D cells.  Figure 5-9 shows the PCR products 
generated from cDNA from CHO-S and CHO-S XE-D cells treated with or without 
tunicamycin, amplified using the endogenous-only primer set.  Untreated CHO-S XE-D 
cells are seen to have more XBP1u and less XBP1h than untreated CHO-S cells.  This 
indicates that XBP1S is able to upregulate XBP1u transcription, and also that XBP1 
splicing is downregulated in XE-D when compared to CHO-S.  These results in untreated 
XE-D cells are similar as previously observed in induced X1-B, and are likely to be due to 
the constitutive expression of XBP1s.   
When treated with tunicamycin, the XBP1 in CHO-S cells is seen to be entirely in the 
spliced and hybrid forms, indicating that the UPR is strongly induced in these cells.  
Conversely, CHO-S XE-D cells do not display the same extent of splicing and the 
majority of XBP1 in these cells remains in the unspliced form.  This is a similar result to 
what was observed in induced X1-B cells, and supports the hypothesis that an 
abundance of XBP1S is able to downregulate XBP1 splicing.  It also indicates that the 
observed effects are not unique to X1-B, and is instead a general consequence of XBP1s 
overexpression. 
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Figure 5-9 – Endogenous XBP1 splicing in CHO-S and CHO-S XE-D cells treated with 
tunicamycin. 
(i) Agarose gel of PCR products from cDNA extracted from CHO-S and CHO-S XE-D cells 
treated with tunicamycin, amplified with primers that anneal to endogenous XBP1.     
(ii) Quantification of the PCR products shown on the above gel. 
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5.2.6 Quantification of XBP1 splicing during a transient transfection 
The assay was then used to determine the extent of XBP1 splicing caused by a standard 
transient transfection protocol, in order to find the severity of cell stress induced by 
transient transfection.  CHO-S and CHO-S X1-B cells were either transfected with 
antibody heavy and light chains using the chemical transfection reagent NovaCHOice, or 
left untreated.  The next day, each population of cells was divided into two and either 
induced with doxycycline or left uninduced.  After an additional two days of growth, the 
cells were homogenised with Trizol Reagent, RNA was extracted and converted into 
cDNA by RT-PCR and used as a template for the XBP1 splice assay.   
Figure 5-10 shows PCR products from a splice assay performed with the primers for 
endogenous XBP1, separated on an agarose gel.  In CHO-S, very little difference in XBP1 
splicing is seen when the cells are transfected or treated with doxycycline.  This 
indicates that transient transfection does not trigger the UPR.  However, when the pixel 
intensity of each band is quantified, as shown in Figure 5-10B(i), a subtle increase in 
spliced XBP1 can be seen in the transfected samples compared to the untransfected 
control.   
A similarly subtle increase can be seen for uninduced, transfected X1-B cells in Figure 5-
10B(ii).  When X1-B cells are induced, however, this small increase in splicing is not 
seen and instead the ratio of spliced:unspliced XBP1 shifts in favour of XBP1u, similar to 
the result shown in Figures 5-7, 5-8 and 5-9.  Generally, this experiment shows that a 
low level of stress is triggered by a transient transfection, but it is small compared to 
the ER stress caused by tunicamycin.   
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Figure 5-10 – Endogenous XBP1 splicing in transiently transfected cells. 
(A) Agarose gels showing endogenous XBP1 splicing in the presence of doxycycline 
and/or a standard transient transfection with IgG antibody in (i) CHO-S cells and (ii) 
CHO-S X1-B cells, n=1. (B) Densitometric quantification of the total XBP1u and XBP1s 
present on the above gels.  For the purposes of quantification, XBP1h is considered to 
be 50% spliced and 50% unspliced.  
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5.2.7 XBP1 splicing in cells treated with the IRE1 inhibitor 4μ8C 
XBP1 splicing is performed by IRE1, a protein with endoribonuclease and kinase 
functions localised to the ER membrane which is activated during the UPR.  IRE1 has 
other roles in the UPR besides XBP1 splicing, as it is also involved in pro-apoptotic 
processes through interaction with Jun Kinase and p38MAP Kinase (Urano et al. 2000b), 
and through a process named IRE1-mediated RNA degradation (RIDD) (Han et al. 2009; 
Hollien et al. 2009), both of which are active during sustained stress responses and can 
lead to cell death.  It was hypothesised that having an exogenous source of XBP1s would 
selectively upregulate the functions of IRE1 that are beneficial to recombinant protein 
production (i.e. XBP1 signalling), while the negative aspects of IRE1 activation (i.e. 
apoptosis) might be downregulated.   
4μ8C is a chemical inhibitor of IRE1 that binds to K907 of its endoribonuclease domain 
to block substrate binding.  This inhibits two of the functions of IRE1: XBP1 splicing and 
RIDD, but does not inhibit its kinase activity (Cross et al. 2012).  By inducing expression 
of XBP1s using doxycycline and subsequently blocking endogenous splicing and RIDD with 
4μ8C, it was hypothesised that the viability of the cell could be improved by blocking 
the apoptotic functions of RIDD (Han et al. 2009; Hollien et al. 2009) while maintaining 
the larger, more efficient ER phenotype caused by XBP1S, allowing for greater 
production of antibody.  
The effect of 4μ8C on the XBP1 splicing function of IRE1 was confirmed by treating CHO-
S X1-B cells with varying combinations of: 1 μg/mL doxycycline for 48 hours; 10 μg/mL 
tunicamycin for three hours; and/or 32 μM 4μ8C for 24 hours.  cDNA was prepared from 
the treated cells as previously described and an XBP1 splicing assay was performed using 
the endogenous XBP1 primers.  The PCR products generated under this range of 
treatments are shown in Figure 5-11.  The ratio of XBP1s:XBP1u is the same under 
tunicamycin and doxycycline treatment as was previously observed in Figure 5-7.  The 
addition of 4μ8C causes all XBP1 to exist in only the unspliced form, which implies that 
IRE1-mediated splicing is blocked.  This effect is the same regardless of the presence of 
either doxycycline or tunicamycin alongside 4μ8C. 
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Figure 5-11 – Endogenous XBP1 splicing in X1-B cells treated with the IRE1 
inhibitor 4μ8C.  
(i) Agarose gel of PCR products resulting from primers that anneal to only endogenous 
XBP1, amplifying cDNA from cells treated with doxycycline, tunicamycin and/or 4μ8C, 
n=2. (ii) Quantification of the PCR products shown on the above gel. 
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To confirm that the presence of 4µ8C does not interfere with the exogenous expression 
of XBP1s from the pTetOne vector, the same CHO-S X1-B cDNA as used in the assay in 
Figure 5-11 was used in a splice assay with the endogenous/exogenous primer pair, 
shown in Figure 5-12.  The pattern of splicing shown in the PCR products from this 
primer pair is unchanged from the endogenous only primers, except for the addition of a 
band for XBP1s in doxycycline treated cells that corresponds to exogenous XBP1s.  As 
previously observed, X1-B cells show a small amount of exogenous XBP1s expression in 
the absence of doxycycline, which is thought to come from leaky expression from the 
pTetOne inducible vector.  4μ8C is shown to not influence the expression of exogenous 
XBP1s, only the XBP1s that is derived from XBP1u by IRE1-mediated splicing. 
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Figure 5-12 – Total XBP1 transcripts in X1-B cells treated with the IRE1 inhibitor 
4μ8C.  
(i) Agarose gel of PCR products resulting from primers that anneal to only endogenous 
XBP1, amplifying cDNA from cells treated with doxycycline, tunicamycin and/or 4μ8C, 
n=1. (ii) Quantification of the PCR products shown on the above gel. 
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5.2.8 Quantification of XBP1S protein in the presence of 4µ8C 
After visualising the effect of 4μ8C on XBP1 transcript levels, the effect of the inhibitor 
on XBP1S protein levels was then determined.  As 4µ8C is seen to block the generation 
of endogenous XBP1s, it could be predicted that the levels of XBP1S derived from 
endogenous XBP1s would drop as a consequence, but that XBP1S translated from 
exogenous XBP1s would be unaffected.  To visualise XBP1S in the presence of 4µ8C, 
CHO-S and X1-B cells were treated with doxycycline and/or 4μ8C over three days and 
then lysed.  Lysates were separated by SDS PAGE and blotted with anti-XBP1S.   
A band corresponding to XBP1S protein can be seen in both CHO-S and X1-B samples.  
The intensity of this band was unexpected, as previous applications of this primary 
antibody did not reveal the endogenous protein, only the overexpressed, exogenous 
protein.  The antibody used in this western blot was a fresh batch ordered from the 
same manufacturer, and there may have been variation in the efficacy of different 
batches of the same antibody.  Induced X1-B cells are seen to have an abundance of 
XBP1S, as previously observed, and CHO-S and uninduced X1-B have relatively little.  
Interestingly, cells treated with 4μ8C show a reduction in XBP1S compared to their 
untreated counterparts, and even induced X1-B has less XBP1S when also treated with 
4μ8C.  This drop in protein levels is likely to be due to two reasons.  Firstly, the 
inhibition of IRE1 by 4μ8C results in the blocking of XBP1 splicing, meaning that there 
are fewer XBP1s transcripts to be translated into XBP1S protein.  Secondly, the 
corresponding increase in XBP1u transcripts results in more XBP1U being translated, 
which functions as a regulator of the levels of XBP1S by binding it and targeting it to the 
proteasome (Yoshida et al. 2006).  Together, these two effects contribute to a drop in 
XBP1S. 
In doxycycline treated X1-B cells, there appears to be two higher molecular weight 
species above XBP1S.  Similar high molecular weight species have been previously 
observed on an anti-XBP1S blot (Chen and Qi 2010), and were proposed to represent 
XBP1S that had undergone SUMOylation. The activity of XBP1S as a transcription factor 
is known to be repressed by SUMOylation at K276 and K297 on the C terminal 
transactivation domain, and the band at approximately 65kDa was therefore identified 
as XBP1S that had undergone one SUMOylation event and the 80kDa band as XBP1S with 
two SUMO tags. 
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Figure 5-13 – XBP1S protein levels in cells treated with 4μ8C. 
Western blot of crude lysates from CHO-S and CHO-S X1-B cells treated with 
doxycycline and/or 4μ8C over three days, separated by SDS PAGE under reduced 
conditions and blotted with anti-XBP1S, n=1. 
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5.2.9 ER amount in the presence of 4µ8C 
As the presence of 4μ8C is shown to reduce the abundance of XBP1S, it was possible 
that this reduction would affect the amount of ER by preventing downstream XBP1S 
signalling.  There were three potential consequences of 4μ8C treatment on ER size: 
firstly, that all 4μ8C treated cells would have less ER than their untreated counterparts 
due to the reduction in XBP1S; secondly, that the presence of 4μ8C would only block the 
expansion of the ER in X1-B cells triggered by exogenous XBP1S expression, but IRE1 
inhibition in CHO-S would have no effect; and thirdly, that 4μ8C would have no effect 
on the amount of ER in any of the cells. 
To test these hypothetical outcomes, a portion of cells from the CHO-S and X1-B 
samples that had been used for the western blot shown in Figure 5-13 were retained 
and treated with ER Tracker.  After quenching and washing, the cells were analysed by 
flow cytometry to measure green fluorescence resulting from the ER specific stain. As 
previously seen in Figure 5-2, the amount of ER membrane in CHO-S cells does not 
change in response to doxycycline.  However, a small degree of expansion can be seen 
in CHO-S cells treated only with 4μ8C.  As the lysates from these cells shown in Figure 
5-13 show that there are undetectable levels of XBP1S in these cells, it is not clear why 
the ER of these cells is seen to expand.  The only conclusion that can be drawn is that 
this expansion is mediated by a mechanism independent of XBP1S.  
CHO-S X1-B exhibits ER expansion in the presence of doxycycline, as previously observed 
in Figure 5-2.  The addition of 4μ8C does not increase or decrease the amount of ER, 
either in doxycycline treated or untreated cells.  This result would appear to correlate 
with the western blot data in Figure 5-13, which displays high levels of XBP1S in X1-B 
cells treated with doxycycline.  As this abundance is only marginally reduced by the 
presence of 4μ8C, it appears that downstream XBP1S is not compromised and ER 
expansion is able to occur. 
  
Chapter 5 Consequence of XBP1s overexpression  
146 
 
 
Figure 5-14 – ER size in 4μ8C treated cells. 
Histograms of green fluorescence, as a representative of ER size, in CHO-S and CHO-S 
X1-B cells resulting from treatment with ER Tracker.  Cells were treated with 
doxycycline and/or the IRE1 inhibitor 4μ8C over three days. 
 
 
Chapter 5 Consequence of XBP1s overexpression  
147 
 
5.2.10 Antibody productivity in the presence of 4µ8C 
The aim of the experiments involving 4µ8C was to find if the inhibition of IRE1 in 
induced X1-B, or any cell line with upregulated XBP1S, would improve cell viability 
during the transient production of recombinant protein by inhibiting IRE1-mediated pro-
apoptotic pathways.  As the induction of XBP1s overexpression has been shown to both 
improve antibody yield (Figure 4-14) and reduce viable cell density (Figure 4-11), it was 
hypothesised that the reduction in cell viability could be alleviated by the presence of 
4µ8C while the secretion of antibody would be either unaffected or improved, leading 
to an overall enhancement in productivity. 
In order to quantify the effect of 4µ8C on productivity, CHO-S X1-B cells were 
transiently transfected with antibody and then split evenly into eight flasks.  Two of 
these flasks were induced with doxycycline, two were treated only with 4µ8C, two were 
treated with both doxycycline and 4µ8C and the final two were left untreated.  The 
flasks were grown for three days in the presence of the treatments, and at the end of 
the experimental period the viable cell density of each flask was measured and the 
concentration of secreted antibody was calculated by antibody capture ELISA.  The 
antibody concentration was normalised against the number of viable cells to calculate 
productivity, as shown in Figure 5-15.   
CHO-S X1-B cells treated only with doxycycline are seen to have an increased 
concentration of secreted antibody compared to untreated cells, which is a result 
consistent to what was observed in Figure 4-14.  The viability of these cells does not 
significantly decrease upon the addition of doxycycline.  While consistent with the 
results in X1-B in Figure 4-14, this is a different result to the drop in viability seen in X1 
in Figure 4-11.  Cells treated only with 4µ8C have a statistically significant lower 
concentration of secreted antibody than untreated cells.  The viability of these cells 
does not drop significantly, although it is not seen to improve either.  The addition of 
4µ8C with doxycycline does not improve antibody productivity beyond the 
improvements achieved through doxycycline treatment alone.  Viable cell density is not 
improved in these cells compared to those only treated with doxycycline either and, in 
the case of experiment 3, viability is seen to drop significantly.  Generally, there is no 
benefit to the productivity of X1-B provided by 4µ8C that could not have been achieved 
by doxycycline alone.  
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Figure 5-15 – Antibody productivity in CHO-S X1-B cells treated with 4μ8C. 
CHO-S X1-B cells transiently transfected with antibody were cultured in duplicate 
with one of the four following conditions: untreated, doxycycline only, 4μ8C only, or 
doxycycline and 4μ8C together.  At the end of the treatment period, the 
concentration of secreted antibody and viable cell density were recorded, and overall 
productivity was calculated.  Each experiment represents a single initial transfection.  
Instances where Dox+ 4µ8C- (red) samples vary significantly from Dox+ 4µ8C+ (purple) 
samples (p<0.05, as determined by Student’s T Test) are indicated by *.  Error bars 
represent standard deviation across duplicate flasks. 
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5.3 Discussion 
The consequences of XBP1s overexpression on the phenotype of CHO-S X1 and CHO-S X1-
B cells were further characterised in order to unravel the reasons behind the increase in 
antibody yield observed in CHO-S X1-B in Chapter 4, and CHO-S XE-D in Chapter 3, as 
well as to gain a greater understanding of XBP1s signalling as a whole.  The effect of 
XBP1s overexpression on ER amount, XBP1 splicing, and the depletion of exogenously 
expressed BFP were examined as consequences that had the potential to be relevant to 
the production of recombinant protein.  In addition to this, the impact of an inhibitor of 
IRE1 on antibody yield, the amount of ER and cell viability in cells with induced XBP1s 
was also investigated in order to find if further improvements to productivity could be 
obtained beyond what was achieved by XBP1s overexpression alone. 
The induction of XBP1s by doxycycline treatment in CHO-S X1 and CHO-S X1-B was 
shown to result in an expansion of the ER.  This correlates with what is known about the 
downstream effect of XBP1s signalling on lipid biogenesis (Shaffer et al. 2004).  
However, CHO-S XE-D, a cell line with constitutive XBP1s overexpression, was observed 
to have a smaller ER than either X1 or X1-B cells with induced XBP1s overexpression.  
One possible explanation for this discrepancy is that the extent of XBP1s expression in 
these cells is different.  As observed in Chapter 4, western blot analysis shows that 
lysates of XE-D contain less XBP1S than lysates from doxycycline treated X1 or X1-B, so 
it is possible that a high degree of XBP1s expression is required for ER expansion. 
CHO-S X1-B cells were also observed have a reduction in both BFP and blue fluorescence 
in the presence of upregulated XBP1s, either through doxycycline induction or through 
the activation of the UPR by tunicamycin.  This depletion of BFP was not alleviated by 
treatment with the 26S proteasome inhibitor MG132 at a dose that was able to cause 
accumulation of XBP1S, which is known to have a high turn-over rate (Tirosh et al. 
2006).  This result indicated that the loss of BFP is mediated by a method other than 
proteasomal degradation. However, another possible explanation for the result is that 
BFP is depleted as part of the upregulated ERAD induced by XBP1s expression, but that 
the protein is merely rendered undetectable by either western blotting or flow 
cytometry before it reaches the proteasome for final degradation.  The primary 
antibody used to probe for BFP may not be able to recognise ubiquitinated BFP, and 
likewise the addition of ubiquitin may also modify its tertiary structure in a manner that 
abolishes its fluorescence. 
It has been previously published that some ER-localised fluorescent proteins are prone 
to aggregation, and oligomers of these proteins can be observed on a non-reducing 
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western blot (Aronson et al. 2011).  The ER-BFP used in this project, also known as 
oxBFP, was engineered from EBFP2 specifically to overcome this shortcoming and adapt 
the protein to the oxidising environment of the ER by the addition of three amino acid 
substitutions: C48S, C70V and V163A (Costantini et al. 2015).  The two cysteine 
substitutions were found to reduce the extent of oligomerisation, and the valine 
substitution was required to retain the fluorescence intensity of EBFP2.  In addition to 
these three amino acid variations, the sequence of oxBFP also contains the eight amino 
acid substitutions responsible for blue fluorescence that distinguish EBFP2 from EGFP 
(Yang et al. 1998), and the six ‘superfolder’ GFP mutations, which improve the folding 
and maturation rate of the protein (Pédelacq et al. 2006).  Two additional modifications 
made that distinguish oxBFP from EBFP2 were a prolactin signal sequence added to the 
N-terminus, upstream of the BFP sequence, to target the protein to the ER, and a KDEL 
motif was added to the C terminus to retain the protein in the ER (Costantini et al. 
2015).  As it has been published that oxBFP is less prone to form oligomers than EBFP2, 
the ability of oxBFP to form oligomers was not reexamined in this project and it was 
assumed that oxBFP exists solely as a monomer.  Likewise, it should also be noted that 
the localisation of oxBFP to the ER was not examined beyond a cursory microscopy 
analysis, as this was also inferred from the original published data.   
The possibility exists that the BFP in X1-B had a propensity to form oligomers, which 
were never observed visually as X1-B lysates were exclusively examined under reduced 
conditions, and that these hypothetical oligomers were bound by BiP and subjected to 
ERAD at a higher rate than the monomeric form of BFP.  The upregulation of ERAD by 
induced XBP1s may increase the unfolding of aggregated BFP, in a manner that rendered 
the protein undetectable by flow cytometry or a reduced gel, but did not lead to the 
degradation of BFP in the proteasome.  It is also possible that BFP does in fact exist 
solely as a monomer, and the loss of BFP is due to it being recognised by ER quality 
control mechanisms as an exogenous molecule.  The mechanism for this recognition is 
unknown, but it could ultimately involve lysosomal degradation as opposed to 
proteasomal degradation as a method for BFP depletion, as this form of degradation is 
not affected by MG132 and it is a possibility that was not investigated.  Regardless of 
the molecular mechanism and the specific site of degradation within the cell, the 
observation that the overexpression of XBP1s leads to an upregulation of BFP depletion 
indicates an enhancement of ERAD in induced X1-B.  This may contribute to an increase 
in protein folding efficiency that in turn leads to an increased yield of antibody. 
The results from the RT-PCR assay of XBP1 splicing revealed that induced X1-B cells, as 
well as XE-D cells, have downregulated XBP1 splicing and upregulated XBP1 
transcription when compared to cells with physiological levels of XBP1s.  This result 
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indicates that XBP1S has the ability to downregulate the endoribonuclease activity of 
IRE1, which reveals a novel aspect of the regulation of XBP1 signalling.  The regulation 
of IRE1 has been the subject of a number of studies, and its activity and abundance are 
known to be controlled at both the protein and the transcript level.  Firstly, IRE1 
activity is at least in part modulated by Sec63, which works in complex with BiP to 
negatively regulate IRE1 autophosphorylation.  A mouse Sec63 knockout cell line was 
shown to have constitutive activation of IRE1 phosphorylation, regardless of the 
presence of ER stress (Fedeles et al. 2015).  Intriguingly, this study also revealed that 
the overexpression of XBP1s in the Sec63 knockout cell line was able to abolish the 
activation of Ire1 almost entirely, even in the presence of tunicamycin, indicating that 
Sec63 and XBP1s work in concert to regulate IRE1 phosphorylation, and an abundance of 
XBP1s is able to block IRE1 activation.  However, this study did not examine the effect 
of XBP1s overexpression on IRE1 activation in a cell line with physiological levels of 
Sec63; circumstances which would be closer to the phenotype of X1-B.  It can be 
inferred from the XBP1 splicing assay in X1-B and XE-D, as well as the work of Fedeles 
and colleagues, that an abundance of XBP1s is a potent inhibitor of IRE1 
autophosphorylation. 
Another level in the regulation of IRE1 activity is that the abundance of IRE1 is 
modulated by the E3 ubiquitin ligase synoviolin (SYVN1).  The ubiquitination of IRE1 by 
SYVN1 leads to its dislocation from the ER and degradation in the proteasome (Gao et 
al. 2008).  SYVN1 is upregulated in collagen induced arthritis, and it is thought that the 
increased degradation of IRE1 administered by SYVN1 is a causative factor in this 
disease via the downregulation of apoptotic functions of IRE1 in synovial fibroblasts, 
leading to abnormal proliferation of these cells and an increase in the severity of 
arthritic symptoms.  As this study reveals that the amount of IRE1 protein, as well as its 
phosphorylation state, influences the extent of its downstream activity, it would be 
interesting to determine IRE1 protein abundance with and without the overexpression of 
XBP1s, as well as levels of autophosphorylation under these circumstances.  This could 
be revealed by western blotting of induced and uninduced X1-B lysates with 
phosphospecific and non-phosphospecific primary antibodies to IRE1, similar to the 
probes used for western blotting in (Fedeles et al. 2015). As transcripts for IRE1 are also 
known to be degraded by the IRE1 endoribonuclease domain as part of RIDD (Tirasophon 
et al. 2000), the quantification of IRE1 transcript levels by PCR with IRE1 specific 
primers would provide a complementary experiment to the western blot data obtained 
for IRE1 protein.  These experiments would reveal whether the downregulation of XBP1 
splicing observed in XBP1s overexpressing cells is due to a loss of IRE1 protein or 
transcripts, or a reduction in IRE1 activation by phosphorylation. 
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The chemical inhibitor of IRE1 endoribonuclease activity, 4µ8C (Cross et al. 2012), was 
used alongside the induction of XBP1s with the aim of potentially improving the viability 
of cells which could be compromised by pro-apoptotic functions of RIDD (Han et al. 
2009; Hollien et al. 2009).  4µ8C was shown to block the XBP1 splicing function of IRE1 
entirely, even in the presence of tunicamycin, and the exogenous XBP1s induced by 
doxycycline treatment was unaffected by the loss of IRE1 activity.  The ability of 4µ8C 
to inhibit RIDD directly was not tested, but was inferred from its original publication 
(Cross et al. 2012).  The addition of 4µ8C was shown not to alter the amount of ER in 
either CHO-S or X1-B; however, levels of endogenous XBP1S were depleted by 4µ8C 
treatment.  When the productivity of antibody in induced X1-B cells was tested it was 
found that both the yield of antibody and the viable cell density were not improved by 
the presence of 4µ8C.  While disappointing, this result could be attributed to the fact 
that 4µ8C is an inhibitor only of XBP1 splicing and RIDD, and does not affect the kinase 
functions of IRE1.  It therefore does not affect its interactions with phosphorylation 
targets such as Jun Kinase, which has known apoptotic functions (Lei and Davis 2003; 
Putcha et al. 2003).  To date, there is no inhibitor of IRE1 available that blocks its 
kinase functions, but hypothetically the inhibition of both the kinase and 
endoribonuclease activities of IRE1 alongside the overexpression of XBP1s could lead to 
an improvement of cell viability.  
5.3.1 Summary 
To summarise the observed consequences of XBP1s overexpression in X1-B cells: 
 Antibody productivity improved by 30-40% 
 Increased ER size 
 Upregulated PDI expression 
 Upregulated degradation of ER-localised BFP 
 Upregulated XBP1u expression 
 Downregulated XBP1 splicing 
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6.1 Summary of objectives 
The work presented in the previous three chapters represents a series of experiments 
designed to achieve the following aims, as described in Chapter 1: 
1. To identify genes or pathways that can be manipulated in order to improve 
antibody yield from CHO host cell lines. 
2. To gain a greater understanding of the biochemistry of ER stress responses; in 
particular, the activity and regulation of XBP1. 
The specific objectives of the project were: 
 To characterise the high yield host cell line CHO-S XE-D. 
 To generate a series of CHO-derived cell lines with inducible overexpression of 
the genes XBP1s, Ero1α or GADD34. 
 To find if the overexpression of these genes individually leads to an increase in 
antibody yield.  
 To investigate the effect of co-overexpressing these genes on antibody yield. 
 To find if a chemical inhibitor of IRE1 is able to improve viability and overall 
productivity of the XBP1s inducible cell line. 
 To investigate the effect of exogenous XBP1s induction on endogenous XBP1 
expression and splicing, and the regulation of IRE1 activity. 
6.1.1 Characterisation of CHO-S XE-D 
The first objective that was investigated was the characterisation of CHO-S XE-D.  It was 
discovered early in the project that the CHO-S XE cells grown at the University of 
Glasgow differed in a number of ways from the CHO-S XE cells grown at UCB.  It was 
assumed that these differences were due to a speciation event that had occurred, 
perhaps as a result of the change in culture environment or the method by which the 
cells were thawed.  Due to these differences, the CHO-S XE cells grown at Glasgow were 
designated as CHO-S XE Derivative (CHO-S XE-D) and considered to be a separate cell 
line from the CHO-S XE1 clone described in (Cain et al. 2013).  One key difference 
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between XE1 and XE-D was in their rate of growth: XE1 was reported to have a fast rate 
of growth and robust viability, whereas XE-D grew significantly slower than parental 
CHO-S cells and generally had poorer viability, particularly when transfected.  It should 
be noted that a direct comparison of the secretory properties of CHO-S XE-D and CHO-S 
XE1 was not performed, and only the growth characteristics and viability were 
compared between these clones.  Despite its poor growth rate, the secretory properties 
of CHO-S XE-D were very strong, and this cell line was shown to secrete more protein 
per cell than CHO-S cells.  This high yield was observed for three model proteins: IgG1 
antibody, a multi-domain protein with 16 disulphide bonds; tPA, which has 23 disulphide 
bonds; and α1AT, which has no disulphide bonds in its native structure.  This result 
appeared to indicate that the higher yield observed in CHO-S XE-D was not dependent 
on the structure or the relative complexity of the model protein being secreted, but 
was instead a general attribute of the cell that could be potentially applied to any 
exogenously expressed protein.   
It was initially thought that the only difference between CHO-S and CHO-S XE, besides 
the differences in yield, would be the presence of overexpressed XBP1s and Ero1α in XE, 
as well as an abundance of any gene upregulated by either of these overexpressed 
genes.  However, work on the CHO-S XE-D lineage appeared to indicate that there was 
more variation than previously thought between these two cell lines, such as the 
differences in rate of growth and cell size, but the exact molecular nature of these 
differences was not known.  CHO-S XE-D was shown to display higher levels of 
transiently transfected GFP, as measured by western blotting, and higher levels of 
green fluorescence resulting from this GFP, as measured by flow cytometry.  This 
interesting result provided the first indication that XBP1s was not solely responsible for 
the strong secretory properties of CHO-S XE-D, as the folding of GFP, a single domain 
cytosolic protein with no disulphide bonds, should not logically have been improved by 
the presence of upregulated chaperones provided by XBP1s.   
CHO-S XE-D was also found to have higher levels of many endogenous proteins than 
CHO-S.  These proteins included chaperones and foldases, such as BiP and PDI, which 
have a known link to XBP1 signalling (Lee et al. 2003), but also the so-called 
‘housekeeping’ proteins actin and GAPDH, which are not known to be affected by 
XBP1s.  Again, this result indicates differences in CHO-S XE-D that are not related to 
XBP1s.  The variations between CHO-S and CHO-S XE-D could have arisen as a result of 
spontaneous genomic mutation, possibly during clonal selection or cryopreservation.  
Transcriptomics analysis could be used to reveal a more complete picture of genes with 
altered expression in CHO-S XE-D compared to CHO-S.  It could be predicted that a large 
number of genes would have varied expression levels between these cell lines, and the 
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identity of these genes could be determined by a transcriptomics method such as a gene 
array.  Any identified gene with a predicted role in protein secretion could then be 
further analysed using an inducible system such as pTetOne to find the individual 
contribution of this gene towards the phenotype of CHO-S XE-D. 
The differences between CHO-S and CHO-S XE-D could also be solely due to the activity 
XBP1s and Ero1α, as initially hypothesised.  In order to determine if this is the case, and 
to find the specific role of XBP1s and Ero1α overexpression to the characteristics of 
CHO-S XE and XE-D, these genes could be knocked down or knocked out to find if this 
results in the high productivity characteristics being compromised.  Knockdown by siRNA 
was attempted in (Page 2012), but only partial knockdown was achieved for Ero1α and 
no reduction in XBP1 expression was observed at all.  Targeting of XBP1 with siRNA 
appeared to induce XBP1 gene expression rather than repress it, therefore, another 
strategy for depleting XBP1 activity may be required.  Genome editing by CRISPR/Cas9 
may be able to remove the sequence of both the endogenous and exogenous forms of 
XBP1 from CHO-S XE-D.  However, the limitation of this powerful technique is that it 
involves the generation of a new clonal cell line derived from the parental CHO-S XE-D 
population.  As CHO cells are known to be prone to genomic mutation (Chasin and 
Urlaub 1975), the process of genome editing followed by clonal selection may result in a 
cell line that differs from CHO-S XE-D by more than simply the loss of either XBP1 or 
Ero1α.  This variation between cell lines may reduce the reliability of any direct 
comparisons made between the populations of cells, therefore, genome editing of CHO-
S XE-D by CRISP/Cas9 may have limited value.  Another possible method of comparing 
CHO-S and CHO-S XE-D would be to obtain full genomic sequences of these cell lines in 
order to undertake genomic analysis; however, this is likely to be prohibitively 
expensive. 
6.1.2 Investigation of CHO-S cell lines with inducible gene overexpression 
Following the characterisation of CHO-S XE-D, the next experimental strategy 
undertaken was to engineer cell lines with inducible overexpression of XBP1s, GADD34 
or Ero1α, as this would allow comparative analysis of populations of cells that differed 
in only the presence or absence of a single overexpressed gene.  This would enable a 
more definitive assessment of the specific roles of each of these genes individually 
towards the secretory characteristics of CHO cells.  Although the GADD34 and Ero1α 
overexpressing cell lines, G1 and E1, did not display any increase in antibody yield with 
gene induction, the XBP1s inducible cell line, X1, and a derivative of this cell line with 
ER-localised blue fluorescent protein, X1-B, both displayed increased antibody 
productivity when XBP1s was overexpressed.  X1 and X1-B were found to have an 
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expanded ER when XBP1s was induced, which correlates with what is known about the 
downstream effects of XBP1s (Lee et al. 2003; Shaffer et al. 2004), and they also 
appeared to have more ER than CHO-S XE-D.  It was initially hypothesised that the 
amount of ER would directly correlate with the ability of that cell to secrete protein, in 
that the larger the ER, the higher yield of protein.  The relative ER amounts of X1, X1-B 
and XE-D do not correlate directly with their yield of transiently transfected antibody, 
as XE-D had a far higher yield than X1 or X1-B, but had the least ER.  Therefore, it 
appears that ER membrane size, as determined by uptake of ER Tracker dye, is not an 
appropriate marker of a high yield cell line.  However, as the yield of X1 and X1-B 
improves with XBP1s overexpression, it is likely that another outcome of XBP1 
signalling, such as chaperone upregulation, is responsible for improving the yield of 
antibody in these cell lines.   
The Ero1α inducing cell line, E1, was shown to have no increase in antibody yield when 
Ero1α was overexpressed.  This partially invalidates one hypothesis about the 
mechanism behind the high yield of CHO-S XE; that XBP1s and Ero1α are individually 
capable of increasing yield when overexpressed, and their effects are cumulative when 
co-overexpressed.  This hypothesis was based on work by UCB researchers, where a 
CHO-K1 cell line overexpressing Ero1α, CHO-K1 E, had a higher yield of antibody than 
either wild-type CHO-S or CHO-K1 (Cain et al. 2013).  The predecessor population to 
CHO-S XE, CHO-S X, which overexpresses only XBP1s, also had higher yield than either of 
these wild-type lineages (Cain et al. 2013).  The variation in the results between E1 and 
CHO-K1 E could be attributed to inherent differences between CHO-S and CHO-K1, in 
that there may be a bottleneck in the CHO-K1 secretory pathway that can be alleviated 
by Ero1α overexpression, whereas no such bottleneck exists in CHO-S and Ero1α 
overexpression in this cell line has no discernible effect.   
One potential area of future investigation into the effects of Ero1α overexpression on 
protein yield would be to examine the effects of a mutant form of Ero1α which is 
engineered to be constitutively active.  This mutant has two regulatory cysteines, C104 
and C131, mutated to alanines to abolish the formation of the regulatory disulphide that 
would normally block the activity of the Ero1α active site (Baker et al. 2008).  The 
C104,131A mutant would hypothetically have a greater ability to reoxidise PDI than 
wild-type; however, as this reoxidation reaction generates the reactive oxygen species 
hydrogen peroxide as a by-product (Gross et al. 2006), it could also be predicted that 
overexpression of this constitutively active form of Ero1α would be damaging to cells.  
This detrimental effect has been shown in a HEK293 cell line with inducible 
overexpression of C104,131A Ero1α, which displayed markers of the UPR when the 
mutant Ero1α was induced (Hansen et al. 2012).  Additional experiments in CHO-S to 
Chapter 6 Discussion  
158 
 
find the effect of C104,131A Ero1α on antibody production, and to confirm any drop in 
cell viability in this cell line, would be an interesting avenue of investigation.  One 
strategy to offset any cellular damage caused by the abundance of hydrogen peroxide 
produced by C104,131A Ero1α activity would be to co-overexpress the mutant Ero1α 
with peroxiredoxin 4 (PRDX4), as this protein utilises hydrogen peroxide in the 
formation of de novo disulphide bonds (Tavender et al. 2010), and could reduce the 
extent of ER stress generated by Ero1α (Tavender and Bulleid 2010).  Co-overexpression 
of these two proteins in an antibody producing cell may result in an environment better 
optimised for producing high titres of secreted protein. 
On the other hand, it could be argued that increased levels of Ero1α would have a 
detrimental effect on protein folding.  The primary purpose of controlling the activity of 
Ero1α by regulatory disulphide bonds is to minimise the generation of hydrogen peroxide 
(Appenzeller-Herzog et al. 2008), but a second purpose is to ensure that a small amount 
of PDI remains in a reduced form in order to catalyse the reduction of non-native 
disulphides, an essential process for folding proteins to achieve their native structure 
(Frand and Kaiser 1998).  The overexpression of Ero1α could offset the balance of 
reduced and oxidised PDI, which could impede the overall efficiency of protein folding.  
Further investigation of the impact of wild-type Ero1α and C104,131A Ero1α 
overexpression on the secretory properties of the cell is required to determine whether 
this protein has a positive effect, a negative effect, or no discernible impact on 
antibody yield. 
The GADD34 inducible cell line, G1, was hypothesised to display an improved rate of 
protein translation in the presence of overexpressed GADD34, as this would result in an 
increased ratio of the active, non-phosphorylated form of eIF2α compared to the 
inactive, phosphorylated form.  It was found that the overexpression of GADD34 did not 
improve antibody yield; however, the direct effect of GADD34 on eIF2α phosphorylation 
was not determined due to the poor quality of the phosphospecific anti-eIF2α primary 
antibody used in western blots of G1 lysates.  Obtaining a functioning primary antibody 
and carrying out the appropriate western blot of induced and uninduced G1 cells would 
determine whether GADD34 overexpression caused the intended effect on cells.   
Another strategy that could potentially improve the viability of the G1 cell line would 
be to treat these cells with a PERK inhibitor alongside the induction of GADD34 
overexpression.  By blocking the phosphorylation of eIF2α by PERK, and subsequently 
overexpressing GADD34, it is hypothesised that this would improve the efficiency of 
protein translation and increase the yield of protein.  However, this treatment would 
also prevent the translation of ATF4, a key UPR transcription factor with a range of both 
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adaptive and pro-apoptotic effects (Vattem and Wek 2004), and the outcome of PERK 
inhibition on induced G1 cells may be difficult to predict.  Another approach that could 
be taken would be to generate a cell line derived from G1 that co-overexpresses 
GADD34 with XBP1s.  This strategy was attempted and a cell line stably transfected with 
both GADD34-pTetOne and XBP1s-pTetOne was generated.  The cell line was 
provisionally named GX1; however, early western blot screening showed an absence of 
XBP1s expression in the presence of doxycycline, and the cell line was discarded.  
Reattempting the generation of a cell line with this combination of inducible gene 
constructs may yield a host cell line with improved protein translation, from the effects 
of GADD34, and improved protein folding, from the effects of XBP1s. 
In addition to GX1, another co-overexpressing cell line was made by stable integration 
of the XBP1s-pTetOne vector into the E1 cell line, which has inducible expression of 
Ero1α.  This cell line was named EX1 and should have had inducible expression of XBP1s 
and Ero1α controlled by doxycycline, but unfortunately, EX1 was found to have lost 
expression of XBP1s over multiple passages.  Experiments into the improvement of 
antibody yield in the EX1 cell line were performed, but these did not reveal an increase 
in antibody yield that was convincingly due to the co-overexpression of these genes.  
This disappointing conclusion meant that the intended experiments into the effect of 
co-overexpression of protein folding-related genes on antibody yield and viability could 
not be performed, but it remains an interesting potential avenue for future 
experiments.  
Other UPR or protein folding related genes could be subcloned into pTetOne for 
controlled analysis of the effects of overexpression of these genes on antibody yield.  
One possibility for investigation is the ERAD component proteins EDEM2 and EDEM3, 
which catalyse the sequential trimming of mannose molecules from terminally 
misfolded proteins to induce their expulsion from the ER (Ninagawa et al. 2014).  As 
these two cleavage events have been proposed to be rate limiting steps in mammalian 
ERAD (Ninagawa et al. 2014), co-overexpression of these proteins may have the effect 
of improving the efficiency and rate of ERAD and alleviating any ER stress caused by 
misfolded proteins, which could have a consequent effect on enhancing protein folding 
and secretion.  Another possibility is to overexpress components of the Sec61 translocon 
using the pTetOne vector.  This may have the effect of improving uptake of nascent 
chains into the ER, or it could also potentially result in overloading of the ER and 
triggering of the UPR.  Co-overexpression of Sec61 components with proteins involved 
with export from the ER, such as COPII and/or SNAREs, could possibly compensate for 
this, but as Sec61, cargo proteins and SNAREs all function as part of complexes, this 
may be an overly simplistic approach. 
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On the other hand, the majority of published work on the effects of genetic 
manipulation of host cell lines on recombinant protein production relates to the 
consequences of overexpression of a single gene.  Positive effects on protein titres have 
been observed from mammalian cells individually overexpressing genes such as XBP1s 
(Tigges and Fussenegger 2006), GADD34 (Omasa et al. 2008), calnexin (Chang et al. 
1997), calreticulin (Chung et al. 2004), ATF4 (Ohya et al. 2008), CHOP (Nishimiya et al. 
2013), ATF6 (Pybus et al. 2014) or BiP (Pybus et al. 2014), to name a few, but very few 
studies have combined these individual results and analysed the potential combinations 
of these genes.  This interesting field of investigation could be explored by generating a 
library of pTetOne constructs, each containing a single gene.  These constructs could be 
co-overexpressed in CHO cells and the effect of different combinations of genes on 
antibody titres could be examined by antibody capture ELISA, or perhaps a high 
throughput system such as ClonePix.  This would allow for an unbiased identification of 
beneficial gene combinations, which could lead the generation of novel host cell lines 
optimised for increased protein production. 
Another strategy to improve protein yield is in the use of chemical inhibitors of UPR 
related proteins.  This possibility was explored using the compound 4μ8C, an inhibitor of 
IRE1 endoribonuclease activity.  As IRE1 has a variety of roles in the UPR in addition to 
XBP1 splicing, including pro-apoptotic signalling (Urano et al. 2000a), it was 
hypothesised that inhibiting the endoribonuclease activity of IRE1 while inducing 
overexpression of XBP1s would result in a cell with favourable secretory properties 
conferred by XBP1s, but improved viability resulting from the inhibition of IRE1.  This 
possibility was tested using 4μ8C on CHO-S X1-B cells with induced XBP1s.  The 
induction of XBP1s in this cell line was already known to improve antibody yield, but it 
was subsequently found that the inhibition of IRE1 in addition to XBP1s overexpression 
did not improve antibody yield beyond XBP1s overexpression alone.  An alternative 
approach would be to use an inhibitor of PERK instead of 4μ8C.  This strategy could 
improve protein translation by preventing the phosphorylation of eIF2α performed by 
PERK, while retaining the improvements in yield conferred by XBP1s.  A third chemical 
inhibitor which could be employed is an inhibitor of the Sec61 translocon named 
eeyarestatin (Cross et al. 2009).  While a strong dose of this inhibitor would block 
import of nascent chains into the ER and succeed only in killing the cell, a low dose of 
this inhibitor over multiple passages could prompt adaptation of cells with stably 
upregulated ER import and improved ER capacity. 
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6.1.3 Investigation into the biochemistry of XBP1 signalling 
The overexpression of exogenous XBP1s was found to upregulate the expression of 
XBP1u transcripts, and also downregulate endogenous XBP1 splicing.  Cells with 
overexpressed XBP1s that were subsequently treated with the ER stress inducing drug 
tunicamycin were found to have reduced XBP1 splicing, which indicated that IRE1 was 
able to sense the abundance of XBP1s in the cell and modulate its own 
endoribonuclease activity.  The molecular mechanism of this downregulation of IRE1 is 
not known, but it could be determined if it is mediated through changes to IRE1 
phosphorylation using a phosphospecific anti-IRE1 antibody.  Western blotting using a 
non-phosphospecific IRE1 primary antibody would also reveal if IRE1 is degraded in the 
presence of an abundance of XBP1S.  The levels of IRE1 transcripts in the presence and 
absence of XBP1S could also be determined by semi-quantitative PCR. 
The effect of XBP1s overexpression on the overall viability and metabolism of cells 
could be determined through an MTS assay, or a similar cell viability assay.  This assay 
uses a tetrazolium salt such as 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) which is metabolised to 
a coloured formazan compound by viable cells (Cory et al. 1991).  The resulting colour 
change is proportional to the number of viable cells in the population and the extent of 
metabolic activity of those cells, and any effect on viability resulting from an 
experimental treatment, such as the overexpression of XBP1s, can be measured through 
the extent of the colour change.  This assay would allow for the quantification of any 
changes to overall cell metabolism caused by the treatment of an XBP1 inducible cell 
line with doxycycline and/or tunicamycin.  As these treatments were shown to affect 
XBP1 splicing, IRE1 activity, and potentially the UPR as a whole, the impact of these 
treatments on cell viability would be interesting to quantify.  
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6.2 Concluding remarks 
The scope of work in this project can be viewed from either an industrial perspective or 
an academic one, reflecting the origins of the project as an academic collaboration with 
industry. When viewed from an industrial, bioprocessing perspective, the most relevant 
aspect of the project is on improvements to antibody titres and overall protein yield 
from cells.  The most promising direction for the future of this aspect of the project is 
in extensive genetic manipulation of host cell lines; in the co-overexpression of genes 
favourable to protein secretion, and downregulation of regulatory processes that lead to 
bottlenecks in production.  Current published work in this area deals predominantly in 
the outcome of manipulation of a single gene, but a broader approach of co-
overexpression may help to adapt the cells better towards an optimum secretory 
phenotype.  The use of specific chemical inhibitors, such as the PERK inhibitor, or the 
slow adaptation of cells to drugs such as the Sec61 inhibitor, is another area with good 
potential for favourable results. These approaches may lead to advancements in host 
cell line generation, and subsequent improvements to industrial outputs of therapeutic 
proteins.  This advancement would impact on the cost-of-goods involved with drug 
development and manufacture, and subsequently of the availability of these drugs to 
patients. 
When the work of the project is examined from an academic perspective, the focus is 
shifted instead onto the broader biochemistry of ER stress responses.  While these 
molecular interactions are relatively well understood, there are many details that are 
not yet unravelled.  The XBP1s overexpressing cell line generated during this project 
allowed for the opportunity to study the consequences of an abundance of XBP1S on the 
regulation of XBP1 splicing and IRE1.  These results indicated a downregulation in IRE1 
activity, although the molecular nature of this downregulation is not known.  Further 
experiments could further elucidate the interplay of XBP1 and IRE1 during the UPR, and 
potentially on other aspects of the UPR.  A greater understanding of ER stress responses 
would impact on the understanding of how host cell lines cope with high levels of 
recombinant protein production, and also on the understanding the molecular basis of 
diseases known to involve dysregulating UPR signalling, such as Parkinson’s disease 
(Mercado et al. 2016), inflammatory bowel disease (Kaser et al. 2010) and certain types 
of cancer (Koong et al. 2006; Romero-Ramirez et al. 2004).    
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Appendix 
 
  
Purpose Gene Orientation Sequence 
Subcloning 
into 
pTetOne 
GADD34 
Forward 5’-GAATTTGCGGCCGCCACCATGGACTACAAG-3’ 
Reverse 5’-GAACGCACCGGTTCATTGGCTTGGGAAG-3’ 
Ero1α 
Forward 5’-GATATATAAGCGGCCGCAAACATGGGCCGCGGC-3’ 
Reverse 5’-GCGCGCACCGGTTTAATGAATATTCTG-3’ 
XBP1 
(Human 
sequence) 
Forward 5’-GAAATTTGCGGCCGCCGAGATGGTGGTGGTG-3’ 
Reverse 5’-GCGCGCACCGGTTTAGACACTAATCAGCTG-3’ 
XBP1 
splicing 
assay 
XBP1 (CHO 
sequence) 
Forward 5’-CGCTTGGGAATGGATG-3’ 
Reverse 5’- CAGGGTCCAACTTGTCC-3’ 
XBP1 
(Human 
sequence) 
Forward 5’- ACAGCGCTTGGGGATGGATG-3’ 
Reverse 5’- TGACTGGGTCCAAGTTGTCC-3’ 
Table 2 – Primers 
Sequences of primers used during the project. 
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